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1. Chapter 1 
 
1.1. Cancer 
Although some promising developments have been achieved thanks to an intensive medical and 
pharmaceutical research, cancer remains one of the leading causes of mortality worldwide.1 
There were an estimated 14.1 million cancer cases around the world in 2012, of these 7.4 million 
cases were in men and 6.7 million in women. This number is expected to increase to 24 million by 
2035.2  
The word "cancer" derives from the father of medicine, Hippocrates, who used the Greek word 
karkinos (crab or crayfish) to describe solid malignant tumour due to the appearance of the cut 
surface of them with "the veins stretched on all sides as 
the animal the crab has its feet, whence it derives its 
name". The Roman physician, Celsus (28-50 B.C.), later 
translated the Greek term into cancer, the Latin word 
for crab.3 The earliest known descriptions of cancer 
appear in seven papyri, discovered and deciphered late 
in the 19th century. Two of them, known as the "Edwin 
Smith" and "George Ebers" papyri, contain descriptions 
of cancer written around 1600 B.C., and are believed to date from sources as early as 2500 B.C.  
Cancer is the general name for a group of more than 100 diseases. Although there are many kinds 
of cancer, all cancers start because abnormal cells 
grow out of control. In most cases, the cancer cells 
form a tumor. Over time, the tumours can invade 
nearby normal tissue, crowd it out, or push it 
aside. Some cancers, like leukemia, rarely form 
tumours but these cancer cells involve the blood 
and blood-forming organs and circulate through 
other tissues where they grow.4 Cancers may be 
caused in one of three ways, namely incorrect 
diet, genetic predisposition, and via the 
                                                          
1 a) S. Sednia, New Approaches to Natural Anticancer Drugs, SpingerBriefs in Pharmaceutilcal Science & Drug Development, 2015; b) A. 
Jemal; F. Bray; M. M. Center; J. Ferlay; E. Ward; D. Forman, CA-Cancer J. Clin., 2011, 61, 69; c) R. Siegel; D. Naishadham; A. Jemal, CA-
Cancer J. Clin., 2012, 62, 10. 
2  J. Ferlay; I. Soerjomataram; M. Ervik; R. Dikshit; S. Eser; C. Mathers; M. Rebelo; D. M. Parkin; D. Forman; F. Bray, 
Cancer Incidence and Mortality Worldwide International Agency for Research on Cancer, 2014. 
3 R. W. Moss, Galen on Cancer, 2004. 
4 http://www.cancer.org/cancer/cancerbasics/what-is-cancer 
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environment. As many as 95% of all cancers are caused by life style and may take as long as 20-30 
years to develop.5 The transformation of a normal cell into a cancerous cell is believed to proceed 
through many stages and one of the most important mechanism contributing to this process is 
considered to be oxidative damage to the DNA. If a cell containing damaged DNA divides before 
the DNA can be repaired, the result is likely to be a permanent genetic alteration constituting a 
first step in carcinogenesis. This stage may remain dormant, and the subject may only be at risk 
for developing cancer at a later stage. The second stage, called promotion, occurs very slowly over 
a period ranging from several months to years. During this stage, a change in diet and lifestyle can 
have beneficial effect so that person may not develop cancer during his or her lifetime. The third 
and final stage involves progression and spread of the disease.6  
A significant feature of tumour cells is their abnormal cell growth and, basically, the conventional 
chemotherapy mostly targets one or more process involved DNA replication and cell division. That 
is why these compounds have high toxicity even with the normal cells, therefore a massive 
fraction of current research in this area is now moving towards molecular therapeutic agents 
targeting the key molecular abnormalities that drive malignant transformation and progression of 
tumours (e.g., kinases related to cell cycle progression or signal transduction).7     
 
1.2. Natural sources as potential anti-cancer agents  
Natural products have been the most significant source of drugs and drug leads in history.8 Plants, 
in particular, have formed the basis of sophisticated traditional medicine systems, with the 
earliest records, dating from around 2600 B.C., documenting the uses of approximately 1000 
plant-derived substances in Mesopotamia. These include oils of Cedrus species (cedar) and 
Cupressus sempevirens (cypress), Glycyrrhiza glabra (licorice), Commiphora species (myrrh), and 
Papaver somniferum (poppy juice), all of which are still used today for the treatment of ailments 
ranging from coughs and colds to parasitic infections and inflammation.9 The ancient medical 
literature reports that the surgery was a common practice, however the physicians also 
recommended the use of some natural products, especially arising from plants. For example, the 
extensive use of traditional Chinese medicine has been documented over the centuries,10 with the 
first record dating from about 1100 B.C. (Wu Shi Er Bing Fang, containing 52 prescriptions). Even 
from the ancient Western world, Dioscorides, a Greek physician (100 C.E.), accurately recorded 
the collection, storage, and use of medicinal herbs during his travels with Roman armies 
                                                          
5 A. Bhanot; R. Sharma; M. N. Nooli; J. of Phytomed., 2011, 3, 9. 
6 L. Reddy; B. Odhav; K. D. Bhoola; Pharm. & Therap., 2003, 99, 1. 
7 K.-H Altmann; Jurg Gertsch; Nat. Prod. Rep., 2007, 24, 327. 
8 G. Tan; C. Gyllenhaal; D. D. Soejarto; Curr. Drug Targets, 2006, 265. 
9 J. K. Borchardt; Drug New Perspect., 2002, 15, 187. 
10 K. C. Huang; The pharmacology of Chinese Herbs, 2nd ed. CRC Press, 1990. 
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throughout the "known world", whilst Galen (130–200 C.E.) a practitioner and teacher of 
pharmacy and medicine in Rome, is well known for his complex prescriptions and formulae used 
in compounding drugs.  
Plants have a long history of use in the treatment of cancer, as reported by Hartwell in his review 
of 1982 where he lists more than 3000 plant species that have reportedly been used against this 
disease.11 To note that in many reports, the word "cancer" is undefined, or related to conditions 
such as "hard swellings", abscesses, warts, calluses, polyps or tumours, to name a few. Such 
symptoms would generally apply to skin, "tangible" or visible conditions, and may indeed 
sometimes correspond to a cancerous condition, but many of the claims for the efficacy of such 
treatment should be viewed with some skepticism because cancer, as a specific disease entity, is 
likely to be poorly defined in terms of folklore and traditional medicine.12 Nevertheless, nature 
has played an important role as a source of effective anticancer compounds. Cragg at al., in their 
well-known publication of 2012, demonstrate as only the 20,2% of the 128 anticancer drugs 
approved or in clinical trials from 01/1981 to 12/2010 are classifiable into the "totally synthetic 
drugs" (S) category. The residual 79.8% are either genuine natural products or are based thereon, 
or mimicked natural products in one form or another (Figure 1).13  
 
Figure 1: N: Derived from an unmodified natural product source; ND: derived from a natural product source (e.g., 
semisynthetics); NM: natural product mimic S: Exclusively from a synthetic source; S*: From a synthetic source, but 
originally modelled on a natural product parent; B: Biologics (monoclonals, etc. derived from mammalian sources); V: 
vaccines; NB: natural product botanical (botanical "defined mixture"). 
In the same review it is possible to find a huge list (filled up to 2012) of anticancer compounds 
arising from natural sources, which normally are classified in plant, marine or microorganism 
                                                          
11 J. Hartwell; Plants Used Against Cancer: A Survey - Quarterman Pub., Incorporated, 1982. 
12 G. M. Cragg; M. R. Boyd; J. H. Cardellina II; D. J. Newman; K. M. Snader; T. G. McCloud; Ethnobotany and drug discovery: The 
experience of the US National Cancer Institute, in: D.J. Chadwick, J. Marsh (Eds.), Ethnobotany and the search for new drugs, ciba 
foundation symposium,  John Wiley & Sons, Inc., New York, NY, 1994, 185, 178. 
13 D. J. Newman; G. M. Cragg; J. Nat. Prod., 2012, 75, 311. 
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sources. It worth to note the incredible diversity and complexity of some molecular structures 
associated with several different mechanisms of action on cancer cells. In the following section 
the most famous classes of anticancer compounds there will be listed, divided on the basis of 
their source (plant, marine-derived or microbial agents). 
1.2.1. Plants as source of anti-cancer agents 
Discovery and development of the vinca alkaloids were the start of the history of plant as source 
of anti-cancer agents (earnest 1950s). Vinblastine and vincristine, belonging to vinca alkaloid 
family, were isolated from the Madagascar periwinkle, Catharanthus roseus or also known as 
Vinca rosea. Regard their general mechanism of action, they bind specifically to -tubulin blocking 
its ability to polymerize with -tubulin into microtubules and therefore prohibiting the mitotic 
spindle formation.14 This leads to the killing of actively dividing cells by inhibiting progression 
through mitosis. Vincristine is largely used in the treatment of haematological and lymphatic 
neoplasm a well as of several solid tumours (vinblastine in breast, testicular cancer ecc.) (Figure 
2).15  
 
Figure 2 
The vinca alkaloids are dimeric asymmetrical compounds consisting of two multi-ringed subunits, 
vindoline and catharantine, linked by a carbon-carbon bridge. From structural modifications of 
vinblastine derive the first new second-generation vinca alkaloid, vinorelbine A. Specifically, the 
carboxylic ester group of vinblastine at position 16 was converted to amide 5 in a reaction with 
refluxing ammonia (Eli Lilly patent)  (Scheme 1).16 
                                                          
14 R. L. Noble; Biochem. Cell Biol., 1990, 68, 1344. 
15 V. T. DeVita; A. A. Serpick; P. O. Carbone; Ann. Intern. Med., 1970, 73, 881. 
16 Eli Lilly Company, DE Patent 22415980, 1974. 
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Scheme 1 
Wall and co-workers in 1971 reported for the first time the structure of paclitaxel (Taxol®; Figure 
3), an high cytotoxic molecule extracted from the bark of Taxus brevifolia which represent today 
the most exciting plant derived anticancer drug discovered in recent years.17 
 
Figure 3 
Its mode of action was discovered by Schiff and Horwitz in 1979 who reported in 1980 its ability 
by inhibiting mitosis through enhancement of the polymerization of tubulin and consequent 
stabilization of microtubules.18 The lack of availability of taxol (yield of extraction: 0.14 g/Kg) have 
prompted extensive searches for alternative sources, such as semisynthesis, total chemical 
synthesis 19  and cellular culture production. 20  In particular the commercial semisynthesis of 
paclitaxel (by Bristol-Myers Squibb), developed by Robert Holton in 1989, starts from 10-
deacetylbaccatin III B (easily extracted with yield 1 g/kg from the fresh leaves of English yew tree 
T. baccata L.) is based on tail addition of the so-called Ojima lactam C to its free hydroxyl group 
(Scheme 2).21 
                                                          
17 M. C. Wani; H. L. Taylor; M. E. Wall; P. Coggon; A. T. McPhail; J. Am. Chem. Soc., 1971, 93, 2325. 
18 P. B. Schiff; S. B. Horwitz; Proc. Natl. Acad. Sci. U.S.A., 1980, 77, 1561. 
19 a) K. C. Nicolaou; Z. Zang; J. J. Liu; H. Ueno; P. G. Nantermet; R. K. Guy; C. F. Claiborne; J. Renaud; E. A. Couladouros; K. Paulvannan; 
E. J. Sorensen; Nature, 1994, 367, 630; b) R. A. Holton; C. Somoza; H. B. Kim; F. Liang; R. J. Biediger; D. Boatman; V. Shindo; C. C. Smith; 
S. Kim; H. Nadizadeh; Y. Suzuki; C. Tao; P. Vu; S. Tang; P. Zhang; K. K. Murthi; L. S. Gentile; J. H. Liu; J. Am. Chem. Soc., 1994, 116, 1597. 
20 S. Kusari; S. Singh; C. Jayabaskaran; Trends in Biotechnology, 2014, 32, 6. 
21 R. A. Holton; Metal Alkoxides. U.S. Patent, 1993, 5, 274, 124.  
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Scheme 2 
Taxol® was approved for clinical use against ovarian cancer in 1992 and against breast cancer in 
1994. The success of paclitaxel spawned extensive studies on the synthesis of analogues: 
docetaxel (Taxotere®; Figure 4), the first one to be developed, was obtained from 10-
deacetylbaccatin III B.  
 
Figure 4 
Paclitaxel and docetaxel are hydrophobic compounds characterized by a taxane ring core and 
unusual fourth ring at the C-4,5 position. The latter, together with a complex ester group at the C-
13 position, is essential for their biological activity. 
In the 1950s, the extraction of the Chinese tree Camptotheca acuminata led to the isolation of an 
high cytotoxic extract active against several solid tumours and leukaemias, but only in 1966 the 
active component of the extract, campthotecin, was identified and characterized.22 Camptothecin 
(as its sodium salt) was dropped after it was found to be really toxic despite promising anti-
tumour activity in the clinical trials. Many years later, irinotecan and belotecan, two semisynthetic 
camptothecin analogues, became the three clinically-active agents against colorectal and ovarian 
cancer (Figure 5).23  
                                                          
22 M. E. Wall; M.C. Wani; C. E. Cook; K. H. Palmer; A. T. McPhail; G. A. Sim; J. Am. Chem. Soc., 1966, 88, 3888. 
23 H. Malonne; G. Atassi; Anticancer Drugs, 1997, 8, 811. 
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Figure 5 
Camptothecin and its derivatives have a basic structure based on five-ring moiety structure with a 
S-conformation chiral centre in the terminal lactone ring. The configuration of stereocenter and 
the hydroxyl group which it is attached are fundamental for biological activity. Camptothecins 
cause DNA damage by stabilizing the covalent topoisomerase I-DNA complex, thus preventing 
religation.24  
1.2.2. Marine organisms as source of anti-cancer agents  
Covering more than 70% of the earth's surface, the world's oceans represent a huge resource for 
the discovery of new anticancer compounds. Marine organisms, such as sponges, bacteria or 
algae, are a unique reservoir for bioactive natural products, with structural features not generally 
found in terrestrial plant metabolites.25 The marine organisms produce these compounds to 
protect themselves against predators, communicate and reproduce. In the last decade, more than 
3000 new compounds have been discovered in marine environments and, among these, a 
number of novel marine compounds have been isolated and tested for anticancer activity.26   
In September 2007 the complex alkaloid isolated from the colonial tunicate Ecteinascidia 
turbinata, ecteinascidin 743, was approved under the name Yondelis® for the treatment of soft 
tissue sarcomas (Figure 6). Moreover it is also currently in a number of clinical trials for breast, 
prostate, liposarcoma and paediatric sarcomas. The issue of compound supply was solved with 
the development of a semisynthetic route from the microbial product cyanosafracin B [48–50] 
(Figure 6).27  
                                                          
24 Y.H. Hsiang; R. Hertzberg; S. Hecht; L.F. Liu; J. Biol. Chem., 1985, 260, 14873. 
25 W. R. Sawadogo; R. Boly; C. Cerella; M. H. Teiten; M. Dicato; M. Diederich; Molecules, 2015, 20, 7097. 
26 H.M. Sarfaraj; F. Sheeba; A. Saba; S.K. Mohd; Indian J. Geo-Mar. Sci., 2012, 41, 27. 
27 C. Cuevas; A. Francesch; Nat. Prod. Rep., 2009, 26, 322.  
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Figure 6 
Another example of anticancer agents extracted from several marine sponges, and approved in 
November 2010 by FDA for the treatment of refractory metastatic breast cancer, is halichondrin B 
(Figure 7).28 
 
Figure 7 
The total synthesis of the complex polyether structure was a hard challange for the drug 
production, but fortunately total synthetic studies revealed that the right hand half of 
halichondrin B (eribulin, Figure 7) retained all or most of the potency of the parent compound. 
Therefore a large-scale synthesis of this bioactive molecule was developed providing the 
necessary amount of eribulin for the clinical trials.29 Eribulin is a microtubule dynamics inhibitor 
that, despite than other known classes of tubulin-targeted agents (taxanes, epothilones, and vinca 
alkaloid) suppresses microtubule polymerization sequestering tubulin into non-functional 
aggregates.30  
Bryostatin 1 (Figure 8), the most-studied member of the family of Bryostatins, was originally 
isolated in the 1960s by Pettit and his collaborators from the invertebrate marine bryozoan, 
Bugula neritina taken from California coast. This marine-metabolite is a complex macrolide 
                                                          
28 M. J. Yu; Y. Kishi; B. A. Littlefield; Anticancer agents from natural products. Taylor and Francis; Boca Raton, FL, 2005, 241. 
29 J. Cortes; J. O’Shaughnessy; D. Loesch; J. L. Blum; L. T. Vahdat; K. Petrakova; P. Chollet; A. Manikas; V. Diéras; T. Delozier; V. 
Vladimirov; F. Cardoso; H. Koh; P. Bougnoux; C. E. Dutcus; S. Seegobin; D. Mir; N. Meneses; J. Wanders; C. Twelves; Lancet., 2011, 377, 
914.  
30 A.I. Spira; N.O. Iannotti; M.A. Savin; M. Neubauer; N.Y. Gabrail; R.H. Yanagihara; E.A. Zang; P.E. Cole; D. Shuster; A. Das; Clin. Lung 
Cancer, 2012, 13, 31. 
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lactone that, thank to its ability to interact with protein kinase C isozymes, it shows an excellent 
anticancer activity against various cancer cells lines, including lung, breast, ovarian, melanoma, 
sarcoma, lymphoma, and leukemia cell lines.31  
 
Figure 8 
The major problem for making it an available drug is the compound supply. Harvesting them from 
the naturally available bryozoan is impractical, and their total chemical syntheses are really long. 
The first total synthesis of bryostatin 1 developed by Gary E. Keck and coworkers of the University 
of Utah in 2011 consists of 58 steps.32  
1.2.3. Microorganisms as source of anti-cancer agents  
Some of the most important drugs of the pharmaceutical industry arise from microorganisms, an 
incredible productive source of structurally diverse bioactive metabolites.33  
Antitumor antibiotics, isolated from various Streptomyces species, represent amongst the most 
important family of the cancer chemotherapeutic agents. Between them, noteworthy are the 
anthracyclines, which their history goes back more than 50 years, when the Italian company, 
Pharmitalia Research Laboratories, found a red pigment expressing antibacterial properties from 
microorganisms living in the soil near the Adriatic Sea. This pigment was purified and studied, and 
became the first recognized anthracycline antibiotic. The first anticancer anthracycline to be 
approved for clinical use was daunomycin in the late 1960s. This compound is still widely used in 
the treatment of several forms of leukemia. A second anthracycline, derived from Streptomyces 
peucetius var. caesius and called doxorubicin, remains a therapeutic milestone for the treatment 
of lymphoma, breast cancer, and most forms of sarcoma (Figure 9).34  
                                                          
31 D. J. Newman; Anticancer agents from natural products. 2. Taylor and Francis; Boca Raton, FL, 2012, 199. 
32 G. E. Keck; Y. B. Poudel; T. J. Cummins; A. Rudra; J. A. Covel; J. Am. Chem. Soc., 2011, 133, 744. 
33 G. M. Cragg; D. J. Newman; Biochim Biophys Acta, 2013, 1830, 3670. 
34 M. S. Ewer; M. D. JDa; D. D. Von Hoff, R. S. Benjamin; Heart Failure Clin., 2011, 7, 363. 
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Figure 9 
Other very important members of antitumor antibiotic family are, for example, bleomycins, 
actinomycins, the enediynes, and the staurosporines.35 
In 1978 Baker e co. reported a new potential antifungal agent produced by Streptomyces 
hygroscopicus, the 31-membered macrocyclic rapamycin (Figure 10).36 
 
Figure 10 
Although the failure of rapamycin as antifungal agent, further studies highlighted its antitumour 
activity against several cancer cell lines. Thus the rapamycin basic structure was used as base for 
further modifications, leading to the development of a wide range of anticancer agents.35    
In recent years, the rise of paclitaxel-resistant tumours in patients encouraged the researchers to 
look for new microtubule stabilizing agents for cancer therapy. The accurate investigation from 
myxobacteria led to the discovery of epothilones, some of the most interesting natural product 
base structures for the development of powerful anticancer drug (Figure 11).37  
                                                          
35 L.-A. Giddings; D. J. Newman; J. Ind. Microbiol. Biotechnol, 2013, 40, 1181. 
36 H. Baker; A. Sidorowicz; S. N. Sehgal; C. Vezina; J. Antibiot., 1978, 31, 539.  
37 D. M. Bollag; P. A. Mcqueney; J. Zhu; O. Hensens; L. Koupal; J. Liesch; M. Goetz; E. Lazarides; C. M. Woods; Cancer Res., 1995, 55, 
2325. 
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Figure 11 
In the mid to late 1980s the 16-membered macrolides epothilones A and B were identified in the 
extracts of the myxobacterium Sorangium cellulosum. Classical fermentation and manipulation of 
the biosynthetic cluster have given significant quantities of different epothilones and, in addition, 
semi- and total syntheses are being performed by a number of research groups affording 
modified macrolide ring. Epothilone B (or patupilone) showed better antineoplastic activity than 
epothilone A in preclinical trials, therefore it has subsequently advanced to further stages of 
clinical development. However, reduced in vivo efficacy was recognized because of its poor 
metabolic stability and pharmacokinetic properties. Since the easy hydrolysis of lactone function 
by esterases was a major obstacle for clinical utility, epothilone B was modified in a lactam 
(ixabepilone). The aza-epothilone B was approved for against metastatic breast cancer by the FDA 
in 2007, and is currently in many trials from Phase I to Phase III against a variety of carcinomas.38 
The last example of a microorganism metabolite reported in this context regard cryptophycins.  
Cryptophycins are a family of macrocylicic depsipeptides firstly isolated from cyanobacteria 
Nostoc sp. ATCC 53789 in 1990. Cryptophycin 1, the main antitumor activity responsible of the 
bacteria extract, and cryptophycin-52, the highly bioactive synthetic derivative, display 
remarkable cytotoxicity even against multi-drug resistance (MDR) cancer cells (Figure 12).  
 
Figure 12 
Their bioactivity is based on their interaction with the -subunit of /-tubulin dimers inducing 
apoptosis due to inhibition of the microtubule dynamics. The IC50 of cryptophycin 1 and 
                                                          
38 G. Hofle; H. Reichenbach; Anticancer agents from natural products. Taylor and Francis; Boca Raton, FL, 2012, 513. 
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cryptophycin-52 show 100- to 1000-fold increased in vitro activity compared to paclitaxel or Vinca 
alkaloids. However, in vivo they display high cytotoxicity, therefore numerous synthetic analogues 
have been designed for structure–activity relationship (SAR) studies to improve the cancer cells 
selectivity. Norbert Sewald and co-workers in 2013 published a comprehensive review regarding 
modified cryptophycins.39  
 
2. Chapter 2 
2.1. Biosynthesis principles 
The life of all living organisms is ensured by continuous transformation and modification of a wide 
number of organic compounds. The metabolic pathway is the term used to indicate the pathways 
in which an integrated network of enzyme-mediated and regulated chemical reaction works for 
this purpose. There are two kinds of metabolisms:  
 primary metabolism, which describes the processes involved the formation of the crucial 
important molecules of life (carbohydrates, proteins, fats and nucleic acids); 
 secondary metabolism, which concerns the production of compounds with more limited 
distribution in nature. 
Despite the incredible varied features of living organisms, the primary metabolites are generated 
essentially through the same pathways, apart from minor variations. In contrast, the secondary 
metabolites are found in only specific organisms, or group of organisms, and are expression of the 
individuality of species. The function of these compounds is not always clear, but it is logical to 
assume that all of them do play some vital role of the producer. Most of the pharmacologically 
active natural products belong in the area of secondary metabolites. 
Surprisingly, only few molecules are used by natural products biosynthesis processes as main 
building blocks. For instance, intermediates of acetyl coenzyme A, shikimic acid, mevalonic acid, 
and 1-deoxyxylulose 5-phosphate, which are furnished from the primary metabolism (Scheme 3).   
In addition to these, other building blocks based on amino acids are frequently employed in 
natural product synthesis. 
 
                                                          
39 C. Weiss; B. Sammet; N. Sewald; Nat. Prod. Rep., 2013, 30, 924. 
 
19 
 
 
Scheme 3 
The follow scheme shows the most frequently basic units that it is possible to encounter when the 
carbon and nitrogen skeleton of each natural product is dissected in a retrosynthesis process 
(Scheme 4).  
Briefly: 
 C2 unit may be supplied by acetyl-CoA; 
 C5 is the so-called "isoprene unit" and it is formed from mevalonate or deoxyxylulose 
phosphate; 
 C6C3 is obtained from the carbon moiety of either L-phenylalanine or L-tyrosine and it is 
referred to a phenylpropyl unit; 
 C6C2N unit has the same origin of  C6C3 unit, but carboxyl group of the amino acid is 
removed; 
 indole.C2CN unit arises from L-tryptophan; 
 C4N unit is produced from the non-protein amino acid L-ornithine and it is usually found 
as a pyrrolidine; 
 C5N unit, found as piperidine, is produced in the same way as unit above, but using L-
lysine instead of L-ornithine. 
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Scheme 4 
Throughout the biosynthetic processes, the formation of new carbon-carbon bonds occur 
generally with Aldol and Claisen condensations, in most cases, between coenzyme A esters; 
otherwise some rearrangements are possible, such as Wagner-Meerwein rearrangement. The 
formation of C-N bonds is frequently achieved either by condensation reactions between amines 
and aldehydes or ketons affording Schiff bases, or in other cases by Mannich reactions. Also 
oxidation and reduction enzyme-mediated reactions are important for reaching the elaborate 
final product, even if these processes are not always completely understood.40   
According to the biosynthetic strategies for their assembly in the producer organisms, therefore 
sharing the same scaffold elements, natural products can be divided into several structural 
classes, mainly in polyketides (PKSs), nonribosomal peptides (NRPs), terpenes, and alkaloids. 
                                                          
40 P. M. Dewick; Medicinal Natural Products: A Biosynthetic Approach, Wiley 
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Polyketides constitute a large family of microbial and plant-derived bioactive natural product 
including linear, polycyclic, and macrocyclic structural forms. These secondary metabolites display 
various molecular weight and functional group modification and, moreover, they show a wide 
range of bioactivity such as antibiotic, antiparassitic, antiviral and antitumor activity. More details 
are described in the chapter 7. 
 
Nonribosomal peptides (NRPs) are a structurally diverse class of peptides with various functions, 
such as cytostatic, immunosuppressive, antibacterial, or antitumor properties produced by a large 
multidomain enzymatic machineries called nonribosomal peptide synthetases (NRPSs). These 
megaenzymes is formed by catalytic domains which catalyse complex regiospecific and 
stereospecific reactions to assemble structurally and functionally diverse peptides in an iterative 
chain elongation process (Figure 13).41 Furthermore, aside from the common amino acids, a larger 
variety of chemical groups, such as D- amino acids, fatty acids ecc., is found in these bioactive 
compounds. They contribute to structural versatility of NRPs and are known to be important for 
bioactivity.
 
a)                                                                                             b) 
Figure 13: a) Simplified mechanism of nonribosomal peptide (NRP) synthesis. (1) The amino acid is activated as 
aminoacyl-AMP by the adenylation domain. (2) Transfer of the amino acid onto the PCP domain. (3) Condensation of 
PCP-bound amino acids. (4) Possibility of amino acid modifications, for example by epimerization domains. (5) 
Transesterification of the peptide chain from the terminal PCP onto the TE domain. (6) TE catalyzed product release by 
either hydrolysis or macrocyclization. b+) Example of nonribosomally assembled, clinically approved antitumour 
peptide.       
Terpenes or isoprenoids constitute the most chemically diverse class of natural products. They are 
found in almost all living organisms where they have a myriad of different vital or no-vital 
functions (cholesterol, carotenoids). Most terpenoids are derived from successive condensations 
"tail-to-tail" or "head-to-tail" between the C5 units dimethylallyl diphosphate (DMAPP) and 
isopentenyl diphosphate (IPP) leading to mono- (C10), sesqui- (C15), di- (C20), sester- (C25), tri- (C30), 
                                                          
41 M. Strieker; A Tanovic; M. A. Marahiel; Current Opinion in Structural Biology, 2010, 20, 234. 
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tetra- (C40), and poly- (C5n (n = > 8)) terpenes (Scheme 5).42 The ability of the Cn precursor to 
undergo various way of cyclization and subsequent “decoration” reactions affords to the chemical 
diversity of terpenoids. For example Baccatin III, the diterpenoid part of the well-known 
anticancer drug paclitaxel, is a monocyclic diterpenoids with a 14-carbon macrocyclic ring called 
cembrane (compound B, Scheme 2).  
Scheme 5 
 
The modern definition for the wide and diversify class of alkaloids has been given by S. W. 
Pelletier, saying: 
"An alkaloid is a cyclic organic compound containing nitrogen in a negative oxidation state 
which is of limited distribution among living organisms." 43  
For this class of natural compounds it is really difficult to find an unified classification due to the 
incredible differences between the members. Therefore they are grouped into many classes 
based on their origin and the nature of the nitrogen-containing moiety. Also the biosynthesis 
pathway of alkaloids could be very different between each other: commonly they are originated 
from the amino acids, but they are also known to arise from mixed biosynthetic processes, the 
most important of which include terpenoid and steroidal alkaloids. 44  Due to their huge 
differences, herein I will not explain more in detail their biosynthesis. 
 
2.2. Design and synthesis of analogues of natural products 
During their biosynthesis, natural products (NPs) interact with biosynthetic enzymes and proteins. 
Thus they have already interacted with different biological systems, such as enzymes and 
proteins, and that is why, essentially, all natural products have some receptor binding capacity 
                                                          
42 E. Oldfield; F.-Y. Lin; Angew. Chem. Int. Ed., 2012, 51, 1124. 
43 S. W. Pellettier; Alkaloids: Chemical and Biological Perspectives, 1st Edition, 2001. 
44 E. Poupon; B. Nay; Wiley-vch Verlag GmbH & Co. KGaa, 2011. 
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and they are so attractive for the drug discovery world.45 Comparing a synthetic molecule with a 
second metabolite, it is noticed that there are a number of structural substantially differences 
between NPs from synthetic ones.46 Jon Clardy and Christopher Walsh in their paper47 describe 
the key futures of these diversities, briefly summarized in the following list: 
 a larger fraction of sp3 carbons (most of the rings are partly or completely saturated); 
 more stereogenic centres often arising from C-C bond formation reactions (aldol 
condensations) or stereoselective reduction of a carbonyl group; 
 relatively more carbon, hydrogen and oxygen, and less nitrogen and other elements; 
 have more fused, bridge, and spiro rings; 
 molecular masses in excess of 500 daltons and high polarities (greater water solubility). In 
those cases, they violate Lipinski’s ‘rule of five’, easy rules based on calculated properties 
that normally help to rationalize and improve the profile of putative synthetic drugs. 
When some interesting compound is identified through the High Throughput Screening (HTS) and 
it is extracted from the original natural source, chemists start to study a possible chemical 
synthesis of it in order to mimic its bioactivity. In fact, it very often happens that it is a hard 
challenge obtaining a renewable supply of active compounds from biological sources. However, 
the high level of their complexity structure can limit the total synthesis and/or the essential 
chemical modifications of the natural scaffold to optimize their therapeutic use.  
The chemistry of NPs, as well as medicinal chemistry, has made massive progress about the 
reproduction of natural compounds in laboratory, developing a collection of typical reactions to 
achieve their respective target compounds. Regarding medicinal chemistry, a set of their common 
transformations used in this topic is enclosed into a medicinal chemist's toolbox". Indeed a 
"process chemist's toolbox" has been described to identified the typical reactions used during the 
scale up of the synthesis of potential new drugs arising from medicinal chemistry studies. Finally, 
the description of a "toolbox of a NPs chemist" was reported by Natalia Vasilevich & co in 2012. 48 
In this paper they compared the three toolboxes in a clear table, herein showed, where there are 
the main reactions used to reach the complexity of NPs-like compounds (Figure 14). On the basis 
of this analysis, there are many different issues between them, and the authors conclude saying:  
"The enrichment of “the toolbox of medicinal chemistry” with reactions used during the synthesis 
of natural product may enable us to hit such difficult drug targets that have emerged in recent 
years". 
                                                          
45 E.Kellenberger; A. Hofmann; R. J. Quinn; Nat. Prod. Rep., 2011, 28, 1483. 
46 K. Grabowski.; G. Schneider; Curr. Chem. Biol., 2007, 1, 115. 
47 J. Clardy; C. Walsh; Nature, 2004, 432, 829. 
48 N. I. Vasilevich; R. V Kombarov; D. V. Genis; M. A. Kirpichenok; J. Med. Chem., 2012, 55, 7003. 
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Figure 14 
Besides single trasformations, chemistry related to NPs also provides many synthetic strategies. 
The first one that herein will be discuss, is the divergent strategy approach. 
Divergent strategy in natural product synthesis allows the construction of array of compounds 
with small structural differences. When they are 
evaluated, they could offer precious information useful to 
build a detailed structure–activity relationship, which 
would not be available from a single-shot scrutiny of a 
certain molecule.49  
Diversity-oriented synthesis is one of the most famous 
divergent strategy. Originally proposed by Schreiber, it is involved the synthesis of a library of 
diverse small molecules covering a large portion of chemical space (multi-dimensional molecular 
descriptor space, where descriptors are characteristics of the compounds such as molecular 
weight) for biological screening. Thus DOS libraries can be used to identify new ligands for a 
variety of targets.50  
Very related with DOS there is the concept of ‘Diverted total synthesis’ (DTS). It was proposed by 
Danishefsky and it is concerned the preparation of a natural product-like compound library by the 
derivatization of a versatile synthetic intermediate. The story of Ixabepilone (Figure 11), the only 
epothilone that has been approved by FDA so far, represents one of the most famous cases of 
                                                          
49R. W. Huigens; K. C. Morrison; R. W. Hicklin; T. A. Flood; M. F. Richter; P. J. Hergenrother; Nat. Chem., 2013, 5, 195. 
50 M. D. Burke; S. L. Schreiber; Angew. Chem. Int. Ed., 2004, 43, 46. 
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diverted total synthesis.51 Its structure has been originated from several SAR studies (structure–
activity relationship) made on many semisynthetic epothilone analogs, and all of them are 
semisynthetic derivatives deriving from the key intermediate Epo B.  
In the DTS field, the case of pironetin analogues is another important example. Pironetin is an 
antitumor agent that exerts its activity by binding to α-tubulin, therefore it inhibits the assembly 
of tubulin to microtubules. Marco et al. simplifying the syntheses significantly, synthesized four 
analogues of the NP pironetin removing the alkyl groups at C4, C8 and C10 (Figure 15).52 
 
Figure 15 
Through the biology-oriented synthesis (BIOS), a NP core scaffold of a lead bioactive compound is 
taken as privileged structure for the creation of a novel compound collection. Basically, the idea is 
that the same core scaffold could maintain the match with many target ligand sites, therefore it 
could have a similar bioactivity. Noscapine is a famous cough suppressant and more recently it 
was discovered an excellent antitumour activity as microtubule inhibitor (Figure 16). Using this 
synthetic approach, 18 compounds based on the tetrahydroisoquinoline scaffold were prepared 
and, not surprisingly, 7 of them interfere with microtubule polymerization.53 
 
Figure 16 
                                                          
51 K.-H. Altmann; F. Z. Gaugaz; R. Schiess; Mol. Diversity, 2011, 15, 383. 
52 M. Carda; J. Murga; S. Díaz-Oltra; J. García-Pla; J. Paños; E. Falomir; C. Trigili; J. F. Díaz; I. Barasoain; J. A. Marco; Eur. J. Org. Chem., 
2013, 1116. 
53 S. Rizzo; H. Waldmann; Chem. Rev., 2014, 114, 4621. 
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In order to create new bioactive molecules it is also possible to combine partial or whole 
structures of molecules: this concept is well explained by the 
term "hybrid molecules".54 There are three categories of 
hybrid molecules: a) both parts act on the same target, b) 
each part acts on a different target, c) both parts bind to one 
target at closely related binding sites. 55  An interesting 
example, from the synthetic point of view, is the synthesis of 
an hybrid between epothilone B and 16-membered 
macrosphelide derivative, which are able to induce apoptosis 
in human lymphoma U937 cells.56 The formed compound showed significantly higher apoptosis-
inducing activity than the parent macrosphelides (Figure 17).  
 
Figure 17 
Finally, in many case a detailed knowledge of the whole biosynthetic process about one particular 
metabolite, can be employ for the synthesis of NPs analogues through a process called 
mutasynthesis. As already mentioned above, in bacteria and fungi several molecules are 
biosynthesized through particular megaenzymes, such as no-ribosomial-peptide synthase and 
polyketide synthase. Exploiting the mutasynthesis concept, a mutant organism could be generate 
modifying or deleting one or more genes responsible for important steps throughout the 
biosynthesis pathway of a bioactive natural product. Therefore it is possible to obtain a new 
natural compound directly from a microorganism that by total synthesis would not be available so 
                                                          
54K. Suzuki; Chem. Rec., 2010, 10, 291. 
55B. Meunier; Acc. Chem. Res., 2007, 41, 69. 
56Y. Matsuya; T. Kawaguchi; K. Ishihara; K. Ahmed; Q.-L. Zhao; T. Kondo; H. Nemoto; Org. Lett., 2006, 8, 4609. 
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efficiently. Geldanamycin is a benzoquinone ansamycin antibiotic that manifests anti-cancer 
activity through the inhibition of HSP90-chaperone function. Kirschning and his group have been 
able to prepare a range of its derivatives feeding various 3-aminobenzoic acids to the mutant 
strain of S. hygroscopicus in which the synthesis of the natural starting unit was blocked (Figure 
18).57 
 
Figure 18  
                                                          
57 S. Eichner; H. G. Floss; F. Sasse; A. Kirschning; Chem. Bio. Chem., 2009, 10, 1801. 
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The present work is focused on the design, synthesis and biological evaluation of several new 
potential anticancer compounds based on natural product scaffolds.  
The third chapter will be described the synthesis and the biological evaluation 
of a 1,7,8,8a-tetrahydro-3H-oxazolo[3,4-a]pyrazin-6(5H)-one series in which 
the basic scaffold should mimic the privileged structure oxazole-piperazine 
unit present in several biological active compounds. Biological tests showed 
that the obtained compounds are endowed with an interesting antitumor activity against two 
human thyroid cancer cell lines, namely FTC-133 and 8305C, by promoting the apoptotic pathway 
and DNA fragmentation. 58 
Develop of two synthetic approaches to obtain the racemic mixture and the pure enantiomers of 
boehmeriasin A is the central topic of chapter 4. Boehmeriasin A is a 
phenanthroquinolizidine alkaloid isolated from Boehmeria siamensis 
Craib and it showed a strong cytotoxic activity at the nanomolar range 
against different cancer cell lines. Topoisomerases and SIRT2 are 
identified as biological targets and the experimental data has been 
supported by docking studies.59 
In the chapters 5 and 6 will be discussed the results regarding the design and synthesis of new 
microtubule-inhibitors.  
In the first one pironetin and dumetorine core are taken as natural 
privileged scaffold for making a hybrid molecule able to covalently bind 
the -tubuline. The novel built molecule can exist in 8 different 
stereoisomers due to the presence of three stereocenters, therefore all 
of them were synthesized and evaluated on their ability to interfere with microtubule assembly in 
vitro. 
Later, following the "diverted total synthesis" approach, the synthesis of epothilone derivative 
was planned in order to reach a new anticancer compound 
having a triazole ring instead of an amide group. The 
microtubule stabilizing ability of epothilones is very attractive 
either for the consequent high cytotoxicity showed against 
                                                          
58U. Chiacchio; V. Barbera; R. Bonfanti; G. Broggini; A. Campisi; S. Gazzola;R. Parenti; G. Romeo; Bioorg. Med. Chem., 2013, 21, 5748. 
59 M. S. Christodoulou; F. Calogero; M. Baumann; A. Garcìa-Argaiez; S. Pieraccini; M. Sironi; F. Dapiaggi; R. Bucci; G. Broggini; S. Gazzola; 
S. Liekens; A. Silvani; M. Lahtela-Kakkonen; N. Martinet, A. Nonell-Canals; E. Santamaria-Navarro; I. R. Baxendale; L. Dalla Via; D. 
Passarella; Eur. J. Med. Chem., 2015, 92, 766.  
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cancer cells or for its demonstrate neuroprotective effect in Parkinson's disease thanks to its 
ability to cross the blood-brain barrier.60 
Chapter 7 gives an account of my research project carried out in my first foreign experience in the 
laboratories of Prof. Manuela Tosin (Warwick University, UK). The Tosin's group has developed a 
chemical strategy for the isolation of biosynthetic intermediates produced by polyketide synthase 
megaenzimes, in order to achieve a deep knowledge of biosynthetic processes of important 
bioactive natural products, such as antibiotics or anticancer compounds for combinatorial 
chemistry or mutasynthesis purpouse. Lasalocid A is 
a polyketide produced by type 1 polyketide synthase 
(PKS1) in S. lasaliensis that belong to the wide family 
of polyether antibiotics. These bioactive natural 
compounds are active against several critical 
infectious diseases and, further, some of them have the ability to selectively kill cancer stem cells. 
A detailed investigation of Lasaloicid A biosynthesis was performed in order to i) identified and 
isolate all polyketide biosynthetic intermediates and ii) to study new chemical functionalizations 
in vivo on polyketide intermediates, affording novel putative bioactive molecules.61  
                                                          
60D. Cartelli; F. Casagrande; C. L. Busceti; D. Bucci; G. Molinaro; A. Traficante; D. Passarella; E. Giavini; G. Pezzoli; G. Battaglia; G. 
Cappelletti; Sci Rep., 2013, 3, 1837. 
61 E. Riva; I. Wilkening; S. Gazzola; A. W. M. Li; L. Smith; P. F. Leadlay; M. Tosin; Angew. Chem. Int. Ed., 2014, 53, 11944. 
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Chapter 3 
 
Synthesis and biological evaluation of 
novel oxazole-pyrazine based derivatives 
as anticancer agents  
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3.1. Introduction 
Due to their biological properties, nitrogen- and oxygen-containing heterocyclic compounds 
constitute a huge group of organic molecules present in the majority of clinically approved 
drugs.62 Compounds currently investigated as natural potent drug candidates incorporate many 
variants of five and six-membered rings, including piperazines and oxazoles.  
The piperazine scaffolds occur frequently in complex natural products, and are reported to elicit a 
broad spectrum of pharmacological activities like antibacterial, antifungal and 
anticancer activity.63  
One of the most famous commerciable available anticancer drug containing the 
piperazine ring is Imatinib (Figure 19), marketed by Novartis as Gleevec (Canada, South Africa and 
the USA) or Glivec (Australia, Europe and Latin America). It is a potent inhibitor of the tyrosine 
kinase activity used in the treatment of multiple cancers of the BCR-ABL1 oncoprotein, as well as 
that of several receptor tyrosine kinases.64  
 
Figure 19 
Imatinib was developed in the late 1990s by rational drug design: after the "Philadelphia 
chromosome" mutation and hyperactive "bcr-abl" protein were discovered, the investigators 
through high-throughput screening identified 2-phenylaminopyrimidine as lead compound. After 
previous tests, it was modified by the introduction of methyl and benzamide groups to give it 
enhanced binding properties, resulting in imatinib.65  
Like piperazines, oxazole containing compounds are very common in natural products, and they 
play an important role in medicinal chemistry showing a broad spectrum of biological 
activity such as antimicrobial, antitumor, analgesics and anti-inflammatory agents.66 
For example, telomestatin (Figure 20), is a potent telomerase inhibitor currently in 
clinical trials, containing linked oxazoles with a thiazoline unit. 
                                                          
62 M. Sainsbury, Heterocyclic Chemistry, Basic Concepts in Chemistry, Wiley Interscience and Royal Society of Chemistry, Bristol, 2002. 
63 Chapter 5; piperazines, Pharm. Lib., 1997, 25, 148. 
64P. W. Manley; F. Blasco; J. Mestan; R. Aichholz; Bioorg. Med. Chem., 2013, 21, 3231. 
65 J. Zimmermann; E. Buchdunger; H. Mett; T. Meyer; N. B. Lydon; Bioorg. Med. Chem. Lett., 1997, 7, 187. 
66 Z. Jin; Nat. Prod. Rep., 2009, 26, 382. 
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Figure 20 
Inhibiting the telomerase activity of cancer cells, telomestatin induces apoptosis once the 
telomeres are too short to be transcribed. Indeed, from literature it is easy to figure the 
pharmacological importance of oxazole derivatives out when it is present into the prospective 
pharmaceutical candidate: typically an improved of compound’s solubility occurs, while 
maintaining hydrogen bond acceptors, as well as an enhancement of compound’s rigidity. 
Furthermore, oxazole provides many sites for potential binding interactions through π- stacking 
with a biological target.67 
Noteworthy natural compounds containing the oxazole ring fused into a piperazine core are (-)-
quinocarcin and (-)-tetrazomine. (-)-Quinocarcin is an alkaloid that was isolated by Takahashi and 
Tomita in 1983 from the culture broth of Streptomyces melunoVinuceus.68 It exhibited potent 
antitumor activities against a variety of tumor cell lines, above of all against lymphocytic 
leukemia). The structurally related (-)-tetrazomine is an antitumor antibiotic that displayed similar 
activity (Figure 21). 
 
Figure 21 
In both molecules seems that the oxazole ring exerts a fundamental role in the bioactivity, in fact 
it has been suggested that their cytotoxic activity arises from the expression of multiple 
mechanisms including the mediation of oxidative damage to DNA via the reduction of molecular 
oxygen to superoxide by the autoredox disproportionation of the fused oxazolidine.69  
From the biological point of view, in anticancer drug discovery, small-molecular-weight 
compounds, that are able to activate many proteins by signal transduction cascades, have 
attracted significant scientific interest due to the medicinal, biochemical and biological 
                                                          
67 G. Haberhauer; E. Drosdow, T. Oeser; F. Rominger; Tetrahedron, 2008, 64, 1853. 
68 K. Takahashi; K. Shimizu; J. Antibiot., 1983, 463. 
69 Y.-C. Wu; M.´l. Liron; J. Zhu; J. Am. Chem. Soc., 2008, 130, 7148. 
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implications of important molecular recognition events. These events occur when an extracellular 
signalling molecule activates a specific receptor located on the cell surface or inside the cell and, 
in turn, this receptor triggers a biochemical chain of events inside the cell, creating a response 
(Figure 22). 
 
Figure 22 
Depending on the cell, the response alters the cell's metabolism, shape, gene expression and thus 
it could induce the programmed cell death (apoptosis). 
 
3.2. Aim of this work 
As part of our medicinal chemistry program aimed at the discovery of potential anticancer agents, 
we have addressed our attention to the synthesis of a novel series of derivatives containing the 
oxazolo–piperazine pharmacophore 2 through a selective palladium-catalyzed double 
intramolecular domino process of alkenylureas (Scheme 6). 
 
Scheme 6 
Thanks to previous computational studies, these "small molecules" have been traced to 
commercial available drug sunitinib, a tyrosine kinase inhibitors used in the treatment of various 
thyroid cancer (Figure 23). 
 
Figure 23 
 
36 
 
Therefore all bicyclic products were evaluated for their antitumor activity on human follicular 
(FTC-133) and anaplastic (8305C) thyroid carcinoma cell lines, as representatives of two 
aggressive types of thyroid cancer.  
 
3.3. Chemistry 
In the field of our ongoing interest regarding the construction of hetero-polycyclic compounds 
through palladium catalysis,70 we have recently reported the selective double intramolecular 
aminooxygenation and diamination reactions of alkenylureas to yield bicyclic products containing 
a piperazinone ring (Scheme 7).71 
 
Scheme 7 
These Pd(II)-catalyzed protocols under microwave irradiation provided selectively 3-arylimino-
oxazolo[3,4-a]pyrazin-6-one and 2-aryl-imidazo[1,5-a]pyrazin-3,6-dione derivatives in few steps 
from readily available precursors. The isomeric oxazolo- and imidazo-piperazinone structures 
were defined thanks to 13C NMR spectra, where the resonance of the methylene group of the five-
membered ring resulted to be less shielded for the oxazole ring compared with the imidazole one 
(65-70 ppm vs. 41-46 ppm), consistent with the literature data.72  
The aminooxygenation process, which can also be carried out in satisfactory yield by conventional 
heating, was used to prepare 1,7,8,8a-tetrahydro-3H-oxazolo[3,4-a]pyrazines 2a-d, target 
compounds for later biological studies. Firstly, the reaction between N-Boc-glycine 3 with 
cyclohexyl- or phenyl-allylamine 4, activated by DCC and DMAP, afforded the N-allyl-amides of 
Boc-glycine 5. These intermediates were converted to the corresponding allylamides 6 by removal 
of the t-butoxycarbonyl group, and then treated with the respective aryl isocyanates 7. Finally, 
the double cyclization of the alkenyl ureas 1a-d was performed using PdCl2(MeCN)2 as catalyst 
and CuCl2 (3 equiv) as oxidant in THF under reflux for 12 hours with high yields (Scheme 8). 
                                                          
70 G. Broggini; E. Borsini; A. Fasana; G. Poli; F. Liron; Eur. J. Org. Chem., 2012, 3617. 
71 G. Broggini; V. Barbera; E. M. Beccalli; U. Chiacchio; A. Fasana; S. Galli; S. Gazzola; Adv. Synth. Catal. 2013, 355, 1640. 
 
72 a) T. H. Kim; G. J. Lee; J. Org. Chem., 1999, 64, 2941; b) F. Saczewski; J. Saczewski; M. Gdaniec; Chem. Pharm. Bull., 2001, 49, 1203; c) 
T. H. Kim; N. Lee; G. J. Lee; J. N. Kim; Tetrahedron, 2001, 57, 7137. 
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Scheme 8 
In mechanicistic point of view, the aminooxygenation product could arise from an intramolecular 
nucleophilic attack by the oxygen atom of the urea on the -alkyl-complex A (Scheme 9). In 
particular, CuCl2 would inhibit the palladium -hydride elimination favouring the loss of the Pd 
species through the formation of a heterobimetallic -Pd/Cu complex.73 The process generates 
the intermediate B and the elimination of H+ furnishes the products 2a-d.  
 
Scheme 9 
  
                                                          
73 For the concept of a heterobimetallic -Pd/Cu complex, see: a) P. Szolcsanyi; T. Gracza; Tetrahedron. 2006, 62, 8498; b) D. Zargarian; 
Organometallics, 1991, 10, 2914; c) T. Hosokawa; T. Uno; S. Inui; S.-I. Murahashi; J. Am. Chem. Soc., 1996, 118, 3990. 
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3.4. Biological evaluation 
3.4.1. Cytotoxic effect of the compounds 
The synthesized final products 2a-d (Figure 24) were tested to investigate their potential 
antitumor activity on two cancer cell lines, FTC-133 and 8305C, as representative of follicular and 
anaplastic thyroid human cancer, respectively. 
 
Figure 24 
The cell viability was monitored by MTT assays. 
The MTT colorimetric assay uses the tetrazolium yellow dye 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) to quantify the metabolic activity of cells. In fact this 
molecule is easily reduced by NAD(P)H-dependent cellular oxidoreductase enzymes to its 
insoluble formazan, which has a purple colour (Scheme 10).  
 
Scheme 10 
Rapidly dividing cells like tumour cells exhibit high rates of MTT reduction, that is why this assay 
can be useful for measuring cytotoxicity (loss of viable cells) or cytostatic activity (shift from 
proliferation to quiescence) of potential medicinal agents and toxic materials.  
In preliminary experiments, FTC-133 and 8305C cell line cultures were exposed to different 
concentrations (5–100 M) of the synthesized compounds 2a-d. Using the respective untreated 
cell cultures as controls, it was found that 50 M is the optimal concentration for having a 
significant reduction in cellular viability in both FTC-133 and 8305C cell lines after 24 h of 
treatment. Analysing the IC50 values (50% cytotoxic inhibitory concentration) reported in Table 1, 
it is evident that all compounds displayed cytotoxic effects on the both cell lines, at 
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concentrations ranging from 44 to 80 M and that FTC-133 cells were more susceptible to 
treatment with compounds 2a-d, than the 8305C cells. 
Table 1: Concentrations (M) of compounds 2a-d that induced 50% decrease (IC50) in FTC-133 and 8305C 
cell proliferationa 
Cell lines Untreated 
cells 
2a 2b 2c 2d 
FTC-133 >100 50.03 ± 3.90 44.79 ± 4.27 48.32 ± 2.98 74.21 ± 3.93 
8305C >100 70.66 ± 2.13 61.03 ± 3.71 68.45 ± 3.71 80.28 ± 4.52 
a FTC–133 and 8305C cell lines were incubated with drug compounds in concentration ranging from 5 to 100 M at 37 
°C in a 5% CO2 atmosphere for 24 h. Viability was determined by the MTT assay. Each data represents mean ± SD from 
four independent experiments, performed in triplicate. 
 
3.4.2. Evaluation of the apoptotic pathway activation 
In mammals the apoptosis can be initiated by three different pathways, each of these converges 
to a common execution phase of apoptosis that requires 
proteolytic activation of caspases-3, a cysteine-aspartic 
protease, from its inactive proenzymes (Figure 25). 74 
To investigate whether the new compounds could 
activate the caspase-3 dependent apoptotic pathway 
process in the treated cancer cells, the amount of 
caspase-3 was evaluated after 24 h of cell incubation at 
50 M concentration of 2a-d using fluorescent 
microscope analysis. Significant enhancement of caspase-3 positive cells was detected after 24 
hours of treatment in FTC-133 and 8305C cell lines, when compared to the untreated control. The 
effect appeared more evident in FTC-133 cell lines, with compound 2d showing the lowest activity 
with respect 2a-c (Figure 25).  
 
Figure 25: Fluorescent microscope analysis of caspase-3 cleavage in (A) FCT-133 and (B) 8305C human thyroid cancer 
cell lines, untreated (control) and treated with 50 M 2a-d for 24 h. Scale bars = 50 m. 
                                                          
74 S. Ghavami; M. Hashemi; S. R. Ande; B. Yeganeh; W. Xiao; M. Eshraghi; C. J. Bus; K. Kadkhoda; E. Wiechec; A. J. Halayko; M. Los; J. Med. Genet., 
2009, 46, 497. 
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Table 2 show the quantification and statistical analysis of caspase-3 immunolabeling in FCT–133 
and 8305C human thyroid cancer cell line cultures untreated (Control) and treated with 50 M 2a-
d for 24 h. 
Table 2 
 % Caspase-3 positive FTC-133 cell lines % Caspase-3 positive 8305C cell lines 
Treatment 24 h 24 h 
Control 2.51 ± 1 3.22 ± 1 
2a 88.68 ± 1 75.88 ± 1 
2b 90.56 ± 2 78.56 ± 2 
2c 89.24 ± 2 68.30 ± 3 
2d 29.30 ± 3 18.24 ± 2 
 
3.4.3. Evaluation of DNA fragmentation and molecule/DNA labeling 
The apoptosis process involves also the DNA fragmentation. The synthesized compounds were 
tested to prove the DNA fragmentation and the eventual molecule/DNA labeling in untreated and 
treated FTC-133 and 8305C thyroid cancer cell lines. We observed that all the molecules tested, 
and prevalently 2a-c compounds, were able to induce DNA fragmentation in treated cancer cell 
lines. The effect appeared more evident in FTC-133 cancer cell lines. Furthermore, to assess the 
molecule/ DNA labeling, gel electrophoresis was performed in absence or in presence of SYBR 
Green I, a well-known fluorescent dye that binds specifically to double-stranded DNA (Figure 26). 
Molecule/DNA labeling was detected only in presence of the fluorescent dye. The obtained data 
show that all the molecules induced DNA fragmentation at a different degree. 
 
Figure 26: DNA fragmentation in untreated or treated FTC-133 (left) and 8305C (right) cells with 50 M of 2a-d for 24 h. 
Gel electrophoresis was performed in presence of SIBER Green I. Glyceraldehyde-3-phosphate dehydrogenase-1 
(GAPDH-1) gene was used as a reference gene to normalize target gene expression. 
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3.5. Conclusion 
In summary, with this work we developed an efficient synthesis of a series of oxazolo[3,4-
a]pyrazin-6(3H)-ones through a procedure based on a double intramolecular domino process 
catalyzed by PdCl2(MeCN)2/ CuCl2 performed on different alkenyl ureas.  
Biological tests indicate that the obtained compounds have an interesting antitumor activity 
against two thyroid human cell lines, by activating caspase-3 dependent apoptotic pathway and 
DNA fragmentation with a prevalent action on follicular type.  
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3.6. Experimental part 
3.6.1. Synthesis 
Flash column chromatography was performed employing 230 – 400 mesh silica gel. Analytical thin 
layer chromatography was performed on silica gel 60 F254. Melting points were measured with a 
Büchi B-540 apparatus and are uncorrected. IR spectra were recorded on a Nicolet 550 FT-IR 
spectrophotometer. Nuclear magnetic resonance spectra were acquired on Varian instrument at 
200 or 500 MHz for 1H NMR and 125 MHz for 13C NMR. 13C spectra were 1H decoupled and 
multiplicities were determined by the APT pulse sequence. EI mass spectra were recorded at an 
ionizing voltage of 6 KeV on a VG 70-70 EQ. Elemental analyses were executed on a Perkin–Elmer 
CHN Analyzer Series II 2400.  
General procedure for the preparation of alkenyl ureas 1  
 
Trifluoroacetic acid (3 mL) was added to a solution of allyl-amide 5 (1 mmol) in CH2Cl2 (3 mL). The 
mixture was stirred at room temperature for 1 h. The solvent was evaporated to dryness and the 
residue was taken with a 1 M solution of NaOH up to pH 13. The mixture was extracted with 
CH2Cl2 (3 10 mL) and the organic layer was dried over Na2SO4. Concentration at reduced pressure 
gave a colourless oil, which was dissolved in THF (5 mL) and treated with the appropriate 
isocyanate 7 (1 mmol). The solution was stirred at room temperature overnight and then the 
solvent was evaporated to give a crude residue that was chromatographed on silica gel column.  
N-Allyl-N-cyclohexyl-2-(3-phenylureido)-acetamide (1a)  
 
Eluent: light petroleum–AcOEt 3:2. White solid; yield 82%, mp 97–99 °C. IR (nujol): = 3301, 1750, 
1654 cm-1. 1H NMR (500 MHz, CDCl3, mixture of two rotamers in 7:6 ratio) major rotamer:  1.07–
1.82 (m, 10H), 3.91 (d, J = 4.8 Hz, 2H), 4.13 (s, 2H), 4.34–4.46 (m, 1H), 5.06–5.26 (m, 2H), 5.72–
5.87 (m, 1H), 6.45 (br s, 1H), 7.00–7.03 (m, 1H), 7.24–7.28 (m, 2H), 7.32–7.36 (m, 2H) 7.64 (br s, 
1H) ppm; minor rotamer:  1.07–1.82 (m, 10H), 3.47–3.59 (m, 1H), 3.94 (d, J = 5.1 Hz, 2H), 4.23 (s, 
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2H), 5.06–5.26 (m, 2H), 5.72–5.87 (m, 1H), 6.45 (br s, 1H), 7.00–7.03 (m, 1H), 7.24–7.28 (m, 2H), 
7.32–7.36 (m, 2H), 7.64 (br s, 1H) ppm; 13C NMR (125 MHz, CDCl3) major rotamer:  25.3, 25.5, 
29.7, 44.7, 46.1, 52.4, 117.5, 118.5, 121.1, 128.8, 129.1, 137.7, 155.5, 164.4 ppm; minor rotamer: 
 25.3, 25.4, 29.3, 44.5, 46.1, 47.6, 116.8, 118.5, 121.1, 128.8, 129.1, 138.3, 155.6, 164.4 ppm. MS: 
m/z 315 (M+). Anal. Calcd for C18H25N3O2: C, 68.54; H, 7.99; N, 13.32; Found C, 68.72; H, 7.73; N, 
13.41.  
N-Allyl-N-cyclohexyl-2-(3-naphthalen-1-ylureido)-acetamide (1b)  
 
Eluent: light petroleum–AcOEt 3:2. Beige solid; yield 75%, mp 173–174 °C. IR (nujol):  = 3287, 
1745, 1656 cm-1. 1H NMR (500 MHz, CDCl3, mixture of two rotamers in 4:3 ratio) major rotamer:  
1.02–1.79 (m, 10H), 3.74 (d, J = 4.8 Hz, 2H), 4.11 (s, 2H), 4.19–4.32 (m, 1H), 4.98–5.16 (m, 2H), 
5.56–5.72 (m, 1H), 6.73 (br s, 1H), 7.42–7.50 (m, 3H), 7.63 (br s, 1H), 7.82–7.86 (m, 2H), 8.08–8.13 
(m, 2H) ppm; minor rotamer:  1.02–1.79 (m, 10H), 3.39– 3.45 (m, 1H), 3.81 (d, J = 5.4 Hz, 2H), 
4.20 (s, 2H), 4.98–5.16 (m, 2H), 5.56–5.72 (m, 1H), 6.81 (br s, 1H), 7.42–7.50 (m, 3H,), 7.67 (br s, 
1H), 7.82–7.86 (m, 2H), 8.08–8.13 (m, 2H) ppm; 13C NMR (125 MHz, CDCl3) major rotamer:  25.3, 
25.5, 29.6, 42.6, 44.8, 54.3, 114.1, 116.9, 121.3, 122.0, 125.2, 125.8, 126.0, 128.3, 128.5, 134.1, 
134.3, 157.0, 169.6 ppm; minor rotamer:  25.3, 25.4, 29.2, 42.4, 44.3, 56.4, 114.1, 116.1, 121.1, 
121.9, 125.1, 125.5, 125.9, 128.3, 128.5, 133.7, 134.5, 156.9, 168.4 ppm; MS: m/z 365 (M+); Anal. 
Calcd for C22H27N3O2: C, 72.30; H, 7.45; N, 11.50; Found C, 72.09; H, 7.61; N, 11.73. 4.1.3.  
N-Allyl-N-cyclohexyl-2-(3-pyren-1-ylureido)-acetamide (1c)  
 
Eluent: light petroleum–AcOEt 3:2. Brown solid; yield 70%, mp 97–99 °C; 1H NMR (200 MHz, 
CDCl3):  1.02–1.79 (m, 10H), 3.58– 3.69 (m, 1H), 3.94–4.02 (m, 1H), 4.44 (d, 1H), 4.53 (d, 1H), 
5.10– 5.37 (m, 2H), 5.72–5.90 (m, 2H), 7.34 (br d, 1H), 8.00–8.24 (m, 9H), 8.70 (d, 1H) ppm; 13C 
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NMR (125 MHz, CDCl3):  24.9, 25.8, 29.2, 29.7, 43.1, 46.0, 52.5, 118.4, 121.4, 122.8, 124.5, 124.8, 
125.0, 125.3, 125.9, 126.5, 127.3, 127.5, 128.0, 129.0, 129.7, 131.0, 131.3, 131.7, 132.1, 140.1, 
157.0, 169.3 ppm; MS: m/z 439 (M+); Anal. Calcd for C28H29N3O2: C, 76.51; H, 6.65; N, 9.56; Found 
C, 76.39; H, 6.88; N, 9.59.  
N-Allyl-N-phenyl-2-(3-pyren-1-ylureido)-acetamide (1d)  
 
Eluent: light petroleum–AcOEt 3:2. Brown solid; yield 67%, mp 103–105 °C; 1H NMR (200 MHz, 
CDCl3):  3.81 (d, J = 4.4 Hz, 1H), 4.15 (d, J = 6.3 Hz, 2H), 4.90–4.99 (m, 2H), 5.61–5.74 (m, 1H), 
6.30 (br s, 1H), 7.01–7.05 (m, 2H), 7.23–7.27 (m, 4H), 7.81 (br s, 1H), 7.98–8.05 (m, 3H), 8.11–8.30 
(m, 6H) ppm; 13C NMR (125 MHz, CDCl3):  24.9, 25.8, 29.2, 43.1, 45.8, 52.5, 118.4, 121.2, 122.8, 
124.7, 124.7, 125.0, 125.3, 126.0, 126.5, 127.2, 127.5, 128.0, 128.6, 129.8, 130.9, 131.3, 132.1, 
140.2, 156.9, 169.2 ppm; MS: m/z 433 (M+); Anal. Calcd for C28H23N3O2: C, 77.58; H, 5.35; N, 9.69; 
Found C, 77.76; H, 6.11; N, 9.92.  
General procedure for synthesis of 3-arylimino-1,7,8,8atetrahydro-3H-oxazolo[3,4-a]pyrazin-
6(5H)-ones 2a–d  
 
A solution of the appropriate alkenyl urea 1a-d (1 mmol) in dry THF (3 mL) was added to a 
suspension of PdCl2(MeCN)2 (13 mg, 0.05 mmol) and CuCl2 (402 mg, 3.0 mmol) in dry THF (3 mL). 
The reaction was heated at 60 °C for 12 h. After addition of brine, the mixture was extracted with 
CH2Cl2 (3 10 mL). The organic layer was dried over Na2SO4 and the solvent was evaporated under 
reduced pressure to give a crude product that was purified by silica gel column chromatography.  
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Cyclohexyl-3-phenylimino-1,7,8,8a-tetrahydro-3H-oxazolo[3,4-a]pyrazin-6(5H)-ones (2a)  
 
Eluent: light petroleum–AcOEt 3:7. White solid; yield 85%, mp 155–156 °C. IR (nujol): = 1757, 
1585 cm-1. 1H NMR (500 MHz, CDCl3):  1.25–1.82 (m, 10H), 3.15 (dd, J = 11.1, 9.3 Hz, 1H), 3.28 
(dd, J = 12.0, 3.8 Hz, 1H), 3.82–3.87 (m, 1H), 3.88 (d, J = 17.8 Hz, 1H), 4.02 (dd, J = 8.6, 4.4 Hz, 1H), 
4.43 (dd, J = 8.6, 7.4 Hz, 1H), 4.46–4.52 (m, 1H), 4.53 (d, J = 17.8 Hz, 1H) 6.89–6.98 (m, 1H), 7.05 
(d, J = 7.6 Hz, 2H), 7.20–7.24 (m, 2H) ppm; 13C NMR (125 MHz, CDCl3):  25.3, 25.4, 25.6, 29.3, 
29.6, 43.6, 46.4, 51.6, 52.6, 67.9, 122.5, 123.4, 128.5, 146.6, 150.9, 164.3 ppm; MS: m/z 313 (M+). 
Anal. Calcd for C18H23N3O2: C, 68.98; H, 7.40; N, 13.41; Found C, 69.09; H, 7.17; N, 13.66.  
7-Cyclohexyl-3-(naphthalen-1-ylimino)-1,7,8,8a-tetrahydro-3H-oxazolo[3,4-a]pyrazin-6(5H)-
ones (2b)  
 
Eluent: light petroleum–AcOEt 3:7. White solid; yield 69%, mp 175–176 °C. IR (nujol):  = 1753, 
1581 cm-1. 1H NMR (500 MHz, CDCl3):  1.05–1.82 (m, 10H), 3.24 (dd, J = 11.3, 10.6 Hz, 1H), 3.34 
(dd, J = 12.0, 3.9 Hz, 1H), 3.92–3.98 (m, 1H), 4.02-4.07 (m, 2H), 4.47 (dd, J = 8.7, 7.2 Hz, 1H), 4.53–
4.60 (m, 1H), 4.75 (d, J = 18.3 Hz, 1H), 7.19–7.21 (m, 1H), 7.36–7.45 (m, 3H), 7.52 (d, J = 8.2 Hz, 
1H), 7.29–7.32 (m, 1H), 8.19–8.22 (m, 1H) ppm; 13C NMR (125 MHz, CDCl3):  25.3, 25.4, 25.6, 
29.3, 29.7, 43.6, 46.6, 51.7, 52.6, 67.8, 117.4, 122.6, 124.1, 124.9, 125.7, 125.8, 127.7, 129.3, 
134.3, 142.8, 150.9, 164.4 ppm; MS: m/z 363 (M+); Anal. Calcd for C22H25N3O2: C, 72.70; H, 6.93; N, 
11.56; Found C, 72.63; H, 7.19; N, 11.80.  
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7-Cyclohexyl-3-(pyrenyl-1-ylimino)-1,7,8,8a-tetrahydro-3H-oxazolo[3,4-a]pyrazin-6(5H)-ones 
(2c)Z 
 
Eluent: light petroleum–AcOEt 3:7. Yellow bright solid; yield 65%, mp 132–134 °C. 1H NMR (500 
MHz, CDCl3):  1.05–1.82 (m, 10H), 3.34 (dd, J = 11.3, 10.6 Hz, 1H), 3.40 (dd, J = 12.0, 3.9 Hz, 1H), 
4.02–4.07 (m, 1H), 4.16–4.12 (m, 2H), 4.56–4.60 (m, 2H), 4.85 (d, J = 18.3 Hz, 1H), 7.19–7.21 (m, 
1H), 7.36–7.45 (m, 3H), 7.52 (d, J = 8.2 Hz, 1H), 7.29–7.32 (m, 1H), 8.19–8.22 (m, 2H), 8.45 (d, 1H) 
ppm; 13C NMR (125 MHz, CDCl3):  25.3, 25.4, 25.6, 29.3, 29.7, 43.7, 46.7, 51.9, 52.6, 68.0, 120.4, 
123.6, 124.1, 124.2, 125.0, 125.4, 125.5, 125.7, 126.2, 127.0, 127.4, 131.6, 142.1, 151.8, 164.4 
ppm; MS: m/z 437 (M+); Anal. Calcd for C28H27N3O2: C, 76.86; H, 6.22; N, 9.60; Found C, 77.05; H, 
6.07; N, 9.87.  
7-Phenyl-3-(pyrenyl-1-ylimino)-1,7,8,8a-tetrahydro-3H-oxazolo[3,4-a]pyrazin-6(5H)-ones (2d)  
 
Eluent: light petroleum–AcOEt 3:7. Light yellow solid; yield 67%, mp 93–96 °C. 1H NMR (500 MHz, 
CDCl3):  3.58–3.66 (m, 2H), 3.89–3.94 (m, 1H), 4.06–4.09 (m, 2H), 4.52–4.55 (m, 2H), 5.04 (d, J = 
18.8 Hz, 1H), 7.32 (d, 2H) 7.44 (t, 2H) 7.86 (d, J = 7.9 Hz 1H), 7.90–8.01 (m, 4H), 8.1–8.06 (m, 3H), 
8.49 (d, J = 9.2 Hz, 1H) ppm; 13C NMR (125 MHz, CDCl3):  29.7, 31.6, 46.7, 46.9, 51.7, 52.8, 67.7, 
96.1, 120.3, 123.6, 124.1, 124.3, 124.7, 125.0, 125.1, 125.5, 125.7, 125.8, 126.2, 126.3, 127.0, 
127.4, 127.5, 127.6, 129.4, 129.5, 131.5, 131.6, 140.9, 141.9, 150.8, 165.0 ppm; MS: m/z 431 (M+); 
Anal. Calcd for C28H21N3O2: C, 77.94; H, 4.91; N, 9.74; Found C, 78.01; H, 4.76; N, 9.48. 4.3. 
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3.6.2. Biological assay 
Materials: Dulbecco’s modified Eagle medium (DMEM) and Minimum Essential Medium (MEM) 
containing 2 mM GlutaMAX (GIBCO), Ham’s F12 (GIBCO), nonessential amino acids, heat 
inactivated Fetal Bovine Serum (FBS, GIBCO), Normal Goat Serum (NGS, GIBCO), Streptomycin and 
penicillin antibiotics, Trypsin–EDTA 0.05% solution were from Invitrogen (Milan, Italy). Lab-Tek™ 
Chamber Slides II, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide salts (MTT), 
agarose, and other chemicals of analytical grade were obtained from Sigma–Aldrich (Milano, 
Italy).  
Mouse monoclonal antibody against caspase-3 was from Becton–Dickinson (Milan, Italy). 
Tetrarhodamine isothiocyanate (TRITC)-conjugated anti-mouse IgG polyclonal antibody, were 
from Chemicon (Prodotti Gianni, Milan, Italy). QIAamp DNA Mini kit was from Qiagen.  
Cell cultures: FTC-133 and 8305C cell lines were suspended in appropriate medium and plated in 
flasks at a final density of 2 x 106 cells or in Lab-Tek™ Chamber Slides II at a final density 0.5 x 105 
cells/ well. Specifically the medium for FTC-133 cell lines was: DMEM containing 2 mM Gluta-
MAX, 10% FBS, streptomycin (50 g/mL), penicillin (50 U/mL); whereas the medium for 8305C cell 
lines was: MEM containing 2 mM Gluta-MAX, 10% FBS, streptomycin (50 g/mL), penicillin (50 
U/mL), and 1% nonessential amino acids. Cell lines were then incubated at 37 °C in humidified 
atmosphere containing 5% CO2 and the medium was replaced every 2 or 3 days. When the 
cultures were about 85–90% confluent, cells were trypsinized by 0.05% trypsin and 0.53 mM 
EDTA at 37 °C in humidified atmosphere containing 5% CO2 for 5 min. Trypsinization was stopped 
by adding 20% FBS, resuspended and plated in flasks fed with fresh basic complete media. Cells 
were seeded again at 1:4 density ratio and incubated at 37 °C in humidified atmosphere 
containing 5% CO2.  
Treatment of the cells: FTC-133 and 8305C were replated on to Lab-Tek™ Chamber Slides II at a 
final density of 1 104 cells/well, and fed in fresh complete medium. In preliminary experiments, 
we exposed the both cultures in the absence or the presence of different concentrations of 2a-d 
(5, 10, 25, 50, 75, 100 M) for 12, 24 h, in order to establish the optimal concentrations and their 
exposure times to all synthesized compounds. For this purpose, MTT test and morphological 
characterization were utilized.75 We found that for the both cultures the optimal concentration of 
all synthesized compounds was 50 M and the optimal exposure time was 24 h.  
 
                                                          
75 A. Campisi; D. Caccamo; G. Raciti; G. Cannavò; V. Macaione; M. Currò; S. Macaione; A. Vanella; R. Ientile; Brain Res., 2003, 978, 24. 
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MTT bioassay Cell survival analysis was performed by MTT reduction assay, evaluating 
mitochondrial dehydrogenase activity.76 Cells were set up 6 105 cells per well of a 96-multiwell, 
flat-bottomed, 200 L microplate, and maintained at 37 °C in a humidified 5% CO2/95% air 
mixture. At the end of treatment time, 20 L of 0.5% MTT in (pH 7.4) PBS were added to each 
microwell. After 1 h of incubation with the reagent, the supernatant was removed and replaced 
with 200 L of dimethyl sulfoxide (DMSO). The optical density of each well was measured with a 
microplate spectrophotometer reader (Titertek Multiskan; Flow Laboratories, Helsinki, Finland) at 
570 nm.  
Immunocytochemistry: Expression of caspase-3 in FTC-133 and 8305C cells was identified by 
immunocytochemical procedures. Untreated or 2a-d treated FTC-133 and 8305C were fixed by 
exposing to 4% paraformaldehyde in 0.1 M PBS for 20 min. Then, cells were washed three times 
with PBS and incubated for 1 h at 37 °C in humidified air and 5% CO2 with 1% NGS in PBS to block 
unspecific sites. The cells were successively incubated overnight at 37 °C in humidified air and 5% 
CO2 with mouse monoclonal antibody against caspase-3 (1:200). Finally, the slides were washed 
three times with PBS, mounted in PBS/glycerol (50:50), and analyzed on a Leica fluorescent 
microscopy (Germany). No nonspecific staining of hMSCs was observed in control incubations in 
which the primary antibody was omitted.  
DNA labelling assay: DNA extraction from both untreated and treated FTC-133 and 8305C cells 
with 75 M of 2a-d for 24 h was performed according to the user’s manual. Gel electrophoresis 
separates DNA fragments by size in an 2% agarose gel. DNA is visualized by including in the gel an 
intercalating dye, SYBER Green I. GAPDH-1 as housekeeping gene was used.  
Statistical analysis: data were statistically analysed using one-way analysis of variance (one-way 
ANOVA) followed by post hoc Holm–Sidak test to estimate significant differences among groups. 
Data were reported as mean ± SD of four experiments in duplicate, and differences between 
groups were considered to be significant at p < 0.05. 
 
 
  
                                                          
76 a) A. Campisi; D. Caccamo,; G. LiVolti; M. Currò; G. Parisi; R. Avola; A. Vanella; R. Ientile; FEBS Lett., 2004, 578, 80; b) A. Campisi; M. 
Spatuzza; A. Russo; G. Raciti; A. Vanella; S. Stanzani; R. Pellitteri; Neurosci. Res., 2012, 72, 289. 
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Chapter 4 
 
Boehmeriasin A as new lead compound 
for the inhibition of topoisomerases and 
SIRT2 
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4.1. Introduction 
Since the first isolation of tylophorine in 1935 from the perennial climbing plant Tylophoria indica, 
the class of phenanthroizidine alkaloids has grown considerably. The main future of these 
pentacyclic plant-derived small molecules is the presence of a highly oxygenated phenanthrene 
ring fused to a saturated N-heterocycle (Figure 27).  
 
Figure 27 
Historically, the plant extracts have been used in herbal medicine and the isolated compounds 
have displayed a range of promising therapeutic activity such as anti-viral, anti-inflammatory and 
anti-cancer activity. The phenanthroindolizidines are much more prevalent in natural sources than 
the corresponding quinolizidines. In fact, cryptopleurine, which was isolated as early as 1948 from 
the bark of Cryptocarya pleurosperma, was considered for a long time to be the sole example of 
this rare class of alkaloids. This family was later enriched by isolation other derivatives, among 
whom Boehmeriasin A and B (Figure 28).77 
 
Figure 28 
The structural difference between phenanthroindolizidine and phenanthroquinolizidine alkaloids 
lies in the size of the E-ring. The presence of the six-membered ring in the 
phenanthroquinolizidine skeleton led to a significant increase in cytotoxicity in comparison to 
phenanthroindolizidine skeleton, which has a five-membered ring. Despite their therapeutic 
potential, no compounds in these classes have fully passed clinical trials so far, due to their main 
                                                          
77 D. Dumoulin; S. Lebrun; A. Couture; E. Deniau; P. Grandclaudon; Eur. J. Org. Chem., 2010, 1943. 
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drawbacks, including low in vivo anti-cancer activity, central nervous system toxicity and low 
natural availability.78  
Boehmeriasin A and B were isolated from the aqueous ethanolic extract of Boehmeria siamensis 
Craib by Luo et al. in 2003. In vitro tests showed that boehmeriasin A possesses a strong cytotoxic 
activity, more potent than Paclitaxel, against 12 different cancer cell lines with GI50 values in the 
range 0.2-5 ng/mL for all but one cell lines. Boehmeriasin B showed lower activity.79 
As a consequence of its promising biological profile, coupled with its low natural abundance and 
unusual architecture, Boehmeriasin A continues to be target for synthesis, modification, and 
structure-activity relationship (SAR) studies with the hope that a new drug will emerge. Recently, 
few synthetic methodology have been developed for the elaboration of the 
phenanthroquinazolidine scaffold of Boehmeriasin. Two important examples are shown to follow. 
In 2010 A. Couture at al. reported the first asymmetric synthesis of Boehmeriasin A in which the 
key intermediate with the piperidine template was achieved through two alternative and 
elaborate synthetic pathways. A subsequent acylation/oxidation/aldol condensation/radical 
cyclization sequence completed the assembly of the title (R)-configured natural product (Scheme 
11).77 
 
Scheme 11 
Afterward, both enantiomers of boehmeriasin A were synthesized by Georg in seven steps each 
using a chiral pool approach. Key steps in the syntheses were a one-flask, two-step protocol to 
generate the quinolizine core and a C-H functionalization reaction between 
tetrahydroquinolizinones and an aryltrifluoroborate (Scheme 12).80 
                                                          
78a) S.R. Chemler; Curr. Bioact. Compd., 2009, 5, 2. 
79 a) Y. Luo; Y. Liu; D. Luo; X. Gao; B. Li; G. Zhang; Planta Med., 2003, 69, 842; b) J. P. Michael; Nat. Prod. Rep.; 2005, 22; 603. 
80 M. W. Leighty; G. I. Georg; ACS Med. Chem. Lett.; 2011, 2, 313. 
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Scheme 12 
 
4.2. Aim of this work 
In this context, we planned two synthetic approaches to obtain the racemic mixture and the pure 
enantiomers of boehmeriasin A which, in spite of previous reported preparations, present an 
increased efficacy and simplicity, relevant features for large-scale synthesis and analogue 
preparation.  
 
Scheme 13 
Further, we wanted to test their biological activity and identify the biological target with the help 
of virtual screening (Hurakan tool) and docking studies. 
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4.3. Chemistry 
As shown in the retrosynthetic plan in Scheme 13, the first step would be the formation of the 
phenanthrene nucleus and then, through a further cyclization, the quinolizidine ring (path A) or 
(path B). This would permit the generation of the nitrogen containing bicyclic system in a 
stereospecific way by an intramolecular aldol type reaction followed by an intramolecular 
arylation reaction.  
4.3.1.  Racemic preparation 
First of all, Boehmeriasin A was prepared as racemic mixture with a simple and robust synthetic 
pathway, which has been allowed to prepare gram quantities of the desired natural product 
(Scheme 14). 
 
Scheme 14 
The synthesis started with a Perkin reaction between commercially available 4-
methoxybenzaldehyde 9 and 3,4-dimethoxyphenylacetic acid 10. This reaction can be easily 
performed at >100 mmol scale. Next, a microwave-assisted Fischer esterification delivered the 
corresponding ester 11 in quantitative yield and then the quinolizidine ring 12 was obtained 
through a ferrous chloride mediated oxidative biaryl coupling. Also this transformation can be 
performed on multigram scale in an efficient way, even if the generation of stoichiometric 
amounts of insoluble inorganic secondary products requires close reaction monitoring and 
specific work-up strategies in order to achieve a reproducible reaction outcome. The ester 
functionality was reduced using LiAlH4 and chlorodehydroxylation of the resulting benzylic alcohol 
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13 with concentrated HCl cleanly affords the benzylic chloride 14. A selective nucleophilic 
substitution was performed with the potassium salt of racemic pipecolic acid, furnishing the 
desired adduct 15. A Friedel-Crafts acylation in neat polyphosphoric acid was used to prepare the 
pentacyclic scaffold 16 of boehmeriasin A in good yield. This reaction afforded an instable 
material under basic conditions, therefore was necessary to maintain the pH during the aqueous 
work-up below 8. Finally, removal of the ketone functionality was accomplished in a two-step 
fashion firstly using LiAlH4 followed by dehydroxylation under TFA/triethylsilane conditions. In 
summary, this sequence allowed the preparation of racemic boehmeriasin A 7a,b in a short 7 step 
sequence and in 22% overall yield.  
Indeed, the resolution of the racemic natural product by chiral HPLC was evaluated. For analytical 
purposes a short chiral HPLC column (AD, 5 cm) in direct phase (10% ethanol and 90% hexane) 
was used in order to achieve resolution of the racemic boehmeriasin A (Figure 29). 
 
Figure 29 
The successful resolution let us to be confident regard the possibility to separate the two 
enantiomers also on a preparative scale using a larger AD column. However, we firstly preferred 
to carry out an asymmetric synthesis of both (S)- and (R)-boehmeriasin A.  
4.3.2. Enantioselective synthesis 
In this second approach we developed an enantioselective synthesis using enantiopure 
piperidinethanol 8 as the starting material, which can be produced at gram scale through an 
enzymatic process (Scheme 15, (S)-enantiomer shown). 81 
 
                                                          
81 M. Angoli; A. Barilli; G. Lesma; D. Passarella; S. Riva; A. Silvani; B. Danieli; J. Org. Chem., 2003, 68, 9525. 
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Scheme 15 
After oxidation of the alcohol 8b, the aldehyde was treated with 4-methoxyphenyl-magnesium 
bromide affording the secondary alcohol 17 in high yield. Dess-Martin periodinane was used as 
excellent oxidant to generate the intermediate 18, and the deprotection of the Boc group (19) 
and N-acylation with the easily prepared 2-bromo-4,5-dimethoxyphenylacetic acid (20) afforded 
the compound 21 in 63% (3 steps). An intramolecular aldoltype condensation in the presence of 
KOH furnished the desirable intermediates 22 as mixture of atropisomers (85%, 1:1 ratio). To 
obtain the phenanthroquinolizidine skeleton a palladium catalysed intramolecular coupling was 
investigated (Table 3).  
Table 3: 
 
 
entry 
Pd(OAc)2 
(mmol) 
Ligand 
(mmol) 
K2CO3 
(mmol) 
Time (h) 
Temperature 
(°C) 
Yield (%) 
1 0.05 0.1 2 16 h 125 - 
2 0.05 0.1 2 5 125 29 
3 0.05 0.1 2 5 155 11 
4 0.24 0.3 2 5 125 60 
The reaction carried out with Pd(OAc)2 as catalyst, 2'-(diphenylphosphino)-N,N' -dimethyl- (1,1'-
biphenyl)-2-amine as the ligand and K2CO3 in dimethylacetamide at 125 °C for 5 h, furnished 23 in 
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60% yield. Finally, a reduction with LiAlH4 completed the synthesis of boehmeriasin A with 80% of 
yield. 
HPLC analysis confirmed that the purity of both enantiomers was in accordance with the e.e. of 
the starting materials 8. 
 
4.4. Biological evaluation 
4.4.1. Anti proliferative activity 
With the enantiomers of boehmeriasin A and the racemic mixture in our hands, we wanted to 
evaluate their anti proliferative activity on three selected cancer cell lines (human lymphoblastic 
leukaemia (CEM), human cervical carcinoma (HeLa) and mouse lymphocytic leukaemia (L1210) 
cells) and on two endothelial cell lines (human microvascular endothelial cells (HMEC-1) and 
bovine aortic endothelial cells (BAEC)). The chose reference compounds has been combretastatin 
A4P (CA-4P), that is a vascular-targeting agent which inhibits the proliferation of the tumour cells, 
and endothelial cells with IC50 values around 80 nM and 3 nM, respectively (Table 4). 
Table 4: Anti-proliferative activity of (R)- and (S)-boehmeriasin A in comparison with combretastatin A4P. 
Compound 
Tumor cell lines 
(IC50[a] [nM]) 
Endothelial cell lines 
(IC50[a] [nM]) 
 HeLa CEM L1210 HMEC-1 BAEC 
(R)-7 66 ± 56 185 ± 156 19 ± 10 7.4 ± 1.1 23 ± 13 
(S)-7 182 ± 164 201 ± 127 111 ± 11 82 ± 66 23 ± 6 
rac.-7 76 ± 52 119 ± 71 71 ± 23 29 ± 8 9.0 ± 2.1 
CA-4P 79 ± 3 95 ± 6 82 ± 12 2.9 ± 0 3.9 ± 0.1 
[a] 50% inhibitory concentration. CA-4P: combretastatin A4P. CEM: human lymphoblastic leukemia.  HeLa: human 
cervical carcinoma. L1210: mouse lymphocytic leukemia cells. HMEC-1: human microvascular endothelial cells. BAEC: 
bovine aortic endothelial cells. 
In accordance with other results reported in the literature,79 both enantiomers showed potent 
cytostatic activity against the different tumour cells, with IC50 values in the nanomolar range. 
Interestingly, (R)-7 proved to be significantly more potent than the (S)-enantiomer against HeLa 
and L1210 cells. Both compounds also inhibited the proliferation of endothelial cells, with IC50 
values of 23 nM in BAEC and 82 nM for the (R)- and (S)-enantiomers in HMEC- 1, respectively. 
Together, these data confirm the inhibitory activity of (R)- and (S)-boehmeriasin A against both 
tumour and endothelial cells, the (R)-enantiomer being up to 11-fold more potent than the (S)-
enantiomer in selected cell lines. The anti-proliferative activity of the racemic mixture was 
comparable to the activity of the (R)- enantiomer, being equally active in HeLa cells, about 2-fold 
more active in CEM cells and BAEC and 3e4-fold less active in L1210 cells and HMEC-1.  
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4.4.2. Virtual screening 
The specific cellular target of the Boehmeriasin A, as well as of the others 
phenanthroquinolizidine alkaloids, is still unknown. For developing and optimizing this scaffold 
into therapeutic drugs, the identification of the biological target is fundamental to have a starting 
point to identify the eventual and proper alterable region of the molecule through structure and 
activity relationship studies (SAR).  
The use of a virtual screening would have helped us to identify the biological target that could 
justify the anti-proliferative activity on different cell lines. Hurakan software82 is a 3D ligand-based 
virtual screening tool that compares the input molecule with the structures present in the 
reference database. In particular Hurakan uses ChemblDB83 as a reference database which 
contains molecules, targets and biological activities of many compounds and thus it is able to 
compare the behaviour of the molecules instead of comparing their structure. In this way, 
Hurakan predicts the biological profile of an input molecule and, in the case of Boehmeriasin A, it 
predicted 13 proteins for the R-enantiomer and 15 proteins for the S-enantiomer (Table 5).  
Table 5: Target proteins for (R)- and (S)-boehmeriasin A 
entry (R)-Boehmeriasin A (S)-Boehmeriasin A 
1 Proto-oncogene c-JUN Proto-oncogene c-JUN 
2 DNA polymerase eta Serotonin 2a (5-HT2a) receptor 
3 Aryl hydrocarbon receptor nuclear 
translocator 
Aryl hydrocarbon receptor nuclear translocator 
4 Hypoxia-inducible factor 1 alpha Alpha-1a adrenergic receptor 
5 Chromobox protein homolog 1 Hypoxia-inducible factor 1 alpha 
6 Cruzipain Acetylcholinesterase 
7 Sphingomyelin phosphodiesterase DNA topoisomerase II alpha 
8 Arachidonate 15-lipoxygenase, type II DNA topoisomerase II beta 
9 DNA dC->dU-editing enzyme APOBEC-3F DNA topoisomerase I 
10 Lysine-specific demethylase 4A Acetylcholinesterase 
11 Peptidyl-prolyl cis-trans isomerase NIMA-
interacting 1 
DNA dC->dU-editing enzyme APOBEC-3F 
12 Nonstructural protein 1 Lysine-specific demethylase 4A 
13 Nuclear factor erythroid 2-related factor 2 DNA polymerase eta 
14  Nuclear factor erythroid 2-related factor 2 
15  Cholinesterase 
                                                          
82 E. Santamaría-Navarro; A. Nonell-Canals; Hurakan, Ligand-based 3D Screening Software, 2013. Available at: www.mindthebyte.com. 
83 A.P. Bento; A. Gaulton; A. Hersey; L.J. Bellis; J. Chambers; M. Davies; F.A. Kruger; Y. Light; L. Mak; S. McGlinchey; M. Nowotka; G. 
Papadatos; R. Santos; J.P. Overington; Nucleic Acids Res., 2014, 42, D1083. 
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Among all these probably target proteins, topoisimerases (entry 7-9, (S)-boehmeriasin) attracted 
our attention, since many famous chemotherapy drugs, called topoisomerase inhibitors, work by 
interfering with eukaryotic topoisomerases and inducing the apoptosis. 
Topoisomerases are enzymes that regulate the overwinding or underwinding of DNA. The winding 
problem of DNA arises due to the intertwined nature of 
its double-helical structure. During DNA replication and 
transcription, DNA becomes overwound ahead of a 
replication fork. If left unabated, this tension would 
eventually stop the ability of the enzymes involved in 
these mechanisms to continue the replication process. 
In order to prevent and correct these types of 
topological problems caused by the double helix, topoisomerases bind to either single-stranded 
or double-stranded DNA and cut the phosphate backbone of the DNA.84  
Based on this scenario, we were driven to evaluate the effect of both enantiomers of 
boehmeriasin A on topoisomerases. 
4.4.3. Topoisomerases inhibition 
We tested the effect of (R)- and (S)-boehmeriasin A on the relaxation of supercoiled plasmid DNA, 
that is an enzyme that relaxes supercoiled DNA giving rise to a series of topoisomers, representing 
differently relaxed forms (Topo II).  
The test compounds were assayed at 10, 25 and 50 M concentration, while m-AMSA, taken as 
reference drug, was used at 10 M. In Figure 31 is evident that both enantiomers of boehmeriasin 
A exhibit a comparable and dose-dependent effect on enzymatic activity. At 10 M both (R)- and 
(S)-enantiomers are unable to exert a significant inhibitory activity, while at 50 M, the higher 
concentration taken into account, the topoisomerase-mediated relaxation is completely inhibited 
(Figure 30). 
 
Figure 30 
                                                          
84 J. J. Champoux; Annu. Rev. Biochem., 2001, 70, 369. 
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Similar experiments were performed to assay the effect on topoisomerase I relaxation activity, 
and the results indicate a higher inhibitory effect compared to the data obtained on 
topoisomerase II. Indeed, at 10 М concentration both (R)- and (S)-boehmeriasin A completely 
inhibit the relaxation mediated by topoisomerase I (Figure 31).  
 
Figure 31 
The topoisomerase enzymes can be inhibit at different stage of their activity. Some anti-
proliferative agents, called topoisomerase poisons, interfere by stabilizing a biological 
intermediate into a lethal agent. This intermediate is called "cleavable complex" and it is a 
biochemical species arising from the cut of DNA strands, and subsequent formation of covalent 
bonds between each protein subunits and the newly formed 5'-phosphate ends of the DNA. This 
complex is considered "cleavable", since removal or disruption of the protein would result in a 
permanent double-strand break. The stabilization prevents the resealed of the breaks and the 
release of the topoisomerases.85 Experimentally, the occurrence of cleavable complex can be 
demonstrate by the enzyme-dependent formation of linear (topo-II) or nicked (topo-I) DNA from 
supercoiled DNA. To verify whether both enantiomers of behmeriasin A would be involved in the 
stabilization of cleaveble complex, first a biological assay was performed on topoisomerase II in 
the presence of 100 M of (R)- and (S)-boehmeriasin A and 10 M m-AMSA used as reference 
because is a well-known topoisomerase II poison (Figure 32). 
                                                          
85 W. B. Pratt, The Anticancer drugs, Oxford University Press, 1994. 
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Figure 32 
The results show that both derivatives do not stabilize the formation of the cleavage complex, 
although tested at a significantly higher concentration compared to that of the reference drug. 
Otherwise, as expected, m-AMSA, induces the formation of a detectable amount of linear DNA.  
Considering topoisomerase I, the bioassay reported in Figure 34, using the topoisomerase I poison 
camptothecin (CPT) as reference compound, also show the inability of both (R)- and (S)-
boehmeriasin A to act as a poison at the considered concentration (0.5 M). By contrast, in the 
same experimental results, camptothecin induces the formation of the corresponding nicked DNA 
(Figure 33).  
 
Figure 33 
The polycyclic structure of Boehmeriasin A, which contains a phenanthrene moiety that could act 
as a DNA intercalant, along with the lack of poisoning effects, suggests that the ability of (R)- and 
(S)-boehmeriasin A to interfere with topoisomerase-mediated relaxation activity could come from 
the capacity of the compounds to form a molecular complex with DNA.  
To gain better insight into the interactions between boehmeriasin A and the topoisomerases, 
molecular dockings studies were carried out. 
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The structure of topoisomerase I/DNA complex has been crystallised in complex with 
camptothecin, while topoisomerase II-beta/DNA has been obtained in complex with amsacrine, 
both well-known topoisomerase inhibitors, which are bound into the enzyme mediated DNA 
cleavage site intercalating between DNA base pairs.  
The pockets formed by camptothecin and amsacrine upon binding to DNA in complex with 
topoisomerase I and II, respectively have been chosen as the putative binding sites of 
boehmeriasin A. Both (R)- and (S)- enantiomers have been docked. Docking simulations on 
topoisomerase I showed that both boehmerasin enantiomers display good binding affinity to the 
target. Cluster analysis showed two major clusters, comprising 50% and 36% of the docked 
structures of the (S)- enantiomer, and two minor clusters. All these clusters are almost 
isoenergetic, with binding energy around -14 kcal/mol (Figure 34a). The (R)-boehmeriasin A, on 
the other hand, displayed one dominant cluster, comprising 98% of the docking decoys (Figure 
34b). 
 
Figure 34: a) Docked structure of (S)-boehmeriasin A. The best fit structure of the principal cluster is depicted in orange, 
while the best fit structure of secondary cluster is green. Boehmerasin is intercalated between DNA bases of the nucleic 
acid double helix complexed with topoisomerase I; b) Docked structure of (R)-boehmeriasin A (blue molecule).  
Cluster analysis of the docking results on the topoisomerase II showed only one cluster for the (S)-
enantiomer, with the phenantrene moiety stacked between the DNA bases (Figure 35a). The (R)- 
enantiomer showed two distinct clusters: the principal one populated by 66% of the docked 
structures and the secondary one containing 34% of the docked structures (Figure 35b). 
 
a) b) 
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Figure 35: a) Docked structure of (S)-boehmeriasin A (orange molecule). The phenanthrene moiety is intercalated 
between base pairs of the DNA in complex with topoisomerase II; b) docked structure of (R)-boehmeriasin A. The best 
fit structure of the principal cluster is depicted in red, while the best fit structure of secondary cluster is in blue. A very 
similar binding energy corresponds to these structurally different poses. 
A slight preference toward topoisomerase II can, on the other hand, be inferred on the basis of 
the docking results. It is worth noting that in all of the docked conformations both (S)- and (R)-
enantiomers of boehmeriasin A do not display any significant contact with either one of the 
topoisomerase isoforms that have been tested, but seem to mainly interact with the DNA strand 
through stacking interactions. 
4.4.4. Sirtuins inhibition 
The similar structure of boehmeriasin A with known sirtuin inhibitors86 drove us to study its 
activity against sirtuins.  
Sirtuins are NAD-dependent protein deacetylase of which there are seven isoforms (SIRT1–7). 
They are fundamental for the modulation of multiple and diverse biological processes such as cell 
cycle control, microtubule dynamics, cell differentiation and so on. Recently, multiple research 
groups have pursued the identification and development of small-molecule compounds that 
modulate sirtuins, which can also be potentially useful as therapeutic agents because upregulated 
SIRT1 has been described in cancers.87 Indeed, sirtuin 2 (SIRT2), has been shown to be a key 
regulator of cell division and differentiation.88  
Both enantiomers were screened in vitro against SIRT1 and SIRT2 at 200 M concentration For 
SIRT1 (R)- and (S)-boehmeriasin A showed no inhibition. Interestingly, for SIRT2 (R)-boehmeriasin 
A gave ~65% inhibition, whereas (S)-boehmeriasin A gave only 41% inhibition (Table 6). 
  
                                                          
86 D. Rotili; D. Tarantino; V. Carafa; E. Lara; S. Meade; G. Botta; A. Nebbioso; J. Schemies; M. Jung; A.G. Kazantsev; M. Esteller; M.F. 
Fraga; L. Altucci; A. Mai; ChemMedChem, 2010, 5, 674. 
87 T. Liu; P.Y. Liu; G.M. Marshall; Cancer Res., 2009, 69, 1702. 
88 T. Kozako; T. Suzuki; M. Yoshimitsu; N. Arima; S. Honda; S. Soeda; Molecules, 2014, 19, 20295. 
b) a) 
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Table 6: Evaluation of (R)- and (S)-boehmeriasin A against SIRT1 and SIRT2 
Compound SIRT1a SIRT2a 
(R)-7 12 ± 1.4 65 ± 1.6 
(S)-7 10 ± 4.2 41 ± 0.56 
a Inhibition % at 200 M inhibitor concentration. 
Docking studies were performed also for the interaction between boehmeriasin A and SIRT1 and 
SIRT2.  
In SIRT1, both enantiomers of boehmeriasin A were docked into the place of the nicotinamide-
moiety (so called C-pocket in sirtuins) showing -interactions with His363 or Phe273 but they 
could not adopt a good orientation in the binding pocket (Figure 36).  
 
Figure 36: (R)-Boehmeriasin A (green) in the putative binding site of SIRT2. NAD+ (black) and Ex-527(purple) is also 
presented based on their position in SIRT1. 
As for SIRT2, (R)-boehmeriasin A was docked into the C-pocket having an interaction of the 
phenyl-ring with Ile169 and showed good complementarity with the binding site. Whereas (S)-
boehmeriasin A had no interactions with SIRT2, but showed also complementary binding (Figure 
37). Based on the modelling there was no clear difference in the putative binding modes of the 
enantiomers. 
 
Figure 37: (R)-boehmeriasin A interacts with Ile169 in SIRT2. Boehmeriasin A doesn’t orientate properly in the putative 
binding site of SIRT1. 
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4.5. Conclusion 
In conclusion two efficient and innovative approaches were performed for the synthesis of both 
enantiomers as well as of racemic boehmeriasin A. Indeed biological assays confirmed the high 
anti-proliferative activity in three endothelial and two cancer cell lines of the two enantiomers. 
Thanks to biological assays, accompanied by virtual screening and docking studies, we could 
identify the interaction between with DNA and SIRT2 and boehmeriasin that presumably are the 
responsible for their biological activity. These results offer new suggestions for the design and 
practical synthesis of new topoisomerase and SIRT2 inhibitors based on the boehmeriasin A 
scaffold. 
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4.6. Experimental part 
4.6.1. Synthesis 
Racemic preparation of Boehmeriasin A 
(E)-Methyl 2-(3,4-dimethoxyphenyl)-3-(4-methoxyphenyl) acrylate (11)  
 
4-Methoxybenzaldehyde 9 (13.6 g, 100 mmol) and 3,4- dimethoxyphenylacetic acid 10 (19.6 g, 
100 mmol) were dissolved in a mixture of triethylamine (10 mL) and acetic anhydride (20 mL) and 
heated at 120 °C for 30 hours. After the reaction mixture was cooled to room temperature, ethyl 
acetate (150 mL) was added leading to precipitation of a yellow solid. After filtration and drying 
this material was charged into 20 mL microwave vessels (~4 g each), filled with 7 mL methanol 
and 0.1 mL conc. sulphuric acid and sealed with the appropriate cap. Each of these samples was 
heated in a Biotage Microwave Synthesizer for 90 min at 125 °C. Upon cooling to room 
temperature the desired ester product precipitated as pale yellow solid and was isolated by 
filtration.  
Yield (over 2 steps) 70 and 75%; mp 106.7 e 107.9 °C; 1H NMR (400 MHz, CDCl3):  7.77 (s, 1H), 
7.02 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 8.0 Hz, 1H), 6.78 (dd, J = 8.0, 1.6 Hz, 1H), 6.73 (d, J = 1.6 Hz, 1H), 
6.69 (d, J = 8.8 Hz, 2H), 3.92 (s, 3H), 3.80 (s, 3H), 3.78 (s, 3H), 3.75 (s, 3H); 13C NMR (100 MHz, 
CDCl3,):  52.3, 55.2, 55.8, 55.9, 111.4, 112.8, 113.7, 122.1, 127.3, 128.6, 129.6, 132.4, 140.2, 
148.6, 149.1, 160.3, 168.7; MS: m/z 351.8 [M+Na]+; HR-MS: calculated for C19H21O5: 329.1389, 
found 329.1393.  
Methyl-3,6,7-trimethoxyphenanthrene-9-carboxylate (12)  
 
(E)-Methyl 2-(3,4-dimethoxyphenyl)-3-(4-methoxyphenyl) acrylate (11) (4 g, 12.2 mmol) was 
dissolved in DCM (40 mL) at room temperature. To this solution anhydrous FeCl3 (5 g, 31 mmol) 
was added portion-wise. The resulting reaction mixture was stirred at room temperature for 3 
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hours after which more anhydrous FeCl3 (1 g, 6 mmol) was added. After a total reaction time of 5 
h, complete consumption of substrate was achieved (monitored by 1H NMR). Methanol (~30 mL) 
was added to this crude mixture resulting in a homogeneous red-brownish solution, which was 
subsequently extracted with DCM/water giving the desired phenanthrene product as dark brown 
foam after evaporation of the solvents. Filtration of the dried organic layer over a plug of silica gel 
(10 g), prior to solvent removal, yields the desired product as light brown foam.  
Yield commonly varied from 60 to 75% (>90% purity). 1H NMR (400 MHz, CDCl3):  8.64 (s, 1H), 
8.43 (s, 1H), 7.85 (s, 1H), 7.84 (d, J = 8.8 Hz, 1H), 7.79 (d, J = 2.4 Hz, 1H), 7.20 (dd, J = 8.8, 2.4 Hz, 
1H), 4.10 (s, 3H), 4.08 (s, 3H), 4.02 (s, 3H), 4.01 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3):  52.0, 
55.5, 55.8, 55.9, 103.2, 103.7, 106.9, 116.0, 121.6, 124.2, 125.0, 125.2, 131.3, 131.8, 133.4, 148.9, 
149.9, 160.2, 168.2 ppm; MS: m/z 327 [M]+; HR-MS: calculated for C19H19O5: 327.1232, found 
327.1240.  
(3,6,7)-Trimethoxyphenanthren-9-yl)-methanol (13)  
 
Methyl 3,6,7-trimethoxyphenanthrene-9-carboxylate (12) (3.26 g, 10.0 mmol) was dissolved in 
THF (20 mL) and cooled to 0 °C. To this vigorously stirred solution, LiAlH4 (880 mg, 25 mmol) was 
added in small portions over a period of 10 min. After 30 min the ice bath was removed allowing 
the reaction mixture to warm to room temperature where it was maintained for 2 h. Upon 
quenching of the reaction mixture with sat. NH4Cl (2 mL) a greyish slurry was obtained which was 
filtered over a plug of silica (eluent DCM). The desired reduction product was obtained after 
removal of the volatiles as a pale yellow amorphous solid.  
Yield 95%. 1H NMR (700 MHz, CDCl3):  7.79 (s, 1H), 7.73 (d, J = 2.1 Hz, 1H), 7.69 (d, J = 9.1 Hz, 1H), 
7.51 (s, 1H), 7.45 (s, 1H), 7.15 (dd, J = 9.1, 1.2 Hz, 1H), 5.01 (s, 2H), 4.06 (s, 3H), 4.01 (s, 3H), 3.99 
(s, 3H,), 1.92 (br. s, 1H) ppm; 13C NMR (175 MHz, CDCl3):  55.5, 55.8, 55.9, 64.6, 103.7, 103.9, 
104.8, 115.4, 124.4, 124.8, 125.5, 125.7, 130.1, 131.1, 131.3, 148.7, 149.3, 158.3 ppm; MS: m/z 
281.0 [MOH]+; HR-MS: calculated for C18H17O3 (MOH) 281.1178, found 281.1186.  
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10-(Chloromethyl)-2,3,6-trimethoxyphenanthrene (14)  
 
To a vigorously stirred solution of (3,6,7)-trimethoxyphenanthren-9-yl-methanol (13) (3.0 g, 10 
mmol, in DCM) was added conc. HCl (37%, 5 mL) changing the colour of the initial pale yellow 
solution to dark brown. After 2 h at room temperature the reaction is directly extracted 
(DCM/H2O) giving the title compound 14 as brown solid after removal of the solvent.  
Yield 98%. 1H NMR (400 MHz, CDCl3):  7.76 (s, 1H), 7.70 (d, J = 2.4 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 
7.51 (s, 1H), 7.40 (s, 1H), 7.14 (dd, J = 8.4, 2.4 Hz, 1H), 4.92 (s, 2H), 4.05 (s, 3H), 4.04 (s, 3H), 3.96 
(s, 3H) ppm; 13C NMR (, 100 MHz, CDCl3):  46.1, 55.5, 55.9, 55.9, 103.8, 104.7, 115.6, 125.0, 
125.1, 125.2, 126.8, 127.9, 127.9, 130.4, 131.7, 148.9, 149.4, 158.8 ppm; MS: m/z 316.1 [radical 
cation]; HR-MS: calculated for C18H18O3Cl 317.0944, found 317.0931. 
Potassium 1-[(3,6,7-trimethoxyphenanthren-9-yl)methyl] piperidine-2-carboxylate (15)  
 
A suspension containing rac-pipecolic acid (750 mg, 5.8 mmol) and potassium hydroxide (1.0 g, 
17.9 mmol) in isopropanol (6 mL) was stirred at room temperature for 30 minutes. To this mixture 
10-(chloromethyl)-2,3,6- trimethoxyphenanthrene (14) (1.6 g, 5 mmol) was added portionwise 
over 30 min generating a light brown slurry. The mixture was stirred at 40 °C for 14 hours before 
cooling to rt. Filtration and washing of this crude material, with a minimal amount of cold 
isopropanol (3 mL), yielded the title compound 15 as light brown solid which was used in the 
subsequent step without further purification.  
Yield 87%. 1H NMR (700 MHz, d6-DMSO):  8.81 (s, 1H), 7.94 (br s, 2H), 7.73 (d, J = 8.4 Hz, 1H), 
7.39 (s, 1H), 7.11 (dd, J = 8.4, 2.8 Hz, 1H), 4.58 (d, J = 12.6 Hz, 1H), 3.97 (s, 3H), 3.96 (s, 3H), 3.92 (s, 
3H), 3.03 (d, J = 12.6 Hz, 1H), 2.54 (m, 1H), 2.49 (m, 1H), 1.68-1.73 (m, 2H), 1.50-1.58 (m, 2H), 
1.25-1.30 (m, 1H), 1.10-1.18 (m, 2H) ppm; 13C NMR (175 MHz, d6-DMSO):  24.6, 25.9, 30.9, 51.4, 
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55.9, 56.1, 56.7, 60.5, 71.8, 103.8, 104.2, 109.6, 115.9, 124.5, 125.5, 126.0, 127.8, 130.0, 131.0, 
131.3, 149.0, 149.2, 158.1, 177.7 ppm. 
3,6,7-Trimethoxy-12,13,14,14a-tetrahydro-9H-dibenzo[f,h]pyrido[1,2-b]isoquinolin-15(11H)-one 
(16)  
 
Potassium 1-((3,6,7-trimethoxyphenanthren-9-yl)methyl) piperidine-2-carboxylate (15) (900 mg, 
2.0 mmol) was added to polyphosphoric acid (~3 g) and stirred at 90 °C for 5 h. Within 30 min, a 
thick black solution was obtained which was maintained at this temperature until full conversion 
of the substrate (monitored by LC-MS). The reaction mixture was then cooled to room 
temperature and carefully quenched by addition of methanol (the temperature cannot rise above 
40°C). The resulting solution was then neutralized by careful addition of a saturated solution of 
potassium carbonate. Extractive work-up of this material with DCM/H2O gave a crude product 
which was purified by column chromatography (15% EtOAc/Hex) providing the title compound 16 
as a pale yellow solid.  
Yield 70%. 1H NMR (700 MHz, CDCl3):  9.26 (d, J = 9.8 Hz, 1H), 7.24 (s, 1H), 7.72 (d, J = 1.4 Hz, 1H), 
7.22 (1H, dd, J = 9.8, 1.4 Hz), 7.11 (s, 1H), 4.36 (d, J = 15.4 Hz, 1H), 4.07 (s, 3H), 4.01 (s, 3H), 3.97 (s, 
3H), 3.65 (d, J = 15.4 Hz, 1H), 3.19 (d, J = 10.5 Hz, 1H), 2.77 (d, J = 10.5 Hz, 1H), 2.47 (d, J = 13.3 Hz, 
1H), 2.40 (t, J = 13.3 Hz, 1H), 1.96 (d, J = 13.3 Hz, 1H), 1.70-1.77 (m, 1H), 1.66 (tq, J = 13.3, 2.8 Hz, 
1H), 1.60 (q, J = 13.3 Hz, 1H), 1.45 (tq, J = 13.3, 2.8 Hz, 1H) ppm; 13C NMR (175 MHz, CDCl3):  23.9, 
24.9, 27.4, 54.8, 55.3, 55.8, 55.9, 56.0, 68.9, 103.7, 104.3, 115.6, 122.7, 123.0, 123.1, 127.3, 129.3, 
130.9, 139.3, 149.5, 151.0, 157.8, 197.3 ppm; MS: m/z 392.0 [M]+; HR-MS: calculated for 
C24H26O4N 392.1861, found 392.1855. 
3,6,7-Trimethoxy-11,12,13,14,14a,15-hexahydro-9H-dibenzo-[f,h]pyrido[1,2-b]isoquinoline 
(Rac-7)  
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To a solution of 16 (391 mg, 1.0 mmol) in THF (5 mL, cooled to 0 °C), LiAlH4 (100 mg, 2.6 mmol) 
was added portionwise. After 10 min the mixture was allowed to warm to room temperature 
where it was stirred for 2 hours, prior to careful quenching by addition of aqueous NH4Cl solution. 
After aqueous extraction with DCM the combined organic layers were dried over anhydrous 
Na2SO4 and evaporated under reduced pressure to give the intermediate aminoalcohol product as 
yellow oil which was not purified further. This crude material was redissolved in DCM (2 mL) and 
combined with TFA (0.3 mL) and Et3SiH (0.3 mL). After stirring for 4 h at 40 °C the reaction had 
reached completion (monitored by LC-MS) and was quenched by addition of aqueous NaHCO3 
solution. The crude product was isolated after aqueous extraction as yellow foam. Final 
purification was accomplished by flash column chromatography furnishing racemic boehmeriasin 
A (Rac-7) as solid after evaporation of the solvents.  
Yield: 82%. IR (neat):  2931.1, 1610.4, 1511.5, 1467.9, 1253.9, 1201.9, 1138.6, 1038.7 cm-1. MS: 
m/z 377.9 (M+); HR-MS: calculated for C24H28O3N 378.2069, found 378.2055.  
HPLC conditions: (AD 5 cm, EtOH: Hexane 1:9, 1 ml/min, 22 °C) can be used in order to achieve 
resolution of racemic boehmeriasin A. 
 
Enantioselective synthesis of Boehmeriasin A 
1-(4-Methoxyphenyl)-2-(1-tert-butoxycarbonylpiperidin-2-yl)ethanol (17) 
 
To a solution of aldehyde (0.34 g, 1.5 mmol) in THF (13 mL) at 78 °C, (4-
methoxyphenyl)magnesium bromide (6 mL, 3 mmol) was added, and the new solution was stirred 
for 10 min at 78 °C and then overnight at room temperature. After the completion of the reaction, 
the solvent was evaporated in vacuum, sat. NH4Cl was added and the aqueous layer was 
extracted 3 times with EtOAc. The combined organic layers were washed with water and brine, 
dried with Na2SO4, filtered and evaporated. The residue was purified by flash column 
chromatography (Hex/EtOAc 7:3) to provide the two diastereomer alcohols 17 as oils. 
17a (R-COH) and 17b (S-COH) 
Yields 92e95%; 17a (R-COH): []D = + 35.9 (c 0.90 in CHCl3), 17b (S-COH): []D = - 36.6 (c 0.92 in 
CHCl3); 1H NMR (400 MHz, CDCl3):  7.32 (d, J = 8.4 Hz, 2H), 6.90 (d, J = 8.4 Hz, 2H), 4.61 (m, 1H), 
4.41 (m, 1H), 4.04 (m, 1H), 3.82 (s, 3H), 2.80 (t, J = 11.6 Hz, 1H), 2.20 (td, J = 14.0, 2.0 Hz, 1H), 
1.78-1.47 (m, 8H), 1.52 (s, 9H) ppm; 13C NMR (100 MHz, CDCl3):  19.9, 26.2, 29.1, 29.9, 40.2, 40.9, 
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47.4, 56.0, 70.2, 81.1, 114.4, 127.5, 136.9, 155.6, 159.0 ppm; HR-MS: calculated for C19H30NO4 
336.2175, found 17a: 336.2156; HR-MS found 17b: 336.2179. 
17a (S-COH) and 17b (R-COH) 
Yields 92e95 %; 17a (S-COH): []D = + 71.9 (c 1.06 in CHCl3), 17b (R-COH): []D = - 73.3 (c 0.98 in 
CHCl3); 1H NMR (400 MHz, CDCl3):  7.32 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 8.4 Hz, 2H), 4.71 (m, 1H), 
4.38 (m, 1H), 3.94 (m, 1H), 3.82 (s, 3H), 2.82 (td, J = 13.2, 1.6 Hz, 1H), 2.12 (dt, J = 14.4 Hz J ¼ 6.8 
Hz, 1H), 1.85 (dt, J = 14.4, 5.6 Hz, 1H), 1.62-1.51 (m, 6H), 1.48 (s, 9H), 1.43-1.40 (m, 1H) ppm; 13C 
NMR (100 MHz, CDCl3):  19.8, 26.0, 29.2, 30.4, 40.2, 40.9, 49.3, 56.0, 73.0, 80.4, 114.4, 127.7, 
137.6, 156.2, 159.6 ppm; HR-MS: found 17a 336.2160, HR-MS: found 17b 336.2158.  
1-(4-Methoxyphenyl)-2-(1-tert-butoxycarbonylpiperidin-2- yl)ethanone (18)  
 
To a solution of alcohol 17 (0.22 g, 0.65 mmol) in DCM (8.4 mL), Dess-Martin periodinane (0.34 g, 
0.78 mmol) was added and the new mixture was stirred for 1 h at room temperature. After the 
completion of the reaction, the solvent was evaporated in vacuum, 10% K2CO3 was added and the 
aqueous layer was extracted 3 times with EtOAc. The combined organic layers were washed with 
water and brine, dried with Na2SO4, filtered and evaporated. The residue was purified by flash 
column chromatography (Hex/EtOAc 7:3) to provide ketone 18 as oil.  
Yield 83%; 18a: []D = - 34.2 (c 0.95 in CHCl3), 18b: []D = +35.6 (c 1.00 in CHCl3); 1H NMR (400 
MHz, CDCl3):  8.00 (d, J = 8.8 Hz, 2H), 6.96 (d, J = 8.8 Hz, 2H), 4.82 (m, 1H), 4.05 (m, 1H), 3.89 (s, 
3H), 3.18 (dd, J = 14.0, 6.4 Hz, 1H), 3.12 (dd, J = 14.0, 6.4 Hz, 1H), 2.90 (td, J = 13.0, 2.3 Hz, 1H), 
1.64 (m, 5H), 1.41 (s, 10H) ppm; 13C NMR (100 MHz, CDCl3):  18.9, 25.3, 28.1, 28.4, 39.0, 39.4, 
48.4, 55.5, 79.6, 113.8, 130.1, 130.6, 154.8, 163.6, 197.0 ppm; HR-MS: calculated for C19H28NO4 
334.2018, found 18a 334.2009; HR-MS: found 18b 334.2006.  
 
1-(4-Methoxyphenyl)-2-(piperidin-2-yl)ethanone hydrochloride (19) 
 
To a cooled solution at 0 °C of ketone 18 (0.31 g, 0.94 mmol) in MeOH (7.5 mL), TMSCl (0.59 mL, 
5.7 mmol) was added and the solution was stirred overnight at room temperature. After the 
completion of the reaction, the solvent was evaporated in vacuum, to provide ketone 19 as oil.  
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Yield 95%; 19a: []D = +17.5 (c 1.14 in CHCl3); 19b: []D = - 18.5 (c 1.25 in CHCl3); 1H NMR (400 
MHz, CDCl3):  9.73 (s, 1H), 9.30 (s, 1H), 7.92 (d, J = 8.0 Hz, 2H), 6.86 (d, J = 8.0 Hz, 2H), 3.84 (s, 
3H), 3.78e3.72 (m, 1H), 3.70e3.64 (m, 1H), 3.55e3.47 (m, 2H), 2.97e2.91 (m, 1H), 2.00e1.80 (m, 
5H), 1.58e1.50 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3):  22.8, 23.1, 29.1, 41.6, 45.8, 54.7, 56.2, 
114.6, 129.7, 131.4, 164.7, 195.7 ppm.  
2-(2-Bromo-4,5-dimethoxyphenyl)-1-(2-(2-(4-methoxyphenyl)-2-oxoethyl)piperidin-1-
yl)ethanone (21)  
 
To a solution of 2-bromo-4,5-dimethoxyphenylacetic acid 20 (0.25 g, 0.90 mmol) in THF (23 mL), 
HATU (0.39 g, 0.99 mmol) and DIPEA (0.31 mL, 1.8 mmol) were added and the new mixture was 
stirred for 30 min at rt. Then, the solution was cooled at 0 °C and a solution of compound 19 (0.24 
g, 0.90 mmol) in THF (12 mL) and DIPEA (200 mL) was added and the new solution was stirred for 
1 h at rt. After the completion of the reaction, the solvent was evaporated in vacuum, sat. NH4Cl 
was added and the aqueous layer was extracted 3 times with DCM. The combined organic layers 
were washed with water and brine, dried with Na2SO4, filtered and evaporated. The residue was 
purified by flash column chromatography (Hex/EtOAc 3:7) to provide compound 21 as oil.  
Yield 80%; 21a: []D = - 1.2 (c 0.82 in CHCl3); 21b: []D = + 1.3 (c 0.86 in CHCl3); 1H NMR (400 MHz, 
CDCl3, amide rotamers 1:1): rotamer a  8.05 (d, J = 8.8 Hz, 2H), 7.03 (s, 1H), 6.97 (d, J = 8.8 Hz, 
2H), 6.83 (s, 1H), 5.33-5.28 (m, 1H), 4.00 (d, J = 16.0 Hz, 1H), 3.90 (s, 3H), 3.87 (s, 3H), 3.85 (s, 3H), 
3.78-3.72 (m, 2H), 3.26 (, d, J = 6.8 Hz, 2H), 3.23-3.20 (m, 1H), 1.78-1.56 (m, 5H), 1.46-1.30 (m, 1H) 
ppm; rotamer b  7.93 (d, J = 8.8 Hz, 2H), 6.96 (s, 1H), 6.95 (d, J = 8.8 Hz, 2H), 6.83 (s, 1H), 4.78-
4.74 (m, 1H), 4.67-4.64 (m, 1H), 3.87 (s, 3H), 3.85 (s, 3H), 3.81 (s, 3H), 3.78-3.72 (m, 2H), 3.18-3.09 
(m, 2H), 2.70 (td, J = 13.0, 2.4 Hz, 1H), 1.78-1.56 (m, 5H), 1.46-1.30 (m, 1H) ppm; 13C NMR (100 
MHz, CDCl3): rotamer a  20.0, 26.3, 30.0, 39.6, 41.5, 42.7, 47.4, 56.2, 56.7, 114.0, 115.3, 116.0, 
128.1, 130.5, 131.5, 149.0, 149.2, 164.5, 170.4, 197.5 ppm; rotamer b  19.3, 26.2, 27.9, 38.3, 
39.2, 41.1, 50.4, 56.7, 113.5, 114.6, 115.0, 116.0, 127.7, 130.3, 131.0, 149.0, 149.2, 164.3, 170.1, 
196.4 ppm; HR-MS: calculated for C24H29BrNO5 490.1229, found 21a 490.1215, HR-MS: found 21b 
490.1210. 
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3-(2-Bromo-4,5-dimethoxyphenyl)-2-(4-methoxyphenyl)-1,6,7,8,9,9a-hexahydroquinolizin-4-one 
(22)  
 
A solution of compound 21 (0.37 g, 0.76 mmol) in 5% ethanolic KOH (15.8 mL) was refluxed for 2 
hours. After the completion of the reaction, the solvent was evaporated in vacuum, sat. NH4Cl 
was added and the aqueous layer was extracted 3 times with DCM. The combined organic layers 
were washed with water and brine, dried with Na2SO4, filtered and evaporated. The residue was 
purified by flash column chromatography (Hex/EtOAc 4:6) to provide atropisomer compounds 22 
as oils.  
Yield 85%; 22a (mode 1): []D = + 57.6 (c 0.89 in CHCl3); 22b (mode 1): []D = - 58.4 (c 0.62 in 
CHCl3); 1H NMR (400 MHz, CDCl3):  7.01 (d, J = 8.4 Hz, 2H), 7.00 (s, 1H), 6.70 (d, J = 8.4 Hz, 2H), 
6.46 (s, 1H), 4.56 (br d, J = 13.6 Hz, 1H), 3.86 (s, 3H), 3.76 (s, 3H), 3.68 (m, 1H), 3.65 (s, 3H), 2.86-
2.69 (m, 3H), 1.95-1.84 (m, 3H), 1.58-1.44 (m, 3H) ppm; 13C NMR (100 MHz, CDCl3):  23.9, 25.4, 
34.1, 38.3, 43.5, 54.1, 55.8, 56.6, 56.7, 114.0, 115.5, 115.6, 116.1, 129.6, 131.2, 131.3, 132.2, 
146.3, 148.7, 149.3, 159.8, 166.8 ppm; ESI-MS 392: [M-Br]; HR-MS: calculated for C24H27BrNO4 
472.1123, found 22a 472.1110, HR-MS: found 22b 472.1109. 
22a (mode 2): []D = - 39.2 (c 1.09 in CHCl3); 22b (mode 2): []D = + 40.4 (c 1.10 in CHCl3); 1H NMR 
(400 MHz, CDCl3):  7.04 (d, J = 8.8 Hz, 2H), 6.99 (s, 1H), 6.71 (d, J = 8.8 Hz, 2H), 6.50 (s, 1H), 4.62 
(br d, J = 13.6 Hz, 1H), 3.85 (s, 3H), 3.76 (s, 3H), 3.70 (s, 3H), 3.67-3.60 (m, 1H), 3.09 (dd, J = 17.2, 
6.4 Hz, 1H), 2.69-2.63 (m, 2H), 1.97-1.92 (m, 1H), 1.89-1.82 (m, 1H), 1.76-1.73 (m, 2H), 1.70-1.59 
(m, 2H) ppm, 13C NMR (100 MHz, CDCl3):  24.4, 25.1, 32.5, 36.1, 44.6, 53.5, 55.2, 55.9, 56.1, 
113.4, 115.0, 115.2, 115.8, 128.9, 130.4, 130.5, 131.9, 145.7, 148.0, 148.6, 159.2, 166.1 ppm; HR-
MS: found 22a 472.1113, HR-MS: found 22b 472.1111. 
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3,6,7-Trimethoxy-11,12,13,14,14a,15-hexahydro-9H-phenanthro[9,10-b]quinolizin-9-one (23)  
 
To a solution of compound 22 (0.12 g, 0.24 mmol) in DMA (5.3 mL), Pd(OAc)2 (13 mg, 0.058 
mmol), 2'-(diphenylphosphino)-N,N' -dimethyl-(1,1'-biphenyl)-2-amine (28 mg, 0.072 mmol) and 
K2CO3 (0.066 g, 0.48 mmol) were added and the new mixture was heated at 125 C for 5 h. After 
the completion of the reaction, H2O was added and the aqueous layer was extracted 3 times with 
EtOAc. The combined organic layers were washed with water and brine, dried with Na2SO4, 
filtered and evaporated. The residue was purified by flash column chromatography (Hex/EtOAc 
4:6) to provide compound 17 as oil.  
Yield 60%; 23a: []D = - 108.4 (c 0.44 in CHCl3), 23b: []D = +110.2 (c 0.65 in CHCl3); 1H NMR (CDCl3, 
400 MHz):  9.41 (s, 1H), 8.01 (d, J = 8.8 Hz, 1H), 7.88 (d, J = 3.2 Hz, 1H), 7.87 (s, 1H), 7.23 (dd, J = 
9.2, 2.4 Hz, 1H), 4.74 (br d, J = 11.6 Hz, 1H), 4.12 (s, 6H), 4.05 (s, 3H), 3.64-3.56 (m, 1H), 3.52 (dd, J 
= 16.4, 4.8 Hz, 1H), 3.05 (dd, J = 16.0, 5.2 Hz, 1H), 2.90 (td, J = 13.2, 3.2 Hz, 1H), 2.01 (br d, J = 10.0 
Hz, 1H), 1.93-1.91 (m, 2H), 1.67-1.48 (m, 3H) ppm, 13C NMR (100 MHz, CDCl3):  23.6, 25.4, 33.4, 
36.6, 43.5, 53.5, 56.2, 56.5, 56.6, 103.7, 105.1, 109.5, 116.1, 120.3, 123.4, 125.2, 126.4, 127.2, 
134.0, 135.1, 149.0, 150.2, 160.2, 168.2 ppm; EI-MS: 391 [M]. HR-MS calculated for C24H26NO4 
392.1861, found 23a 392.1850; HR-MS: found 23b 392.1847. 
3,6,7-Trimethoxy-11,12,13,14,14a,15-hexahydro-9H-dibenzo[f,h]pyrido[1,2-b]isoquinoline, 
boehmeriasin A [7a and 7b] 
 
To a cooled at 0 °C suspension of LiAlH4 (0.020 g, 0.49 mmol) in THF (5 mL), a solution of 
compound 23 (48 mg, 0.12 mmol) in THF (2.5 mL) was added dropwise and the new mixture was 
refluxed for 2 h. After the completion of the reaction, the reaction mixture was cooled at 0 °C, and 
carefully quenched by addition of 10% NaOH aqueous solution and after the THF was evaporated 
in vacuum. Then, the aqueous layer was extracted 3 times with EtOAc. The combined organic 
layers were washed with water and brine, dried with Na2SO4, filtered and evaporated. The residue 
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was purified by flash column chromatography (DCM/MeOH 9.6:0.4) to provide boehmeriasin A (7) 
as solid.  
Yield 80%; 7a: []D = - 79.2 (c 0.12 in MeOH), 7b: []D = + 80.6 (c 0.10 in MeOH), 1H NMR (400 
MHz, CDCl3):  7.92-7.90 (m, 3H), 7.22 (dd, J = 8.8, 2.4 Hz, 1H), 7.14 (s, 1H), 4.64 (d, J = 15.2 Hz, 
1H), 4.12 (s, 3H), 4.07 (s, 3H), 4.03 (s, 3H), 3.58 (d, J = 15.2 Hz, 1H), 3.30 (d, J = 11.2 Hz, 1H), 3.18 
(dd, J = 16.4, 2.8 Hz, 1H), 2.94 (dd, J = 16.4, 6.0 Hz, 1H), 2.41-2.29 (m, 2H), 2.03 (d, J = 13.2 Hz, 1H), 
1.92-1.78 (m, 3H), 1.56-1.45 (m, 2H) ppm; 13C NMR (100 MHz, CDCl3):  25.1, 26.7, 34.4, 35.3, 
56.2, 56.7, 56.8, 57.1, 58.2, 103.8, 104.7, 105.3, 115.4, 123.9, 124.9, 125.7, 125.9, 126.6, 130.9, 
148.9, 150.1, 158.2 ppm; HR-MS: calculated for C24H28O3N 378.2069, found 7a 378.2057; Anal. 
Calcd for C24H27NO3: C, 76.36; H, 7.21; N, 3.71; Found 7a: C, 75.58; H, 7.02; N, 3.56; HR-MS: found 
7b 378.2058; Found 7b: C, 75.53; H, 7.04; N, 3.53. 
4.6.2. Virtual screening  
(R)-And (S)-boehmeriasin A were used as input structures for Hurakan running the jobs on default 
parameters.  
4.6.3. Biological assay 
Cell proliferation  
 Endothelial cells. Bovine aortic endothelial cells (BAEC) and human dermal microvascular 
endothelial cells (HMEC-1) were seeded in 48-well plates at 10,000 cells/well and 20,000 
cells/well, respectively. After 24 h, 5-fold dilutions of the compounds were added. The cells 
were allowed to proliferate 3 days (or 4 days for HMEC-1) in the presence of the compounds, 
trypsinized, and counted by means of a Coulter counter (Analis, Belgium).  
 Tumour cells. Human cervical carcinoma (HeLa) cells were seeded in 96- well plates at 15,000 
cells/well in the presence of different concentrations of the compounds. After 4 days of 
incubation, the cells were trypsinized and counted in a Coulter counter. Suspension cells 
(Mouse leukaemia L1210 and human lymphoid Cem cells) were seeded in 96-well plates at 
60,000 cells/well in the presence of different concentrations of the compounds. L1210 and 
Cem cells were allowed to proliferate for 48 h or 96 h, respectively and then counted in a 
Coulter counter. The 50% inhibitory concentration (IC50) was defined as the compound 
concentration required to reduce cell proliferation by 50%. Combretastatin A-4 phosphate was 
added as reference compound.  
Analysis of in vitro sirtuin inhibition - SIRT1 and SIRT2 in Vitro Assay. The compounds were 
studied using the Fluor de Lys fluorescence assays which are described in the BioMol product 
sheet (Enzo Life Sciences). In assays the BioMol KI177 substrate was used for SIRT1 and the KI179 
substrate for SIRT2. The determined Km value of SIRT1 for KI177 was 58 M and the Km of SIRT2 
 
76 
 
for KI179 was 198 M.89 The Km values of SIRT1 and SIRT2 were 558 M and 547 M for NAD+ 
reported by BioMol, respectively. Briefly, assays were carried out using the Fluor de Lys acetylated 
peptide substrate at 0.7 Km and NAD+ (Sigma N6522 or BioMol KI282) at 0.9 Km, recombinant 
GST-SIRT1/2-enzyme and SIRT assay buffer (KI286). GST-SIRT1 and GST-SIRT2 were produced as 
described previously.90 The buffer together with Fluor de Lys acetylated peptide substrate, NAD+ 
and DMSO/compounds in DMSO (2.5 mL in 50 mL total reaction volume; DMSO from Sigma, 
D2650) were preincubated for 5 min at room temperature. Then enzyme was added to start the 
reaction. The reaction mixture was incubated for 1 h at 37 °C and after that, Fluor de Lys 
developer (KI176) and 2 M nicotinamide (KI283) in SIRT assay buffer (total volume 50 mL) were 
added. The incubation was continued for 45 min at 37 °C. Finally, fluorescence readings were 
obtained using EnVision 2104 Multilabel Reader (PerkinElmer) with excitation wavelength 370 nm 
and emission 460 nm. The Fluor de Lys fluorescence assays of sirtuins are regularly performed 
with compounds from our own collections to calibrate data between assay runs. 
Topoisomerase-mediated DNA relaxation: Supercoiled pBR322 plasmid DNA (0.25 mg, Fermentas 
Life Sciences) was incubated with 1U topoisomerase II (human recombinant topoisomerase II a, 
USB Corporation) or 2U topoisomerase I (human recombinant topoisomerase I, TopoGen) and the 
test compounds as indicated, for 60 min at 37 °C in 20 L reaction buffer. Reactions were stopped 
by adding 4 mL stop buffer (5% sodium dodecyl sulphate (SDS), 0.125% bromophenol blue, and 
25% glycerol), 50 mg/mL proteinase K (Sigma) and incubating for a further 30 min at 37 °C. The 
samples were separated by electrophoresis on a 1% agarose gel at room temperature. The gels 
were stained with ethidium bromide 1 mg/mL in TAE buffer (0.04 M Triseacetate and 0.001 M 
EDTA), transilluminated by UV light, and fluorescence emission was visualized by a CCD camera 
coupled to a Bio-Rad Gel Doc XR apparatus.  
Topoisomerase II-mediated DNA cleavage: Reaction mixtures (20 L) containing 10 mM TriseHCl 
(pH = 7.9), 50 mM NaCl, 50 mM KCl, 5 mM MgCl2, 0.1 mM EDTA, 15 g/mL bovine serum albumin, 
1 mM ATP, 0.25 g pBR322 plasmid DNA (Fermentas Life Sciences), 10 U topoisomerase II (human 
recombinant topoisomerase II a, USB Corporation) and test compounds were incubated for 60 
min at 37 °C. Reactions were stopped by adding 4 L stop buffer (5% SDS, 0.125% bromophenol 
blue and 25% glycerol), 50 g/mL proteinase K (Sigma) and incubating for a further 30 min at 37 
°C. The samples were separated by electrophoresis on a 1% agarose gel containing ethidium 
bromide 0.5 g/mL at room temperature in TBE buffer (0.09 M Triseborate and 0.002 M EDTA), 
                                                          
89 P. H. Kiviranta; T. Suuronen; E. A. A. Wallen; J. Leppanen; T. H. Nyronen; T. Jarvinen; A. Poso; J. Med. Chem., 2004, 47, 6292. 
90 P. H. Kiviranta; J. Leppanen; V. M. Rinne; T. Suuronen; O. Kyrylenko; S. Kyrylenko; E. Kuusisto; A. J. Tervo; t. Jarvinen; A. Salminen; A. 
Poso; E. A. A. Wallen; Bioorg. Med. Chem. Lett., 2007, 17, 2448. 
 
77 
 
transilluminated by UV light, and fluorescence emission was visualized by a CCD camera coupled 
to a Bio-Rad Gel Doc XR apparatus.  
Topoisomerase I-mediated DNA cleavage: Reaction mixtures (20 L) containing 35 mM Tris-HCl 
(pH = 8.0), 72 mM KCl, 5 mM MgCl2, 5 mM DTT, 5 mM spermidine, 0.01% bovine serum albumin, 
20 ng pBR322 plasmid DNA (Fermentas Life Sciences), 5 U topoisomerase I (human recombinant 
topoisomerase I, TopoGen) and test compounds were incubated for 60 min at 37 °C. Reactions 
were stopped by adding 4 L of stop buffer (5% SDS, 0.125% bromophenol blue and 25% 
glycerol), 50 g/ mL proteinase K (Sigma) and incubating for a further 30 min at 37 °C. The 
samples were separated by electrophoresis on a 1% agarose gel containing ethidium bromide 0.5 
g/mL (Sigma) at room temperature in TBE buffer (0.09 M Triseborate and 0.002 M EDTA), 
transilluminated by UV light, and fluorescence emission was visualized by a CCD camera coupled 
to a Bio-Rad Gel Doc XR apparatus. 
4.6.4. Docking studies 
Topoisomerase: (R)- and (S)-Boehmeriasin A were docked in the enzyme mediated DNA cleavage 
site in the crystal structure of the topoisomerase I and of the topoisomerase II-beta, both in 
complex with DNA using AutoDock 4.2 software.  
Sirtuins: (R)- and (S)-Boehmeriasin A were docked in the crystal structure of SIRT1 complex with 
Ex-527(PDB id 4I5I) and the homology model of SIRT2 using Schrodinger's Glide software.  
 
78 
 
 
 
 
Chapter 5 
 
Synthesis of pironetin-dumetorine hybrids 
as new tubulin binders 
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5.1. Introduction 
Natural compounds that target microtubules have proven to be one of the best classes of cancer 
chemotherapeutic drugs available in clinics to date.91 Microtubules (MTs) are cylinders of linear 
polymers (protofilaments), formed by the polymerization of the -tubulin heterodimers which 
are arranged head to tail in a polar fashion (Figure 38).92 
 
Figure 38 
In eukaryotes, microtubules are one of the major components of the cytoskeleton, and thus they 
are fundamental in many biological processes, such as structural support, motility, intracellular 
transport, and DNA segregation. They are also involved in chromosome separation during the 
mitosis because they are the major constituents of mitotic spindles, the subcellular structure that 
separates chromosomes between daughter cells.  
Their wide bioactivity in all cells is regulated in large part by their dynamic instability, referred to 
the individual microtubule ability to switch between growing and shrinking phases at the ends 
(Figure 39). 
 
Figure 39 
                                                          
91 E. Mukhtar; V. M. Adhami; H. Mukhtar; Mol Cancer Ther., 2014, 13, 275. 
92 L. A. Amos; Org .Biomol. Chem., 2004, 2, 2153. 
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Cell division is required for tumour growth, both directly, by cancer cell division, and indirectly, by 
endothelial cell division as a step in angiogenesis and tumour vascularisation. Some of the 
discovered natural compounds able to interfere with microtubules, blocking the cell cycle and 
inducing apoptosis, act by inhibiting the polymerisation of tubulin, while others inhibit 
depolymerisation.93  
A large number of drugs are known to be able to bind -tubulin and in this context it is possible to 
identify three well established drug binding domains: i) the vinca domain, ii) the taxane site and 
iii) the colchicine site (Figure 40).94 
 
Figure 40 
By contrast, the number of molecules that bind to α-tubulin is very small. The first reported 
example is pironetin, a potent microtubule polymerization inhibitor, isolated from the 
fermentation broth of Streptomyces Discodermolide,95 followed, a short time later, by the 
peptide-like hemiasterlin family (Figure 41).96 
 
Figure 41 
This polyketide has a unique structure containing the pharmacophoric alkenyl-5,6-dihydro-2H-
pyran-2-one moiety and an alkyl chain, which is simpler than the structure of other M phase 
inhibitors. From the analyses of structure-activity relationship, it was revealed that pironetin 
binds to Lys352 of -tubulin by Michael addition on ,-unsuturated-pyranone ring. In addition, it 
                                                          
93a) N.G. Vindya; N. Sharma; M. Yadav; K.R. Ethiraj; Curr. Top. Med. Chem., 2015, 15, 73; b) E.C. Breen; J.J. Walsh; Curr. Med. Chem., 
2010, 17, 609. 
94 K. H. Downing; Annu. Rev. Cell. Dev. Biol., 2000, 16, 89. 
95 F. Sarabia; M. García-Castro; A. Sánchez-Ruiz; Curr. Bioact. Compd., 2006, 2, 269. 
96 H. J. Anderson; J. E. Coleman; R. J. Andersen; M. Roberge; Cancer Chemother. Pharmacol., 1997, 39, 223. 
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has been suggested that the Asn258 residue of α-tubulin fixes the pironetin molecule through two 
hydrogen bonds with the pyrone carbonyl and the methoxy oxygen atom (Figure 42).97  
 
 
Figure 42: a) Schematic model of the cavalent union of pironetin with its binding site at the tubulin suface;b) 
secondary structure around the pironetin binding site on tubulin and binding model. 
Since it is known that most of the compounds containing -unsaturated lactone covalently bind 
to sulfhydryl group of cysteine residue of proteins, pironetin is a unique compound which binds 
specific lysine residue on -tubulin. These features of pironetin suggest that it is possible to 
create a new drug useful for cancer therapy from pironetin as a lead compound. In this context, 
several efforts have been done by J. Alberto Marco and his group in the design and development 
of novel -tubulin-binding pironetin analogues during last years.98 
 
5.2. Aim of this work 
This project was born in collaboration with the group Daniele Passarella of the university of Milan, 
which in the last years has addressed its attention toward the total synthesis of 2-piperidinyl 
alkaloids, such as (+)- dumetorine (Figure 43).99 Dumetorine was isolated in 1985 from the tubers 
                                                          
97 a)T. Usui; H. Watanabe; H. Nakayama; Y. Tada; N. Kanoh; M. Kondoh; T. Asao; K. Takio; H. Watanabe; K. Nishikawa; T. Kitahara; H. 
Osada; Chem. Bio., 2004, 11, 799; b) H. Watanabe; H. Watanabe; T. Usui; M. Kondoh; H. Osada; T. Kitahara; J. Antibiot., 2000, 53, 540. 
98 a) J. Paños; S. Díaz-Oltra; M. Sánchez-Peris; J. García-Pla; J. Murga; E. Falomir; M. Carda; M. Redondo-Horcajo; J. F. Díaz; I. Barasoain; 
J. A. Marco; Org. Biomol. Chem., 2013, 11, 5809; b) M. Carda; J. Murga; S. Díaz-Oltra; J. García-Pla; J. Paños; E. Falomir; C. Trigili; J. F. 
Díaz; I. Barasoain; J. A. Marco; Eur. J. Org. Chem., 2013, 1116; c) J. A. Marco; J. García-Pla; M. Carda; J. Murga; E. Falomir; C. Trigili, S. 
Notararigo; J. F. Díaz; I. Barasoain; Eur. J. Med. Chem., 2011, 46, 1630. 
99 a) E. Riva; A. Rencurosi; S. Gagliardi; D. Passarella; M. Martinelli; Chem. Eur. J., 2011, 17, 6221; b) D. Passarella; S. Riva; G. Grieco; F. 
Cavallo; B. Checa; F. Arioli; E. Riva; D. Comi; B. Danieli; Tetrahedron: Asymmetry,2009, 20, 192. 
 a)  b) 
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of Dioscorea dumetorum Pax, a West African yam whose extracts have found a notable use in folk 
medicine and arrow poisons.100  
Based on this background, we decided to prepare a new pironetin-like compound with the ability 
to bind selectively -tubulin. The molecule target was designed as a hybrid 20 between pironetin 
and dumetorine, given that it is possible to identify a similar lactonic moiety in both of them. 
Indeed, the nitrogen atom of the piperidinic ring of dumetorine could mimic the hydroxylic group 
bound to C9 in the pironetin, important in terms of hydrogen bonds with tubulin residues (Figure 
43).  
 
Figure 43 
The presence of 3 stereocentres opens the way toward 8 stereoisomers that could interact in 
different ways with the biological target. Our purpose is to identify the most bioactive 
stereoisomer and, as an extension of the project, connect it to a -tubulin binder in order to 
achieve a cytotoxic TBMs with a potential ability to bind to either - or -tubulin and produce a 
microtubule-destabilizing effect.  
 
5.3. Docking studies 
Previous docking studies were performed by Professor S. Pieraccini from University of Milan in 
order to support the disegn of the novel compound. First of all, they allowed to highlight a similar 
orientation of the hybrid 20 compared with pironetin on the binding site of -tubulin: the lactonic 
ring is direct toward the enter of the binding task, while the piperidinic ring fills the position of the 
pironetin alkyl chain. Also, our molecule would seem to form a major number of hydrogen bonds 
with tubulin than pironetin, whereby a stronger interaction is expected (Figure 44).  
                                                          
100 D. G. Corley; M. S. Tempesta; M. M. Iwu; Tetrahedron Lett., 1485, 26, 1615. 
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Figure 44: a) Docked structure of pironetin in the binding task of -tubulin; b) docked structures of hybrid in 
the binding task of -tubulin. 
Molecular dockings of the eight possible stereoisomers 38b-45b were performed (Figure 45). 
 
Figure 45 
The docked compounds show different orientation and a moderate affinity for the putative 
binding site. One of the main features in common between most of the docked molecules (except 
41b and 45b) is the formation of an H-bond involving the N-H group of the piperidinic ring with 
either Val260 or with Thr257 backbone oxygen and a hydrophobic interaction with Pro261 (Figure 
46). 
a)
) 
b)
) 
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Figure 46: a) Docking pose of compound 38b. The piperidine N-H group forms an H-bond with Thr257 backbone oxygen; 
b) Docking pose of compound 40b. N-H group of piperdine forms an H-bond with Thr257 backbone oxygen. Indeed it 
also presents a hydrophobic interaction between piperidine ring and Pro261; c) Docking pose of compounds 42b and 
44b. The docked structures show an H-bond between piperidine N-H group and Thr257 backbone oxygen; d) Piperidine 
N-H groups of compounds 39b and 43b interact with Val260 backbone oxygen. There is a hydrophobic interaction 
between the lactones and Pro261. 
Compounds 41b and 45b have the same orientation within the binding site and preferentially 
exhibit an intramolecular interaction (Figure 47) between the carbonyl of the lactone ring and the 
amino group of piperidine.  
 
Figure 47: Compounds 41b and 45b have a peculiar behaviour, they exhibit an intramolecular interaction between the 
carbonyl of the lactone and the N-H group of the piperidine. 
a) b) 
c) d) 
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Albeit the exhibited affinity of the the proposed pironetine derivatives is not impressive, pironetin 
binding site seems to be a plausible putative binding site for all of them due to the flexibility of 
the skeleton. Therefore experimental investigations are needed to check the reality and potency 
of these interactions.  
 
5.4. Chemistry 
As consequence of the computational results, we planned the preparation of the eight 
stereoisomers according to the retrosynthetic scheme showed in Scheme 16. 
 
Scheme 16 
The preparation is based on the reactivity and the versatility of aldehyde 21 (previously used as 
enantiopure compound in boehmeriasin A synthesis). The use of allylmagnesium bromide in the 
presence of enantiopure DIP-Cl101 induces the formation of the allylic alcohols 22a-25a with 
complete stereocontrol at C2’ (numbering system of the target compound) with the formation of 
two distereoisomers. By this way the use of (-)-DIP-Cl furnished the distereoisomers 22a and 23a 
while the use of (+)-DIP-Cl led to the compounds 24a and 25a (Scheme 17).  
 
Scheme 17 
The hydroxylic group of compounds 22a-25a was protected as methyl ether forming 22b-25b 
which were treated with ozonolysis conditions in order to achieve the corresponding aldehydes 
26-29 (Scheme 18). 
                                                          
101 M. V. R. Reddy; H. C. Brown; P. V. Ramachandran; J. Orgmet. Chem., 2001, 624, 239. 
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Scheme 18 
The formation of the third stereogenic center is based on the replication of the stereocontrolled 
allylation reaction able to generate 30a-37a. Subsequently, the compounds 30b-37b were 
obtained treating the secondary alcohol with acryloyl chloride (Scheme 19).  
 
Scheme 19 
The target compounds 38b-45b were achieved as salt of acid trifluoracetic carrying out ring 
closing methatesis reactions, in the presence of Hoveyda-Grubbs-II catalyst, and, then, treating 
38a-45a with TFA for the cleavage of the piperidinic nitrogen (Scheme 20). 
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Scheme 20 
5.5. Biological evaluation 
To get an insight into its potential biological activity of compounds 38b-45b, we investigated their 
ability to interfere with microtubule assembly in vitro (Figure 48).  
 
Figure 48: Effects of compounds 38b-45b on tubulin polymerisation. The histogram represent the ratio between 
microtubules and tubulin dimers obtained in control conditions (DMSO), In the presence of 10 M thiocolchicine 
(TioColc), and in presence of 50 M compounds (38b-45b). *p<0.05 according to ANOVA, Fisher post hoc test. 
Thiocolchicine (10 M) was used as reference compound since its ability to inhibit the tubulin 
assembly to form microtubules. In comparison, the new pironetin derivatives appear to 
moderately impact microtubule formation. 38b and 40b significantly increase the ratio between 
microtubules and tubulin dimers, whereas the 42b, 43b and 45b inhibit microtubule assembly. 
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5.6. Conclusion 
In summary, the obtainment of the eight stereoisomers of the target compound has been 
completed. The enantiopure grade of them is under analysis by HPLC. The biological tests showed 
a possible influence of the obtained compounds on tubulin polymerization even if with a not 
relevant inhibition properties. Thus, the present work could suggest the synthesis of new tubulin-
inhibitors based on the designed hybrid.  
Once figure the best candidate out, a future work could be bind it to a well-known -tubulin 
inhibitor in order to create a bivalent molecule. In fact, due to synergic interactions, it finally could 
be result a good microtubule-inhibitor. 
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5.7. Experimental part 
5.7.1. Synthesis 
General procedure for diasteroselective allylation: synthesis of 22a-25a 
 
Allylmagnesium bromide (commercial 1M solution in Et2O, 2.86 mL, 2.86 mmol) was added 
dropwise under nitrogen atmosphere to a solution of suitable enantiopure DIP-Cl (1.06 g, 3.3 
mmol) in dry THF (13.5 mL) at -78°C. The reaction mixture was allowed to warm to 0 °C and 
stirred at that temperature for 1 h. The solution was then allowed to stand until magnesium 
chloride precipitated. The supernatant solution was then carefully transferred via canula to 
another flask and, after its cooling at 78C, a solution of the racemic aldehyde 21 (0.500 g, 2.20 
mmol) in dry THF (6.5 mL) was added dropwise. The resulting solution was further stirred at the 
same temperature for 1 h and then 16 h at room temperature. The reaction was quenched with 
NaH2PO4 buffer solution at pH 7 (13.5 mL), MeOH (13.5 mL) and 30% H2O2 (6.7 mL). After stirring 
for 30 minutes, the mixture was washed with saturated aqueous NaHCO3 and extracted with Et2O. 
The combined organic phases were dried over anhydrous Na2SO4, and filtered. The solvent was 
evaporated under vacuum, and the residue was purified by column chromatography on silica gel 
(hexane /EtOAc, 4:1). The reaction performed with (-)-DIP-Cl afforded 22a and 23a as a yellow oil 
(90% overall yield), while the reaction carried out with (+)-DIP-Cl gave 24a and 25a in 90% overall 
yield. 
(S)-Tert-butyl 2-((S)-2-hydroxypent-4-enyl)piperidine-1-carboxylate (22a)   
 
Yield: 41%. []D = -33.0 (c 1.0, CHCl3). IR: (neat): = 1674 cm-1; 1H NMR (400 MHz, CDCl3):  1.35-
1.59 (m, 6H), 1.42 (s, 9H,), 1.73-1.76 (m, 1H), 2.01 (dt, J = 12.5, 1.8 Hz, 1H), 2.16-2.23 (m, 1H), 
2.27-2.33 (m, 1H), 2.66 (dt, J = 12.7, 2.0 Hz, 1H), 3.39 (br s, 1H), 3.95 (br s, 1H), 4.47 (br s, 1H), 5.05 
(d, J = 9.7 Hz, 1H), 5.08 (d, J = 17.4 Hz, 1H), 5.81-5.91 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3):  
19.4, 25.3, 28.6, 29.2, 36.9, 39.3, 41.1, 46.2, 67.1, 80.2, 116.6, 135.5, 167.1 ppm. 
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(R)-Tert-butyl-2-((R)-2-hydroxypent-4-en-1-yl)piperidine-1-carboxylate (24a) 
 
Yield: 24%. []D = + 35.0 (c 0.8, CHCl3). IR: (neat):  = 1674 cm-1. NMR as 22a 
(R)-Tert-butyl-2-((S)-2-hydroxypent-4-en-1-yl)piperidine-1-carboxylate (23a) 
 
Yield: 50%. []D = + 15.3 (c 0.9, CHCl3); IR: (neat): = 1674 cm-1; 1H NMR (400 MHz, CDCl3):  1.35-
1.59 (m, 6H), 1.42 (s, 9H), 1.77-1.82 (m, 1H), 2.14-2.21 (m, 1H), 2.27-2.32 (m, 1H), 2.79 (dt, J = 
12.8, 0.2 Hz, 1H), 3.65 (tt, J = 7.5, 2.4 Hz, 1H), 3.92 (m, 1H), 4.32 (br s, 1H), 5.07 (d, J = 9.8 Hz, 1H), 
5.09 (d, J = 17.3 Hz, 1H), 5.75-5.85 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3):  18.9, 25.4, 28.4, 
29.3, 36.9, 38.8, 41.8, 48.0, 71.3, 79.6, 117.4, 135.3, 160.1 ppm.  
(S)-Tert-butyl-2-((R)-2-hydroxypent-4-en-1-yl)piperidine-1-carboxylate (25a) 
 
Yield: 37%. []D = - 13.8 (c 13.3, CHCl3). IR: (neat):  = 1674 cm-1. NMR as 23a 
General procedure for methylation: synthesis of 22b-25b 
 
22a (0.319 g, 1.18 mmol) was dissolved in anhydrous THF (7 mL) and the solution was added 
dropwise to a suspension of sodium hydride (0.095 g, 3.90 mmol) in dry THF (3 mL) cooled at -
78°C and it was stirred for 1 h. Then methyl iodide (0.3 mL, 4.70 mmol) was added and the 
reaction mixture was stirred 1 h at -78 °C and 16 h at room temperature. The mixture was 
quenched with cold water (10 mL) and the aqueous layer was extracted with Et2O. The organic 
layer was dried with Na2SO4 and the solvent was removed under vacuum. The residue was 
purified by column chromatography on silica gel (hexane/EtOAc, 4:1) to give 22b (74%) as yellow 
oil. In order to obtain the other compounds 23b, 24b and 25b the reaction was performed in the 
same way. 
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(S)-Tert-butyl-2-((S)-2-methoxypent-4-en-1-yl)piperidine-1-carboxylate (22b) 
 
Yield: 61%. []D = - 36.0 (c 3.64, CHCl3). IR: (neat):  = 1677 cm-1. 1H NMR (400 MHz, CDCl3):  1.37-
1.64 (m, 6H), 1.46 (s, 9H), 1.83-1.90 (m, 1H), 2.21-2.33 (m, 2H), 2.70 (t, J = 13.2 Hz, 1H), 3.11-3.17 
(m, 1H), 3.35 (s, 3H), 3.97 (br s, 1H), 4.44 (br s, 1H), 5.08 (d, J = 17.1 Hz, 1H), 5.10 (d, J = 9.2 Hz, 
1H), 5.73-5.83 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3):  19.4, 25.7, 25.7, 28.5, 29.5, 34.5, 37.7, 
47.6, 56.9, 77.9, 79.1, 117.3, 134.5, 155.1 ppm. 
(R)-Tert-butyl 2-((R)-2-methoxypent-4-enyl)piperidine-1-carboxylate (24b) 
 
Yield: 55%. []D = +33.0 (c 0.5, CHCl3). IR: (neat):  = 1677 cm-1. NMR as 22b 
(R)-Tert-butyl 2-((S)-2-methoxypent-4-enyl)piperidine-1-carboxylate (23b) 
 
Yield: 74%. []D = + 23.4 (c 2.7, CHCl3). IR: (neat):  = 1677 cm-1; 1H NMR (400 MHz, CDCl3):   1.33-
1.59 (m, 6H), 1.43 (s, 9H), 1.88-1.96 (m, 1H), 2.28 (dddd, J = 12.3, 12.3, 6.4, 1.2 Hz, 1H), 2.35 (dddd, 
J = 12.3, 12.3, 6.4, 1.2 Hz, 1H), 2.78 (t, J = 13,3 Hz, 1H), 3.14-3.19 (m, 1H), 3.29 (s, 3H), 3.96 (m, 1H), 
4.32 (br s, 1H), 5.03-5.09 (m, 2H), 5.74-5.84 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3):  23.6, 24.9, 
30.2, 33.7, 35.1, 39.2, 44.7, 47.9, 53.9, 73.9, 80.8, 118.5, 132.4, 153.9 ppm.  
(S)-Tert-butyl-2-((R)-2-methoxypent-4-en-1-yl)piperidine-1-carboxylate (25b) 
 
Yield: 36%. []D = - 19.0 (c 0.9, CHCl3). IR: (neat):  = 1677 cm-1. NMR as 23b 
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General procedure for ozonolysis: synthesis of 26-29  
 
Olefin 22b ( 0.470 g, 1.66 mmol) was dissolved in dry CH2Cl2 (19 mL) and cooled to 78 C. A 
stream of ozone-oxygen was bubbled through the solution until persistence of the bluish color. 
Dry N2 was then bubbled through the solution for 10 min at the same temperature. After addition 
of PPh3 (0.870 g, 3.32 mmol), the reaction mixture was stirred waiting the completion of the 
reaction. Then the solvent was removed under vacuum and the residue was purified by column 
chromatography on silica gel (hexane/EtOAc, 7:3) to give 26 (43%) as orange oil. In order to obtain 
the other compounds 27, 28 and 29 the reaction was performed in the same way. 
(S)-Tert-butyl 2-((R)-2-methoxy-4-oxobutyl)piperidine-1-carboxylate (26) 
 
Yield: 43%. []D = - 21.3 (c 3.45, CHCl3); IR (neat):  = 1679, 1719 cm-1;1H NMR (400 MHz, CDCl3):  
1.37-1.65 (m, 6H), 1.46 (s, 9H), 1.88 (ddd, J = 14.0, 9.3, 4.4 Hz, 1H), 2.63 (ddd, J = 6.3, 4.3, 2.1 Hz, 
2H), 2.75 (t, J = 12.7 Hz, 1H), 3.36 (s, 3H), 3.59-3.65 (m, 1H), 3.98 (br s, 1H), 4.43 (br s, 1H), 9.81 (t, 
J = 2.1 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3):  19.1, 25.6, 28.5, 29.0, 33.6, 38.8, 48.0, 56.6, 
74.4, 76.2, 79.5, 155.0, 201.4 ppm.  
(R)-Tert-butyl 2-((S)-2-methoxy-4-oxobutyl)piperidine-1-carboxylate (29) 
 
Yield: 53%. []D = + 19.1 (c 0.5, CHCl3). IR: (neat):  = 1679, 1719 cm-1. NMR as 26 
(R)-Tert-butyl 2-((R)-2-methoxy-4-oxobutyl)piperidine-1-carboxylate (27) 
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Yield: 51%. []D = + 28.8 (c 2.65, CHCl3); IR (neat):  = 1678, 1719 cm-1; 1H NMR (400 MHz, CDCl3): 
 1.37-1.66 (m, 6H), 1.44 (s, 9H), 2.09-2.19 (m, 1H), 2.59 (ddd, J = 16.4, 7.5, 2.8 Hz, 1H), 2.75-2.82 
(m, 2H), 3.32 (s, 3H), 3.64 (ddd, J = 12.4, 7.7, 5.1 Hz, 1H), 4.00-4.02 (m, 1H), 4.34 (br s, 1H), 9.78 (s, 
1H) ppm; 13C NMR (100 MHz, CDCl3):   19.2, 25.7, 28.6, 29.1, 33.7, 38.8, 48.0, 56.8, 60.5, 74.3, 
79.7, 155.0, 201.6 ppm.  
(S)-Tert-butyl 2-((S)-2-methoxy-4-oxobutyl)piperidine-1-carboxylate (28) 
 
Yield: 47%. []D = - 26.5 (c 0.5, CHCl3). IR: (neat):  = 1679, 1719 cm-1. NMR as 27 
General procedure for diasteroselective allylation: synthesis of 30a-37a 
 
Allylmagnesium bromide (commercial 1M solution in Et2O, 0.87 mL, 0.87 mmol) was added 
dropwise under nitrogen atmosphere to a solution of the suitable enantiopure DIP-Cl (0.323 g, 
1.01 mmol) in dry THF (5 mL) at -78 °C. The reaction mixture was allowed to warm to 0 °C and 
stirred at that temperature for 1 hour. The solution was then allowed to stand until magnesium 
chloride precipitated. The supernatant solution was then carefully transferred via canula to 
another flask and after cooling up to -78 C, a solution of aldehyde 26-29 (0.190 g, 0.67 mmol) in 
dry THF (2.5 mL) was added dropwise. The resulting solution was further stirred at the same 
temperature for 1 h and then 16 h at room temperature. The reaction was quenched with 
NaH2PO4 buffer solution at pH 7 (5.1 mL), MeOH (5.1 mL) and 30% H2O2 (2.5 mL). After stirring for 
30 minutes, the mixture was washed with saturated aqueous NaHCO3 and extracted with Et2O. 
The combined organic phases were dried over anhydrous Na2SO4, and filtered. The solvent was 
evaporated under vacuum, and the residue was purified by column chromatography on silica gel 
(Hexane /EtOAc, 7:3) to give the 30a-37a, respectively, (80%) as a yellow oil.  
(S)-Tert-butyl 2-((2R,4S)-4-hydroxy-2-methoxyhept-6-enyl)piperidine-1-carboxylate (30a)  
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Yield: 42%. []D = - 21.4 (c 0.7, CHCl3); IR (neat):  = 1687 cm-1; 1H NMR (400 MHz, CDCl3):  1.34-
1.63 (m, 8H), 1.45 (s, 9H), 1.74-1.76 (m, 2H), 2.22 (t, J = 6.6 Hz, 2H), 2.72-2.78 (m, 1H), 3.35-3.41 
(m, 1H), 3.36 (s, 3H), 3.78-3.84 (m, 1H), 3.95 (br s, 1H), 4.33 (br s, 1H), 5.07-5.12 (m, 2H), 5.83 (ddt, 
J = 17.5, 10.5, 7.1 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3):  19.3, 25.7, 28.4, 28.6, 34.5, 38.9, 
40.7, 42.4, 48.0, 56.5, 68.31, 70.3, 79.6, 117.7, 135.0, 155.1 ppm.  
(R)-Tert-butyl 2-((2S,4R)-4-hydroxy-2-methoxyhept-6-enyl)piperidine-1-carboxylate (37a)  
 
Yield: 41%. []D = + 24.3 (c 0.1, CHCl3). IR: (neat):  = 1687 cm-1. NMR as 30a 
(R)-Tert-butyl 2-((2R,4S)-4-hydroxy-2-methoxyhept-6-enyl)piperidine-1-carboxylate (31a) 
 
Yield: 45%. []D = - 9.2 (c 0.3, CHCl3); IR (neat):  = 1687 cm-1;1H NMR (400 MHz, CDCl3):  1.37-
1.66 (m, 8H), 1.45 (s, 9H), 1.77-1.84 (m, 1H), 2.14-2.19 (m, 1H), 2.23 (t, J = 6.1 Hz, 2H), 2.80 (t, J = 
13.2 Hz, 1H), 3.29-3.40 (m, 1H), 3.34 (s, 3H), 3.81-3.87 (m, 1H), 4.01 (br s, 1H), 4.30 (br s, 1H), 
5.07-5.12 (m, 2H), 5.82-5.97 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3):  19.2, 25.7, 28.6, 29.5, 
33.7, 39.1, 41.0, 42.2, 47.3, 56.2, 68.3, 71.2, 79.8, 117.4, 135.1, 155.3 ppm.  
(S)-Tert-butyl 2-((2S,4R)-4-hydroxy-2-methoxyhept-6-enyl)piperidine-1-carboxylate (36a)  
 
Yield: 53%. []D = +10.5 (c 0.04, CHCl3). IR: (neat):  = 1687 cm-1. NMR as 31a 
(S)-Tert-butyl 2-((2S,4S)-4-hydroxy-2-methoxyhept-6-enyl)piperidine-1-carboxylate (32a) 
 
Yield: 49%. []D = + 17.8 (c 0.1, CHCl3). IR (neat):  = 1687 cm-1; 1H NMR (400 MHz, CDCl3):  1.33-
1.66 (m, 8H), 1.45 (s, 9H), 1.76-1.84 (m, 1H), 2.15-2.19 (m, 1H), 2.23-2.25 (m, 2H), 2.80 (t, J = 13.8 
Hz, 1H), 3.30-3.39 (m, 1H), 3.33 (s, 3H), 3.81-3.85 (m, 1H), 4.01 (br s, 1H), 4.30 (br s, 1H), 5.06-5.13 
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(m, 2H), 5.87 (ddt, J = 17.3, 10.2, 7.1 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3):  19.3, 25.8, 28.6, 
29.4, 34.4, 38.9, 40.8, 42.3, 47.8, 57.1, 68.1, 71.1, 79.7, 117.5, 135.1, 155.0 ppm.  
(R)-Tert-butyl 2-((2R,4R)-4-hydroxy-2-methoxyhept-6-enyl)piperidine-1-carboxylate (35a) 
 
Yield: 31%. []D = + 15.7 (c 0.07, CHCl3). IR: (neat):  = 1687 cm-1. NMR as 32a 
(R)-Tert-butyl 2-((2S,4S)-4-hydroxy-2-methoxyhept-6-enyl)piperidine-1-carboxylate (33a) 
 
Yield: 43%. []D = + 22.4 (c 1.4, CHCl3). IR (neat):  = 1687 cm-1.  1H NMR (400 MHz, CDCl3):  1.31-
1.66 (m, 15H),1.69- 1.84 (m, 3H), 2.16-2.29 (m, 2H), 2.64-2.82 (m, 1H), 3.33-3.47 (m, 5H), 3.89-
4.02 (m, 3H), 4.27-4.42 (s, 1H), 5.04-5.15 (m, 2H), 5.75-5.91 (m, 1H) ppm; 13C NMR (100 MHz, 
CDCl3):  19.3, 25.8, 28.7, 29.3, 34.2, 38.9, 40.6, 42.5, 48.0, 57.3, 68.2, 70.3, 79.5, 117.7, 135.0, 
155.1 ppm.  
(S)-Tert-butyl 2-((2R,4R)-4-hydroxy-2-methoxyhept-6-enyl)piperidine-1-carboxylate (34a) 
 
Yield: 54%. []D = - 21.6 (c 0.02, CHCl3). IR: (neat):  = 1687 cm-1. NMR as 33a 
General procedure for acroylation: synthesis of 30b-37b 
 
Acryloyl chloride (0.14 mL, 1.71 mmol) and TEA (0.48 mL, 3.42 mmol) were added sequentially to 
a cooled solution (0 °C) of compound 30a-37a (0.140 g, 0.42 mmol) dissolved in dry CH2Cl2 (0.73 
mL). The reaction was stirred for 4 hours at room temperature, then it was quenched with water 
(3 mL) and satd. aqueos NaCl (3 mL). The aqueous layer was extracted with CH2Cl2, and the 
organic layers were dried with Na2SO4 and filtered. The solvent was evaporated under vacuum, 
and the residue was purified by column chromatography on silica gel (Hexane /EtOAc 3:2) to give 
30b-37b (70%) as yellow oil.  
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(S)-Tert-butyl 2-((2R,4S)-4-(acryloyloxy)-2-methoxyhept-6-enyl)piperidine-1-carboxylate (30b) 
 
Yield: 72%. []D = -7.7 (c 0.7, CHCl3); IR (neat):  = 1677, 1719 cm-1;  1H NMR (400 MHz, CDCl3):  = 
0.86-0.97 (m, 2H), 1.45 (s, 9H), 1.51-1.72 (m, 6H), 1.88-1.98 (m, 2H), 2.33-2.45 (m, 2H), 2.70 (t, J = 
13.6 Hz, 1H), 3.09-3.15 (m, 1H), 3.30 (s, 3H), 3.95 (br s, 1H), 4.44 (br s, 1H), 5.06-5.12 (m, 3H), 
5.72-5.82 (m, 1H), 5.82 (dd, J = 10.6, 1.5 Hz, 1H), 6.10 (dd, J = 17.3, 10.4 Hz, 1H), 6.39 (dd, J = 17.3, 
1.5 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3):  19.2, 25.7, 28.5, 29.6, 34.6, 37.2, 38.7, 39.1, 47.0, 
56.4, 70.6, 75.4, 78.9, 118.1, 128.6, 130.6, 133.3, 154.4, 165.6 ppm.  
(R)-Tert-butyl 2-((2S,4R)-4-(acryloyloxy)-2-methoxyhept-6-enyl)piperidine-1-carboxylate (37b) 
 
Yield: 74%. []D = +9.1 (c 0.03, CHCl3). IR: (neat):  = 1677, 1719 cm-1. NMR as 30b 
(R)-Tert-butyl 2-((2R,4S)-4-(acryloyloxy)-2-methoxyhept-6-enyl)piperidine-1-carboxylate (31b) 
 
Yield: 69%. []D = + 20.4 (c 0.5, CHCl3); IR (neat):  = 1677, 1719 cm-1; 1H NMR (400 MHz, CDCl3):  
0.82-0.94 (m, 2H), 1.35-1.59 (m, 6H), 1.45 (s, 9H), 1.86-1.97 (m, 2H), 2.30-2.44 (m, 2H), 2.79 (t, 1H, 
J = 12.6 Hz), 3.21 (tt, 1H, J = 12.3, 6.2 Hz), 3.26 (s, 3H), 3.97 (br s, 1H), 4.35 (br s, 1H), 5.05-5.10 (m, 
2H), 5.12-5.18 (m, 1H), 5.72-5.82 (m, 2H), 5.79 (dd, J = 10.4, 1.5 Hz, 1H), 6.10 (dd, J = 17.3, 10.4 Hz, 
1H), 6.38 (dd, J = 17.3, 1.5 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3):  19.0, 25.6, 28.5, 28.7, 29.3, 
33.5, 37.5, 39.3, 47.3, 56.8, 70.8, 75.7, 79.1, 118.2, 128.4, 130.5, 133.4, 154.7, 165.8 ppm.  
(S)-Tert-butyl 2-((2S,4R)-4-(acryloyloxy)-2-methoxyhept-6-enyl)piperidine-1-carboxylate (36b) 
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Yield: 71%. []D = +15.4 (c 0.005, CHCl3). IR: (neat):  = 1677, 1719 cm-1. NMR as 31b 
(S)-Tert-butyl 2-((2S,4S)-4-(acryloyloxy)-2-methoxyhept-6-enyl)piperidine-1-carboxylate (32b)  
 
Yield: 65%. []D = +12.3 (c 0.5, CHCl3); IR (neat):  = 1677, 1719 cm-1; 1H NMR (400 MHz, CDCl3):  
0.89-0.94 (m, 2H), 1.46 (s, 9H), 1.44-2.00 (m, 8H), 2.30-2.45 (m, 2H), 2.76-2.82 (m,  1H), 3.21 (tt, J 
= 12.3, 6.2 Hz, 1H), 3.26 (s, 3H), 3.97 (br s, 1H), 4.35 (br s, 1H), 5.05-5.10 (m, 2H), 5.12-5.18 (m, 
1H), 5.71-5.82 (m, 2H), 6.10 (dd, J = 17.3, 10.4 Hz, 1H), 6.39 (ddd, J = 17.3, 2.9, 1.5 Hz, 1H) ppm; 
13C NMR (100 MHz, CDCl3):  18.9, 25.6, 28.6, 28.9, 33.2, 37.0, 38.5, 39.0, 47.4, 55.7, 70.9, 75.3, 
79.2, 117.9, 128.8, 130.4, 133.5, 154.8, 165.6 ppm.  
(R)-Tert-butyl 2-((2R,4R)-4-(acryloyloxy)-2-methoxyhept-6-enyl)piperidine-1-carboxylate (35b) 
 
Yield: 64%. []D = -16.5 (c 0.002, CHCl3). IR: (neat):  = 1677, 1719 cm-1. NMR as 32b 
(R)-Tert-butyl 2-((2S,4S)-4-(acryloyloxy)-2-methoxyhept-6-enyl)piperidine-1-carboxylate (33b) 
 
Yield: 78%. []D = +11.49 (c 0.8, CHCl3). IR (neat):  = 1677, 1719 cm-1. 1H NMR (300 MHz, CDCl3):  
1.20-1.65 (m, 19H), 1.65-1.86 (m, 1H), 2.29–2.44 (m, 2H), 2.66-2.81 (m, 1H), 3.05-3.17 (m, 1H), 
3.31 (s, 3H), 3.89-4.03 (m, 1H), 4.26-4.50 (m, 1H), 5.01-5.28 (m, 2H), 5.69-5.85 (m, 2H), 6.03-6.17 
(m, 1H), 6.33-6.45 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3):  18.9, 25.5, 28.4, 28.7, 29.5, 34.7, 
38.6, 39.1, 47.6, 57.1, 70.6, 75.6, 79.1, 117.9, 128.6, 130.4, 133.1, 165.5 ppm.  
(S)-Tert-butyl 2-((2R,4R)-4-(acryloyloxy)-2-methoxyhept-6-enyl)piperidine-1-carboxylate (34b) 
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Yield: 68%. []D = -9.4 (c 0.01, CHCl3). IR: (neat):  = 1677, 1719 cm-1. NMR as 33b 
General procedure for ring closing methatesis reaction: synthesis of 38a-45a 
 
A solution of Hoveyda-Grubbs-II catalyst (0.014 g, 0.02 mmol) in dry CH2Cl2 (3.2 mL) was added 
dropwise to a solution of compound 30b (0.085 g, 0.22 mmol) dissolved in dry CH2Cl2 (9.4 mL). The 
reaction was stirred for 4 h at room temperature, then the solvent was removed under vacuum. 
The residue was purified by column chromatography on silica gel (Hexane /EtOAc, 3:2) to give 18a 
(75%) as dark oil. 
(S)-Tert-butyl 2-((R)-2-methoxy-3-((S)-6-oxo-3,6-dihydro-2H-pyran-2-yl)propyl)piperidine-1-
carboxylate (38a) 
 
Yield: 75%. []D = -50.20 (c 0.6, CHCl3). IR (neat):  = 1677, 1721 cm-1. 1H NMR (400 MHz, CDCl3):  
1.38-1.71 (m, 6H), 1.46 (s, 9H), 1.84-1.92 (m, 2H), 1.99-2.07 (m, 2H), 2.31-2.41 (m, 2H), 2.73 (t, J = 
13.3 Hz, 1H), 3.32 (s, 3H), 3.32-3.37 (m, 1H), 3.96 (br s, 1H), 4.43 (br s, 1H), 4.59 (dt, J = 11.4, 6.2 
Hz, 1H), 6.02 (d, J = 9.9 Hz, 1H), 6.88 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3):  19.6, 25.8, 28.7, 
28.9, 29.94, 30.2, 34.6, 40.6, 56.6, 58.0, 74.9, 75.5, 79.7, 121.7, 146.3, 155.3, 164.7 ppm.  
(R)-Tert-butyl 2-((S)-2-methoxy-3-((R)-6-oxo-3,6-dihydro-2H-pyran-2-yl)propyl)piperidine-1-
carboxylate (45a):  
 
Yield: 64%. []D = + 47.6 (c 0.002, CHCl3). IR: (neat):  = 1677, 1721 cm-1. NMR as 33b 
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(R)-Tert-butyl 2-((R)-2-methoxy-3-((S)-6-oxo-3,6-dihydro-2H-pyran-2-yl)propyl)piperidine-1-
carboxylate (39a) 
 
Yield: 68%. []D = - 15.9 (c 0.7, CHCl3); IR: (neat):  = 1677, 1721 cm-1; 1H NMR (400 MHz, CDCl3):  
1.36-1.58 (m, 7H), 1.44 (s, 9H), 1.91-2.15 (m, 3H), 2.32-2.38 (m, 2H), 2.76-2.82 (m, 1H), 3.24-3.31 
(m, 1H), 3.28 (s, 3H), 3.96 (br s, 1H), 4.35 (br s, 1H), 4.55-4.62 (m, 1H), 6.00 (d, J = 9.8 Hz, 1H), 6.86 
(ddd, J = 9.2, 4.5 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3):  19.3, 25.7, 28.7, 29.5, 29.9, 30.2, 34.4, 
40.7, 54.0, 57.7, 74.8, 75.0, 79.5, 121.6, 145.2, 155.1, 164.4 ppm.  
(S)-Tert-butyl 2-((S)-2-methoxy-3-((R)-6-oxo-3,6-dihydro-2H-pyran-2-yl)propyl)piperidine-1-
carboxylate (44a) 
 
Yield: 71%. []D = + 11.1 (c 0.023, CHCl3). IR: (neat):  = 1677, 1721 cm-1. NMR as 39a 
(S)-Tert-butyl 2-((S)-2-methoxy-3-((S)-6-oxo-3,6-dihydro-2H-pyran-2-yl)propyl)piperidine-1-
carboxylate (40a) 
 
Yield: 69%. []D = - 15.8 (c 0.4, CHCl3); IR: (neat):  = 1677, 1721 cm-1; 1H NMR (400 MHz, CDCl3):  
1.37-1.59 (m, 7H), 1.46 (s, 9H), 1.92-2.17 (m, 3H), 2.32-2.40 (m, 2H), 2.74-2.83 (m, 1H), 3.23-3.27 
(m, 1H), 3.29 (s, 3H), 3.98 (br s, 1H), 4.36 (br s, 1H), 4.61 (td, J = 15.4, 6.5 Hz, 1H), 6.01 (d, J = 9.8 
Hz, 1H), 6.87 (td, J = 9.2, 4.2 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3):  19.1, 25.6, 28.5, 28.7, 28.9, 
29.4, 33.0, 38.0, 47.5, 55.9, 75.2, 75.4, 79.3, 121.4, 145.0, 155.0, 164.4 ppm.  
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(R)-Tert-butyl 2-((R)-2-methoxy-3-((R)-6-oxo-3,6-dihydro-2H-pyran-2-yl)propyl)piperidine-1-
carboxylate (43a) 
 
Yield: 76%. []D = + 13.3 (c 0.001, CHCl3). IR: (neat):  = 1677, 1721 cm-1. NMR as 40a 
(R)-Tert-butyl 2-((S)-2-methoxy-3-((S)-6-oxo-3,6-dihydro-2H-pyran-2-yl)propyl)piperidine-1-
carboxylate (41a) 
 
Yield: 77%. []D = + 6.8 (c 0.038, CHCl3); IR: (neat):  = 1677, 1721 cm-1; 1H NMR (400 MHz, CDCl3): 
 1.19-1.77 (m, 17H), 1.78-1.94 (m, 2H), 1.95-2.11 (m, 1H), 2.29-2.48 (m, 2H), 2.67-2.83 (m, 1H), 
3.38 (s, 3H), 3.40-3.52 (m, 1H), 3.88-4.05 (m, 1H), 4.56-4.72 (m, 1H), 6.02 (dt, 1H, J= 9.8, 1.6 Hz), 
6.84-6.92 (m, 1H) ppm; 13C NMR (100 MHz, CDCl3):  19.2, 25.7, 28.6, 28.7, 29.8, 30.2, 34.5, 40.7, 
56.6, 57.7, 74.8, 75.0, 79.5, 121.6, 145.0, 155.0, 164.4 ppm.  
(S)-Tert-butyl 2-((R)-2-methoxy-3-((R)-6-oxo-3,6-dihydro-2H-pyran-2-yl)propyl)piperidine-1-
carboxylate (42a) 
 
Yield: 81%. []D = - 4.7 (c 0.006, CHCl3). IR: (neat):  = 1677, 1721 cm-1. NMR as 41a 
General procedure for the cleavage of Boc-group: synthesis of 38b-45b  
 
To a stirred solution of compound 38a (0.352 g, 1 mmol) in CH2Cl2 (2 mL) was added TFA (2 mL) at 
0 °C. The reaction mixture was stirred for 30 min. at room temperature. Upon completation, the 
reaction was quenched with NH4OH 5M at pH 9. The organic layer was dried with Na2SO4 and 
concentrated under reduced pressure to give 38b (92%) as colorless oil. 
 
101 
 
(S)-6-((R)-2-Methoxy-3-((S)-piperidin-2-yl)propyl)-5,6-dihydro-2H-pyran-2-one (38b) 
 
Yield: 91%. []D = -21.2 (c 0.8, CHCl3). IR: (neat):  = 1730 cm-1; 1H NMR (400 MHz, CDCl3):  1.33-
1.80 (m, 9H), 2.12 (ddd, J = 7.2, 7.2, 5.7 Hz, 2H), 2.31-2.38 (m, 2H), 2.70 (dt, J = 14.6, 2.6 Hz, 1H), 
2.84-2.88 (m, 1H,), 3.16-3.19 (m, 1H), 3.32 (s, 3H), 3.60-3.67 (m, 1H), 4.30 (br s, 1H), 4.50-4.57 (m, 
1H), 6.00 (d, J = 9.8 Hz, 1H), 6.87 (ddd, J = 9.4, 5.1, 3.2 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3):  
23.9, 24.5, 29.7, 31.6, 38.2, 39.3, 46.1, 54.0, 56.3, 74.1, 75.0, 121.4, 145.3, 164.4 ppm.  
(R)-6-((S)-2-Methoxy-3-((R)-piperidin-2-yl)propyl)-5,6-dihydro-2H-pyran-2-one (45b) 
 
Yield: 92%. []D = + 24.8 (c 0.005, CHCl3). IR: (neat):  = 1730 cm-1. NMR as 38b 
(S)-6-((R)-2-Methoxy-3-((R)-piperidin-2-yl)propyl)-5,6-dihydro-2H-pyran-2-one (39b) 
 
Yield: 82%. []D = - 13.9 (c 1.0, CHCl3); IR: (neat):  = 1730 cm-1; 1H NMR (400 MHz, CDCl3):  1.31-
1.80 (m, 8H), 2.11 (ddd, J = 12.9, 9.6, 6.0 Hz, 1H), 2.31-2.40 (m, 2H), 2.61-2.67 (m, 2H), 3.06-3.09 
(m, 1H), 3.26 (br s, 1H), 3.31 (s, 3H), 3.57-3.63 (m, 1H), 4.53 (ddd, J = 12.5, 10.6, 5.3 Hz, 1H), 6.01 
(d, J = 9.9 Hz, 1H), 6.87 (ddd, J = 12.9, 9.6, 6.0 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3):  24.6, 
25.7, 29.7, 32.7, 38.3, 40.5, 46.9, 55.8, 56.0, 75.0, 75.5, 121.3, 145.1, 164.2 ppm.  
(R)-6-((S)-2-Methoxy-3-((S)-piperidin-2-yl)propyl)-5,6-dihydro-2H-pyran-2-one (44b) 
 
Yield: 89%. []D = + 12.7 (c 0.001, CHCl3). IR: (neat):  = 1730 cm-1. NMR as 39b 
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(S)-6-((S)-2-Methoxy-3-((S)-piperidin-2-yl)propyl)-5,6-dihydro-2H-pyran-2-one (40b)  
 
Yield: 85%. []D = - 9.8 (c 0.5, CHCl3). IR: (neat):  = 1730 cm-1. 1H NMR (400 MHz, CDCl3):  1.33-
1.80 (m, 8H), 1.86-1.93 (m, 1H), 2.29-2.38 (m, 2H), 2.62-2.72 (m, 2H), 3.09-3.15 (m, 1H), 3.33 (s, 
3H), 3.57-3.67 (m, 1H), 4.02 (br s, 1H), 4.57-4.64 (m, 1H), 6.00 (dd, J = 9.8, 1.9 Hz, 1H), 6.84-6.88 
(m, 1H) ppm; 13C NMR (100 MHz, CDCl3):  22.0, 22.3, 29.1, 30.0, 37.7, 40.0, 45.1, 55.8, 62.1, 74.8, 
75.0, 120.9, 145.8, 160.5 ppm.  
(R)-6-((R)-2-Methoxy-3-((R)-piperidin-2-yl)propyl)-5,6-dihydro-2H-pyran-2-one (43b) 
 
Yield: 90%. []D = + 6.3 (c 0.001, CHCl3). IR: (neat):  = 1730 cm-1. NMR as 40b 
(S)-6-((S)-2-Methoxy-3-((R)-piperidin-2-yl)propyl)-5,6-dihydro-2H-pyran-2-one (41b) 
 
Yield: 87%. []D = - 21.8 (c 0.2, CHCl3); IR: (neat):  = 1730 cm-1; 1H NMR (400 MHz, CDCl3):  2.43-
2.01 (m, 10H), 2.32-2.38 (m, 3H), 2.80-2.85 (m, 1H), 3.02 (br s, 1H), 3.34 (br s, 1H), 3.36 (s, 3H), 
3.65-3.72 (m, 1H), 4.57-4.65 (m, 1H), 6.01 (dd, J = 10.3, 1.6 Hz, 1H), 6.88 (ddd, J = 9.5, 5.2, 3.1 Hz, 
1H) ppm; 13C NMR (100 MHz, CDCl3):  23.0, 23.2, 30.0, 37.7, 38.6, 40.3, 44.9, 54.2, 57.2, 74.1, 
74.8, 121.2, 145.3, 164.1 ppm.  
(R)-6-((R)-2-Methoxy-3-((S)-piperidin-2-yl)propyl)-5,6-dihydro-2H-pyran-2-one (42b) 
 
Yield: 85%. []D = + 21.7 (c 0.009, CHCl3). IR: (neat):  = 1730 cm-1. NMR as 41b 
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5.7.2. Biological assay 
Tubulin purification and assembly assay: Tubulin was purified from bovine brain purchased from 
a local slaughterhouse, conserved before use in ice-cold PBS and used as soon as possible. 
According to Castoldi and Popov (2003), pure tubulin was obtained by two cycles of 
polymerization-depoly-merization in a high-molarity PIPES buffer 1mK-PIPES, pH 6.9, 2 mm EGTA 
and 1 mm MgCl2), and protein concentration was determined by the MicroBCA assay kit (Pierce). 
The test the effects on tubulin assembly, 38b-45b were dissolved in dimethyl sulfoxide (DMSO), 
added at 50 M to a reaction mixtures (20 m tubulin, 10% glycerol, 1 mm GTP in BRB80 buffer) 
and incubated for 30 minutes at 37 °C. As control conditions were used either unmodified 
thiocolchicine (10 M) or DMSO alone. At the end of polymerization, unpolymerized and 
polymerized fractions of tubulin were separated by centrifugation at 16500xg for 30 minutes at 
258 °C. The collected microtubules were resuspended in SDS-PAGE sample buffer (2% w/v SDS, 
10% v/v glycerol, 5% v/v b-mercaptoethanol, 0.001% w/v bromophenol blue, and 62.5 mm Tris, 
pH 6.8) and the unpolymerized tubulin was diluted 3:1 with 4X SDS-PAGE sample buffer. Equal 
proportions of each fraction were resolved by a 7.5% SDS-gel and stained with Coomassie blue. 
Densitometric analyses of stained gels were performed by using ImageJ software (National 
Institute of Health), and data were elaborated using STATISTICA (StatSoft Inc., Tulsa, OK). 
Significant differences were assessed by one-way ANOVA with Fisher HSD post hoc test. 
Experiments were done in triplicate and data are expressed as means ± SEM. 
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Chapter 6 
 
Design and synthesis of  
triazole-epothilones  
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6.1. Introduction 
After the elucidation of taxol’s biological mechanism in 1979,18 it took more than a decade before 
other microtubule-stabilizing agents with no-taxol-like structures were discovered. Among these 
new microtubule stabilizers, the most notable are the epothilones, which are myxobacterial-
derived macrolides first isolated from the myxobacterium Sorangium cellulosum Sc 90 by 
Reichenbach and Höfle.102 
Originally, the major products isolated from the fermentation broth were epothilone A and 
epothilone B, but many other members of this natural products family have subsequently been 
obtained from myxobacteria (Figure 49).103  
 
Figure 49 
Structurally, Epothilones A and B are 16-membered polyketide macrolactones that have a 
methylthiazole moiety connected to the macrocycle by a short olefinic spacer. The polyketide 
backbone of the molecule is synthesized by a type I modular polyketide synthase (PKS) through 
nine PKS modules, whereas the thiazole ring is derived from a cysteine incorporated by a single 
nonribosomal peptide synthetase (NRPS) (Figure 50).104 
                                                          
102 K. Gerth; N. Bedorf; G. Höfle; H. Irschik; H. Reichenbach; J Antibiot., 1996, 49, 560. 
103I. H. Hardt; H. Steinmetz; K. Gerth; F. Sasse; H. Reichenbach; G. Höfle; J. Nat. Prod., 2001, 64, 847. 
104 I. Molnár; T. Schupp; M. Ono; R.E. Zirkle; M. Milnamow; B. Nowak-Thompson; N. Engel; C. Toupet; A. Stratmann; D.D. Cyr; J. 
Gorlach; J.M. Mayo; A. Hu; S. Goff; J. Schmid; J.M. Ligon; Chem.& Biol., 2000, 7, 97. 
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Figure 50: Structure of the epothilone biosynthetic gene cluster from Sorangium cellulosum. NRPS = non-ribosomal 
peptide synthase, PKS = polyketide synthase 
Epothilones, in contrast to taxol, can inhibit the growth of multidrug-resistant cancer cell lines at 
concentrations similar to or only slightly higher than those required against drug-sensitive cancer 
cells, including cells whose developed a taxol resistance mediated by specific tubulin mutations. 
As anticipate in the paragraph 1.1.3, Epo A and B were quickly adopted as attractive targets for 
total synthesis as lead structures for anticancer drug discovery.  
Thanks to biological tests, it was possible to gain that the lactone ring of the epothilones was 
sensitive to esterase cleavage. In fact, the incubation of epothilone B in mouse plasma led to loss 
of its cytotoxic activity and resulted in a metabolite with a mass 18 units higher than the parent 
drug.  
This feature prompt toward the synthesis of the lactam analogues of epothilone B, the most 
potent member of the family, with the goal of improving metabolic stability. The key insight into 
the semisynthetic approach to the epothilone lactam was represented by the fact that the 
epothilone lactone is allylic and therefore possibly susceptible to a palladium-catalyzed ring 
opening to form a π-allylpalladium complex, which could be trapped by a nitrogen nucleophile. 
The reaction of unprotected epothilone B with NaN3 in the presence of Pd(PPh3)4 led to azido 
acids 46 as a single diastereomer. The azide is formed with net retention of configuration likely 
through anti-attack by palladium and then reaction with azide from the face opposite the 
palladium. The one-pot process including the reduction of the azide with trimethyl phosphine and 
macrolactam formation with EDCI/HOBt, provides the desired lactam, later to be named 
ixabepilone, in 23% overall yield (Scheme 21). 
 
107 
 
 
Scheme 21 
In vivo studies established that the lactam analogue exhibits antitumor activity similar to that of 
Taxol in Taxol-sensitive tumor models and also more potent than Taxol in Taxol-resistant tumor 
models. In addition, it provides major stability to hydrolysis on incubation in both mouse and 
human sera. Based on its highly profile, Epo B lactam in 2007 was approved by the FDA for the 
treatment of metastatic or advanced breast cancer.105  
6.1.1. Binding site and structure-activity relatioship 
Apart from Taxol, the epothilones were the first natural products known to stabilize microtubules 
triggering apoptosis. Furthermore, their significantly higher activity and their undiminished 
effectiveness against multiresistant tumor cells have raised the possibility that epothilones could 
potentially replace taxanes. After the publication of the electron-crystallographic structure of the 
epothilone A/tubulin complex,106 and the NMR-generated structures through molecular dynamics 
modelling procedures, the interactions of epothilone A with tubulin were described in detail for 
the first time. As expected, epothilone binds within a cavity on the surface of -tubulin. This 
binding site, overlapping with that of Taxol, is partly constituted by the so-called M-loop, which is 
also essential for lateral contacts between protofilaments in the Zn2+-induced tubulin layers and in 
microtubules. Stabilization of the M-loop, and therefore of lateral contacts between 
protofilaments, ultimately stabilizes growing microtubules, preventing their depolymerization 
once formed (Figure 51). 
                                                          
105 a) K.-H. Altmann; F. Z. Gaugaz; R. Schiess; Mol. Divers. 2011, 15, 383; b) John T. Hunt; Mol. Cancer. Ther., 2009, 8 ;275. 
106 J. H. Nettles; H. Li; B. Cornett; J. M. Krahn; J. P. Snyder; K. H. Downing; Science, 2004, 305, 866. 
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Figure 51: The Taxol/epothilone binding cavity in -tubulin from the corresponding electron-crystallographically 
obtained structures with bound epothilone. For -tubulin the surface of the molecule is depicted (C: gray, O: dark pink, 
N: gray-blue). Epothilone A (C: violet, O: red, N: blue) are represented as stick models. 
Direct comparison of epothilone binding with Taxol binding indicates that the smaller epothilone 
molecule fills only about half of the Taxol-binding cavity in -tubulin. The hypotheses concerning a 
common pharmacophore can thus finally be laid to rest, since the Taxol/-tubulin interactions 
differ fundamentally from those in the epothilone A/tubulin complex.107  
In addition to these results, the extensive chemical synthesis–chemical biology study of hundreds 
of epothilone analogues was helpful for a structure– activity relationship analysis (Figure 52). 
 
Figure 52 
The configurations at C6–C8 are essential for the biological activity, probably because this region 
strongly influences the overall conformation of the macrocycle through steric and/or 
stereoelectronic effects. There was initially some speculation that the epoxide oxygen of 
epothilone played a role as a hydrogen bond acceptor, but after independent reports by several 
groups it became clear that the epoxide moiety is not essential for biological activity. However, a 
substituent at C12, particularly a methyl group, consistently enhances the activity. The side chain 
                                                          
107 D. W. Heinz; W.-D. Schubert; G. Hofle; Angew. Chem. Int. Ed,. 2005, 44, 1298. 
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is also highly important for biological activity, and finally, the stereochemistry at C15 play a 
fundamental role, with C15 epimers being lacking of any biological activity. 
 
6.2. Aim of this work 
The chemistry and biology of epothilones have been extensively studied, and numerous analogs 
or derivatives have been discovered that retain potent in vitro activity.108 Our interest is focused 
on developing strategies for the total synthesis of novel triazole-epothilones derivative 47 for 
chemical and biological studies as microtubule-inhibitors (Figure 53). 
 
Figure 53 
Since the lattam derivative ixabepilone is the best candidate in this class so far, the idea of the 
introduction of a triazole moiety into the epothilone arised from the already well-known concept 
of biososterism defined by Langmuir in 1919. The main criteria for isosterism is that two isosteric 
molecules must present similar, if not identical, volumes and shapes. Triazoles are not 
encountered in nature but they have found increasing importance in the field of drug research as 
a bioisostere of the amide linkage and have been established to be resistant against enzymatic 
degradation.109  
 
6.3. Docking studies 
Previous docking studies, performed by Prof. Sironi and Dott. Pieraccini of Milan University, 
indicate that triazole analoge 47 and ixabepilone share the same binding site on -tubulin with 
very similar hydrophobic interaction with the biological target. In both molecules a weak 
Hydrogen bond is present between the OH group on C7 and an arginine residue for ixabepilone 
and an istidine residue for the triazole-epothilone.  
Indeed, the three nitrogen atoms of triazole ring are directed to the inside of macrocyle (Figure 
54).  
                                                          
108 K. C. Nicolaou; A: Ritzén; K. Namoto; Chem. Comm., 2001, 1523. 
109 a) W. S. Horne; M. K. Yadav; C. D. Stout; M. R. Ghadiri; J. Am. Chem. Soc., 2004, 126, 15366. 
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Figure 54: Docked structures of a) ixabepilone in the -tubulin binding site and of b) triazole-epothilone 47 on the -
tubulin binding site. 
 
Indeed, Figure 55 shows that the triazole ring induces a modification in term of arrangement of 
thiazolic chain of macrocycle compared with the commercial one. 
 
 
 
Figure 55: overlapping docked structures of ixabepilone (red) and triazole-epothilone 47 (blue) 
 
6.4. Chemistry 
Inspection of the structure of triazole-epothilone 47 revealed the intriguing possibility of applying 
the Huisgen cycloaddition between fragments E and F to yield the triazole derivative C, which can 
react with D in an aldol condensation giving B. The Ring Closing Metathesis (RCM) reaction to 
bis(terminal) olefin B affords the bicyclic product A, which could be converted to the analogue of 
natural product 47 by simple epoxidation, as retrosynthetically outlined in Scheme 22.  
  
a) b) 
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Scheme 22 
Proceeding with the retrosynthetic analysis, the witting reaction was identified as a method to 
permit disconnection of F to its components, chloromethyl-thiazole G and the enantiopure allyl-
compound H. The alkyne moiety E allowed the indicated disconnection, defining aldehyde I and 
vinyl magnesium bromide as potential intermediates. Aldehyde I could then be derived from 
intermediate J, whose aldol-type condensation of the two commercial available products L and K 
was straightforward.  
In conclusion, this retrosynthetic analysis led to identify 4 main intermediate fragments: 
 Fragment C15 – C19 (intermediate F) 
 Fragment C1 – C6 (Intermediate E) 
 Fragment C13 – C6 (Intermediate C) 
 Fragment C7-C13 (Intermediate D) 
 
6.4.1. Synthesis of fragment F 
Fragment F is summarized in Scheme 23. Starting from the commercially available L-allylglycine, 
protection and conversion to the aldehyde 50 using DIBAL-H was followed by an alkylation with 
methyl-magnesium bromide to yield the secondary alcohol 51. (Scheme 23). 
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Scheme 23 
The compound 52 was then obtained through an oxidation reaction with Dess Martin periodinane 
in 53% of yield. This participated in a Wittig coupling with the easily prepared ylide 54 giving the 
compound 55. The E-configuration of double bond was confirmed by NOESY experimental where 
the presence of a cross peak between the hydrogen of NH group and the hydrogen of CH of 
double bond indicates their proximity. Finally, the free amine group was converted to azide 57 
with the transfer agent 1H-imidazole-1-sulfonyl azide, which corresponds to the C15–C19 region 
of the epothilone derivative (Scheme 24). 
Scheme 24 
 
6.4.2. Synthesis of fragment E 
The synthesis of the fragment E was performed following the published procedure by 
Ramachandran.110 The reaction between dimethylallylmagnesium bromide and propionaldehyde 
furnished the alcohol 58 which was oxidised to the corresponding chetone 59. The terminal 
double bond was then converted to aldehyde by ozonolisis reaction, followed by a Grignard 
                                                          
110 P. V. Ramachandran; J. S. Chandra; B. Prabhudas; D. Pratihar; M.V. R. Reddy; Org. Biomol. Chem., 2005, 3, 3812. 
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reaction in order to introduce the alkyne function into the molecule (61). A final oxidation with 
DMP gave the alkyne 62 in 80% of yield (Scheme 25). 
 
Scheme 25 
6.4.3. Synthesis of fragment C 
The key intermediate C containing the triazole ring was obtained thanks to a Huisgen 1,3-dipolar 
cycloaddition between the alkyne compound 62 and the azide 57 (Scheme 26). 
 
Scheme 26 
The formation of triazoles from azides and terminal alkynes catalyzed by Cu(I) is normally a robust 
reaction, which could be performed under a wide variety of conditions and with almost any 
source of solvated Cu(I). The most important factor seems to be maintaining the Cu(I) at a high 
level at all times during reaction. This is why the use of a Cu(II) source with addition of a reducing 
agent in a large excess has been one of the preferred methods.111 Therefore, following the 
Sharpless conditions, in our case the reaction was performed with copper(II) sulphate 
pentahydrate as catalyst, sodium ascorbate as reducing agent in 1:1 mixture of t-BuOH and water 
at 70 °C for 12 hours. The yield was not satisfactory (only 26%), but the starting material were 
recovered. The same reaction was carried out by microwave activation using THF:H2O 1:1 as 
solvent but it furnished an inseparable mixture of 1,4- and 1,5-triazole derivatives only. 
6.4.4. Synthesis of fragment D 
The synthesis of fragment C7-C13, representing the intermediate D, was accomplished starting 
from the commercial available compound 64. A Wittig reaction with methyl-triphenylphosphine 
converted the ketone group to a terminal olefin 65. Then, an Evans asymmetric alkylation was 
chosen for the introduction of the chiral center. For that, the olefin 65 was treated with oxalyl 
                                                          
111 M. Meldal; C. W. Tornøe; Chem. Rev., 2008, 108, 2952. 
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chloride to generate in situ the acyl chloride of carboxylic acid and then with (R)-(+)-4-isopropyl-2-
oxazolidinone obtaining 66 (Scheme 27). 
  
Scheme 27 
Its enolate was generated by the action of NaHMDS in THF at -78 °C, followed by the reaction with 
excess methyl iodide to afford alkylation product 67, which was isolated in 67% yield 
(diastereoselectivity of the alkylation 10:1 by 1H NMR spectroscopy of the crude product). 
Reductive removal (LiAlH4) of the auxiliary furnished alcohol 68, which should be converted to the 
aldeyde 69 by Dess-Martin oxidation (reaction doesn't carry out).112 
 
6.5. Conclusion 
In order to reach the final epothilone derivatives 47 other reactions are necessary. In particular: 
1. Regio- and stereoselective reduction of carbonilic group on C3 affording 70. This 
reaction may be performed using (+)-DipCl on the alkyne derivative 62, as reported in 
literature,110 or through a hydrogenation process catalysed by [RuCl2(R)-BINAP)]2[Net2], 
method already used for an analogue of the intermediate 63 (Scheme 28).113 
                                                          
112 D. Schinzer; A. Bauer; J. Schieber; Chem. Eur. J. 1999, 5, 2492. 
113 K.C. Nicolaou; A. Ritzen; K. Namoto; Chem. Comm., 2001, 1523. 
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Scheme 28 
Aldol condensation between 69 and 70 affording the bis(terminal) olefin 71 using the conditions 
reported by K. C. Nicolau in the synthesis of epothilone B (Scheme 29).114  
 
Scheme 29 
2. Ring closing metathesis reaction on compound 71 in order to form the macrolactone 
72, followed by epoxidation of endocyclic double bond (Scheme 30). 
                                                          
114 K.C. Nicolaou; Y. He; F. Roschangar; F. Sarabian; S. Ninkovic; Z.Yang; J.I. Trujillo; J. Am. Chem. Soc., 1997, 119, 7960. 
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Scheme 30 
 
Upon completed the synthesis, biological assay will be performed to check the antimicrotubule 
activity either on cancer cells or in Parkinson’s disease, in which recently is emerged the role of 
microtubule dysfunction and the positive response obtained from black mice daily treating with 
EpoD.115  
 
 
 
 
 
  
                                                          
115 D. Cartelli; F. Casagrande; C. L. Busceti; D. Bucci; G. Molinaro; A. Traficante; D. Passarella; E. Giavini; G. Pezzoli; G. Battaglia; G. 
Cappelletti; Sci. Rep., 2013, 3, 1837. 
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6.6. Experimental part 
6.6.1. Synthesis of fragment F 
Compound 49 was prepared following the reported procedure.116 
(S)-2-(Tert-butoxycarbonylamino)-4-pentenal (50) 
 
To a solution of 49 (1.03 g, 4.5 mmol) at -78 °C in 34 mL of CH2CL2, DIBAL-H was added dropwise 
and then the solution was stirred for 4 hours at the same temperature under inert atmosphere. 
After the reaction was completed, 434 L of MeOH and 1.7 mL of a saturated solution of Na2SO4 
were added at -78 °C and the mixture was stirred at room temperature overnight. Finally, 2.26 g 
of Na2SO4 were added, the mixture was filtered, and the solvent was evaporated under vacuum. 
The residue was purified by column chromatography on silica gel (Hexane /EtOAc 4:1) to give 50 
as colourless oil. 
Yield: 68%. []D = + 3.0 (c 1.05, CHCl3); 1H NMR (300 MHz, CDCl3):  1.44 (s, 9H), 2.44-2.62 (m, 2H), 
4.25-4.27 (m, 1H), 5.06-5.19 (m, 3H), 5.63-5.78 (m, 1H), 9.59 (s, 1H) ppm; 13C NMR (75 MHz, 
CDCl3):  28.3, 33.7, 59.0, 77.4, 119.5, 131.9, 199.6 ppm.  
(S)-3-(Tert-butoxycarbonylamino)-hex-5-en-2-ol (51)  
 
To a solution of 50 (607 mg, 3 mmol) in 30 mL of Et2O, methylmagnesium bromide (2.28 mL, 6.8 
mmol) was added at -78 °C and the mixture was stirred 1 hour at 0 °C. The reaction was quenched 
with 20 mL of saturated solution of NH4Cl, the phases were separated and the aqueous layer was 
extracted with Et2O (3x15 mL). The unified organic phases were dried over Na2SO4 and the solvent 
was evaporated under vacuum. The residue was purified by column chromatography on silica gel 
(Hexane /EtOAc 3:1) to give 51 as colourless oil. 
Yield: 70%. 1H NMR (300 MHz, CDCl3):  1.15-1.21 (m, 3H), 1.42 (s, 9H), 2.05-2.37 (m, 2H), 3.50 (bs, 
1H), 3.65 (bs, 1H), 3.78-3.85 (m, 1H), 4.74 (bs, 1H), 5.05-5.13 (m, 2H), 5.72-5.86 (m, 1H), ppm; 13C 
NMR (75 MHz, CDCl3):  20.5, 28.4, 36.9, 55.3, 68.9, 79.4, 117.7, 134.7, 156.5 ppm.  
  
                                                          
116 Patent: GLAXO WELLCOME MANUFACTURING PTE LTD, WO2009/133135 A1, 2009. 
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(S)-3-(Tert-butoxycarbonylamino)-hex-5-en-2-one (52)  
 
To a solution of alcohol 51 (450 mg, 2.1 mmol) in DCM (30 mL), Dess-Martin periodinane (1.24 g, 
2.9 mmol) was added and the new mixture was stirred for 2 h at room temperature. After the 
completion of the reaction, the solvent was evaporated in vacuum, the residue was recovered 
with 15 mL of Et2O and washed with a solution composed by 8 g of Na2S2O3 in 20 mL 80% solution 
of NaHCO3. The phases were separated and the aqueous layer was extracted 3 times with Et2O. 
The combined organic layers were washed with NaHCO3 (20 mL), water (2x15 mL) and brine 2x10 
mL), dried with Na2SO4, filtered and evaporated. The residue was purified by flash column 
chromatography (Hex/EtOAc 3:1) to provide ketone 52 as light yellow oil.  
Yield: 53%. []D = + 2.27 (c 1.13, MeOH); 1H NMR (300 MHz, CDCl3):  1.42 (s, 9H), 2.18 (s, 3H), 
2.34-2.63 (m, 2H), 4.31-4.37 (m, 1H), 5.08-5.19 (m, 3H), 5.58-5.71 (m, 1H) ppm; 13C NMR (75 MHz, 
CDCl3):  27.2, 28.3, 35.7, 59.3, 79.8, 119.0, 132.2, 155.3, 206.5 ppm; MS: m/z 236 [M+Na]+. 
Compound 53 was prepared following the reported procedure.117 
Tributyl((2-methylthiazol-4-yl)methyl)phosphonium chloride (54) 
 
To a solution of 53 (275 mg, 1.9 mmol) in 3 mL of dry toluene, P(n-Bu)3 (0.918 mL, 3.7 mmol) was 
added under nitrogen atmosphere. The reaction was stirred at 100 °C for 3 hours. Then, the 
solvent was evaporated under vacuum and the residue was purified by column chromatography 
on silica gel (DCM/MeOH 9:1) to give 54 as white solid. 
The NMR data are consistent with those reported in literature.118 
(3S,1E)-3-(Tert-butoxycarbonyl)amino-2-methyl-1-(2-methylthiazol-4-yl)hexa-1,5-diene (55) 
 
                                                          
117 J.-C. Jung; R. Kache; K. K. Vines; Y.-S. Zheng; P. Bijoy; M. Valluri; M. A. Avery; J. Org. Chem, 2004, 69, 9269. 
118 J. Mulzer; A. Mantoulidis; E. Oehler; J. Org. Chem., 2000, 65, 7456, 
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To a solution of 54 (371 mg, 1.1 mmol) in 3 mL of dry THF, n-BuLi (0.662 mL, 1.1 mmol) was added 
dropwise at 0 °C under nitrogen atmosphere and the mixture was stirred for 15 minutes. Then, 52 
was added at 0 °C and the temperature was allowed to rise up to rt. After 1 hour the reaction was 
completed (checked with TLC) and it was quenched with saturated solution of NH4Cl (6 mL). The 
phases were separated and the aqueous layer was extracted 3 times with AcOEt. The combined 
organic layers were dried over Na2SO4, filtered and evaporated. The residue was purified by flash 
column chromatography (Hex/EtOAc 3:1) to provide ketone 55 as light yellow oil. 
Yield: 85%. []D = - 21.5 (c 0.625, MeOH); 1H NMR (400 MHz, CDCl3):  1.48 (s, 9H), 2.07 (s, 3H), 
2.35-2.46 (m, 2H), 2.76 (s, 3H), 4.24 (bs, 1H), 4.72 (bs, 1H), 5.10-5.18 (m, 2H), 5.72-5.83 (m, 1H), 
6.49 (s, 1H), 6.96 (s, 1H) ppm; 13C NMR (100 MHz, CDCl3):  16.1, 18.9, 28.4, 38.1, 56.8, 79.5, 
115.4, 118.0, 118.3, 134.0, 140.4, 155.3, 164.9 ppm; MS: m/z 331 [M+Na]+. 
(3S,1E)-2-methyl-1-(2-methylthiazol-4-yl)hexa-1,5-dien-3-aminium chloride (55) 
 
To a solution of 55 (114 mg, 0.5 mmol), the saturated solution of HCl in MeOH was added and the 
reaction was stirred for 30 minutes at r oom temperature. After completion, checked by TLC 
(Hex/AcOEt 2:1), the solvent was removed under vacuum. The crude product was used in the next 
step without further purification. 
Yield: 99%. 1H NMR (300 MHz, CD3OD):  2.08 (s, 3H), 2.58-2.65 (m, 2H), 2.95 (s, 3H), 4.03 (t, J = 
7.4 Hz, 1H), 5.20-5.30 (m, 3H), 5.71-5.85 (m, 1H), 6.59 (s, 1H), 7.81 (s, 1H) ppm; 13C NMR (75 MHz, 
CD3OD):  15.1, 19.4, 41.3, 58.1, 115.4, 116.0, 119.2, 123.1, 132.7, 138.1, 154.8, 168.1 ppm. 
(3S,1E)-3-Azido-2-methyl-1-(2-methylthiazol-4-yl)hexa-1,5-diene (57) 
 
The salt 56 (39 mg, 0.2 mmol) was dissolved in MeOH (0.7 mL) and K2CO3 (125 mg, 0.9 mmol), 
CuSO4 pentahydrate (0.4 mg, 0.02 mmol), and 1H-imidazole-1-sulfonyl azide (50 mg, 0.24 mmol) 
were added. The reaction was stirred at room temperature for 12 hours, then the solvent was 
removed under vacuum. The residue was purified by flash column chromatography (Hex/EtOAc 
9:1) to provide azide 57 as yellow oil. 
 
120 
 
Yield: 50%. IR: (neat):  = 2094 cm-1; 1H NMR (300 MHz, CDCl3):  2.07 (s, 3H), 2.31-2.44 (m, 2H), 
2.74 (s, 3H), 4.01-4.06 (m, 1H), 5.08-5.17 (m, 2H), 5.68-5.82 (m, 1H), 6.54 (s, 1H), 7.01 (s, 1H) ppm.  
 
6.6.2. Synthesis of fragment C 
Compound 62 was prepared following the reported procedure.110  
Synthesis of (3S,1E)-2,2-dimethyl-1-(1-(2-methyl-1-(2-methylthiazol-4-yl)hexa-1,5-dien-3-yl)-1H-
1,2,3-triazol-4-yl)pentane-1,3-dione (63) 
 
To a solution of 57 (19 mg, 0.08 mmol) and 62 (61 mg, 0.4 mmol) in t-BuOH:H2O (1:1, 1 mL), 
CuSO4*5H2O and sodium ascorbate were added and the mixture was heated at 70 °C for 12 hours. 
Then the t-BuOH was evaporated under vacuum, water was added and the residue was extracted 
with DCM (3x5 mL). The combined organic layers were dried over Na2SO4, filtered and 
evaporated. The residue was purified by flash column chromatography (Hex/EtOAc 3:1) to provide 
triazole 63 as yellow oil. 
Yield: 26%. 1H NMR (400 MHz, CDCl3):  1.09 (t, J = 1.4 Hz, 3H), 1.5 (s, 6H), 2.03 (s, 3H), 2.65 (q, J = 
1.4 Hz, 2H), 2.80 (s, 3H), 2.92-2.99 (m, 1H), 3.05-3.12 (m, 1H), 5.11-5.20 (m, 3H), 5.67-5.77 (m, 1H) 
6.71 (s, 1H), 7.09 (s, 1H), 8.13 (s, 1H) ppm; 13C NMR (100 MHz, CDCl3):  7.9, 15.0, 18.6, 22.4, 29.7, 
36.3, 60.0, 68.9, 117.6, 119.3, 122.3, 126.2, 132.1, 136.4, 145.8, 150.4, 166.3, 194.3, 211.2 ppm; 
MS: m/z 409 [M+Na]+. 
6.6.3. Synthesis of fragment D 
Compound 66 was prepared following the reported procedure.119  
Compound 68 was prepared following the reported procedure.112  
 
  
                                                          
119 M. M. Alhamadsheh; S. Gupta; R. A. Hudson; L. Perera; L. M. V. Tillekeratne; Chem. Eur. J., 2008, 14, 570. 
 
121 
 
 
  
 
122 
 
 
 
 
Chapter 7 
In vivo trapping of polyketide 
intermediates from a Type I Polyketide 
Synthase 
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7.1. Introduction 
7.1.1. Polyketide synthase 
Polyketides are a large family of natural products found in bacteria, fungi and plants, which 
exhibit a staggering range of functional and structural diversity and boast a wide range of 
medicinally important activities, including antibiotic, anticancer, antifungal, antiparasitic and 
immunosuppressive properties (Figure 56).120 
 
Figure 56 
Even before the full extent of their utility was known, scientists became interested in how these 
complicated molecules are assembled. The unique structures of thousands of polyketides arise 
from coordinated, multistep action of enzymes organized in assembly lines, termes polyketide 
synthases (PKSs). The chemical logic for their assembly is that a small set of monomer units are 
incorporated into a linear oligomer by successive rounds of decarboxylative Claisen condensations 
between a thioesterified malonate derivative and an acyl thioester. Tipically the monomers are 
acetylCoA, malonyl-CoA, methylmalonyl-CoA, with the carboxyl group activated for capture by 
nucleophiles (Figure 57). 121 
 
Figure 57 
Three types of bacterial PKSs are known to date: type I, type II and type III PKS, but in this thesis 
only type I will be described. 
The modular system is the classic bacterial type I PKS, best exemplified by the PKS responsible for 
assembling the 6-deoxyerythronolide B (6-DEB) scaffold of erythromycin A (Figure 58). 
                                                          
120 B. Shen; Curr. Opin. Chem. Bio., 2003, 7:285 
121 M. A. Fischbach; C. T. Walsh; Chem. Rev., 2006, 106, 3468. 
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Figure 58 
This PKS assembles seven precursors consisting of one propionyl-CoA starter unit and six (2S)-
methylmalonyl-Coenzyme A (CoA) extender units into 6-DEB. The role each of these type of 
precursors plays in polyketide assembly is readily apparent from the unit names: the starter unit is 
the initiating precursor for polyketide synthesis, while the extender units elongate the polyketide 
backbone to completion. A set of catalytic domains, grouped together as a “module,” controls the 
incorporation of each precursor into the polyketide backbone. For modular type I PKSs, the 
number of modules is equivalent to the number of precursors incorporated into the polyketide. 
While the modules that incorporate the starter unit can have variable catalytic domains, the 
modules that incorporate extender units typically consist of three core domains for polyketide 
extension and up to three auxiliary domains involved in β-keto processing. The core domains are 
the ketosynthase (KS), acyltransferase (AT), and acyl carrier protein (ACP). The AT domain is the 
“gate keeper” of the module and recognizes the specific extender unit to be incorporated into the 
growing polyketide chain and covalently tethers the malonyl derivative of the extender unit onto 
the sulfidryl group of the ACP prosthetic group: the 4′-phosphopantetheinyl moiety of CoA. The KS 
domain catalyses the decarboxylative Claisen condensation between a neighboring ACP-linked 
malonate derivative and an ACP-linked acyl thioester to extend the polyketide chain. The 
remaining optional domains (ketoreductase [KR], dehydratase [DH], and enoylreductase [ER]) 
alter the oxidation state of the β-keto group formed after the KS-catalyzed condensation (Scheme 
31). 
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Scheme 31: During PK biosynthesis, decarboxylation of the downstream (methyl)malonyl-S-T yields a nucleophilic 
thioester enolate, which attacks the upstream acyl-S-T thioester in a Claisen condensation to form a C-C bond. KS: 
ketosynthase; AT: acyltransferase. 
As already said above, the enormous structural diversity seen in the polyketide backbones of 
natural products comes predominantly from the diversity of starter and extender units, variations 
in the number of extender units incorporated, alterations in the oxidation state of the β-keto 
groups, and cyclization versus hydrolysis for chain termination.122 
The basic knowledge of PKS system provides context for more efficient efforts in combinatorial 
biosynthesis to create collections of natural product variants with novel structure and function. 
Although the enormous progress made in the determination of their structures and mechanisms 
through the manipulation of the gene clusters encoding putative PKSs (e.g. domain deletion or 
‘relocation’), much more remains to be discovered.  
7.1.2. Polyether antibiotics 
Polyether antibiotics are a unique class of polyketides that are broadly used in veterinary 
medicine as anticoccidial drug. They include monensin and salinomycin among others, and all are 
produced by Streptomyces species (Figure 59).  
 
Figure 59 
Due to their ability to form complexes with metal cations (host-guest complexes) and transport 
these complexes across lipid bilayers and cell membranes, they are widely used as anticoccidial 
drug but also they have shown biological activities against a variety of critical infectious disease 
targets including protozoa, bacteria, and viruses, as well as to selectively kill cancer stem cells. 
                                                          
122 B. S. Moore; C. Hertweck; Nat. Prod. Rep, 2002, 19, 70. 
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According to the results of X-ray studies, the metal cation sites in a cage formed by oxygen atoms 
of the ionophore. Typically, the complexation of the cation is connected with formation of a 
pseudocyclic structure which is stabilized by intramolecular hydrogen bonds formed between the 
carboxylic group and the hydroxyl groups. The ring of ionophore molecule is wrapped around this 
hydrophilic cage rendering the whole complex lipophilic. The mechanism of transport of a cation 
by polyether ionophores is attributed to their ability to exchange protons and cations in an 
electroneutral process. In this type of transport of the cations (M+), the polyether ionophore 
anion (I–COO−) binds the metal cation or proton (H+) to give a neutral salt (I– COO−M+) or a 
neutral polyether ionophore in acidic form (I–COOH), respectively, and only uncharged molecules 
containing either the metal cation or proton can move through the cell membrane. The whole 
process leads to changes in Na+/K+ gradient and to an increase in the osmotic pressure inside the 
cell, causing swelling and vacuolization, and finally death of the bacteria cell.123 
The wide range of biological activity mentioned above basically depends on the structural 
diversity, dictated by the number of ether rings and/or the manner of ring closure. Following 
initial Westley’s speculation124 Cane, Celmer, and Westley proposed a simple model for polyether 
biosynthesis involving the initial formation of an all-trans unsaturated polyketide that would 
undergo oxidative cyclization by stereospecific epoxidation, epoxide hydrolysis, and a cascade of 
nucleophilic hydroxy cyclizations.125 This hypothesis was then validated by the isolation of (E,E,E)-
polyketide triene precursor to monensin from a blocked mutant of Streptomyces 
cinnamonensis.126 
 
7.2. Aim of this work 
7.2.1. Background of the project 
Lasalocid A is one of the simplest polyether composed of THF and THP rings produced by 
Streptomyces lasaliensis by type I polyketide synthase (Figure 60).127 
                                                          
123 J. Rutkowski; B. Brzezinski; BioMed Research International, 2013, 1. 
124 J. W. Westley; J. F. Blount; R. H. Jr. Evans; A. Stempel; J. Bergel; J. Antibiot., 1974, 27, 597. 
125D. E.Cane; W. D.Celmer; J. W.Westley; J.Am.Chem.Soc., 1983, 105, 3594. 
126A. Bhatt; C. B. W. Stark; B. M. Harvey; A. R. Gallimore; Y. A. Demydchuk; J. B. Spencer; J. Staunton; P. F. Leadlay; Angew. Chem. Int. 
Ed., 2005, 44, 7075. 
127 M.-H. Abdulla; D. S. Ruelas; B. Wolff; J. Snedecor; K.-C. Lim; F. Xu; A. R. Renslo; J. Williams; J. H. McKerrow; C. R. Caffrey; PLoS 
Neglected Trop. Dis., 2009, 3, 1. 
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Figure 60 
Its biosynthesis involves the formation of a dodecaketide from the decarboxylative condensation 
of malonate, methylmalonate, and ethylmalonate units. Firstly, Westley et al. suggested that the 
stereoselective bis(epoxidation) of a putative dodecaketide acid precursor, prelasalocid, and a 
subsequent epoxide hydrolysis and cyclization cascade, would lead to lasalocid A and its 
stereoisomer isolasalocid (Scheme 32). 
 
Scheme 32 
However, genetic and proteomic approaches are not always applicable or successful to gain 
insight better to the biomechanism, especially when iterative catalytic activities by single enzymes 
are involved, like in this case. 
In the laboratories of Manuela Tosin and coworkers, in which I spent 6 months during my PhD, 
has been recently developed a chemical strategy for the off-loading of intermediates from PKSs.128 
This employs nonhydrolysable synthetic mimics of malonate units normally recruited for 
                                                          
128a) M. Tosin; D. Spiteller; J. B. Spencer; ChemBioChem., 2009, 10, 1714; b) M. Tosin; L. Betancor; E. Stephens; W. M. A. Li; J. B. 
Spencer; P. F. Leadlay; ChemBioChem., 2010, 11, 539; c) M. Tosin; Y. Demydchuk; J. S. Parascandolo; C. Blasco-Per; F. J. Leeper; P. F. 
Leadlay; Chem. Commun., 2011, 47, 3460. 
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polyketide formation, in particular carba(dethia) cysteamine analogues such as 73a (Scheme 33 
(b)). 
 
Scheme 33: (a) Methylmalonyl-ACP decarboxylative condensation leading to polyketide formation (type I modular PKS); 
(b) a smallmolecule nonhydrolysable mimic of methylmalonyl-ACP (methylmalonyl carba(dethia)-N-acetyl cysteamine, 
73 intervenes, causing the off-loading of intermediates. 
As the polyketide backbone is assembled by sequential decarboxylation and condensation of the 
natural malonate units ((a), Scheme 33), the carba(dethia) substrates compete with the integral 
acyl carrier protein (ACP) domains for the growing polyketide chain, causing the premature off-
loading of truncated intermediates ((b), Scheme 33). Unable to be reloaded onto the enzyme, 
these species diffuse out of the active site and become available for LC-MS characterization. This 
approach has proved successful also in vivo studies, where the PKS catalytic activities can be 
interrogated in their natural context and in relation to environmental signals/responses.  
In particular, S. lasaliensis as well as engineered mutant strains bearing a deletion in either the 
epoxidase LasC or the epoxide hydrolase LasB genes, has been fed with methylester of 73a (10 
mM concentration) over 3–5 days. The protection of carboxylic function is essential to increase 
cell permeation (charged molecule would not readily be taken up by cells) and to avoid 
spontaneous decarboxylation. The ester were hydrolysed by endogenous esterases to the active 
biosynthetic probes 73a in situ. 
 
Scheme 34 
Micro-LC/HRMS analyses of the ethyl acetate extracts of these bacterial cultures provide direct 
evidence for the off-loading of a series of intermediates from lasalocid A PKS (Scheme 35). 
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Scheme 35: In vivo release of derivatives of intermediates from the lasalocid A polyketide synthase by using the 
synthetic chain terminators 73a generated in situ by the hydrolysis of the corresponding methyl esters. The 
stereochemistry of the derivatives has yet to be established. 
In the extracts of the wild-type strain grown in the presence of the malonyl carba(dethia) 
substrate 73a, derivatives of a fully cyclized dodecaketide 74a, a putative linear undecaketide 
diene 75a, and its oxidized counterpart 76a were identified. The postulated structure of these 
compounds is supported by HRMSn experiments and MS/MS analysis. The isolation and 
characterization of the putative undecaketide diene 75a and its oxidized counterparts 76a, 
suggest that epoxidation, not clear yet before these experiments, occurs on an enzyme-bound 
substrate, possibly on the ACP11-bound undecaketide or on the preceding ACP10 bound 
decaketide.  
Indeed, a distinctive feature of lasalocid A is the unusual presence of an aromatic template 
formed by a modular PKS and it would be important to define the mechanism and the timing of 
its formation. The obtained results from feeding experiment using methylester of 73a suggested 
that aromatization may follow ether ring formation and occur as soon as a dodecaketide chain is 
formed, before chain release from the PKS, but further work is needed to confirm it.129 
  
                                                          
129 M. Tosin; L. Smith; P. F. Leadlay; Angew. Chem. Int. Ed., 2011, 50, 11930. 
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7.2.2. My project 
In order to improve the chemical strategy described above in term of number and amount of 
captured biosynthetic intermediates, aim of my work was to develop a novel synthetic chain 
terminator (77) capable of capturing polyketide biosynthetic intermediates in vivo. The idea was 
synthetize a chemical probe having a long hydrophobic chain to mimic the length of 4′-
phosphopantetheinyl moiety normally bound to the ACP domain (Figure 61). 
 
Figure 61 
Firstly, the carboxylic function was protected as methyl ester. However, previous studies showed 
as the hydrolysis in situ by endogenous esterases has been estimated to be in the range of 5-50% 
over five days of culturing, depending on the adopted feeding protocol. Therefore a second 
generation of ACP analogue was investigate to check whether, by changing the nature of the ester 
protection, a higher concentration of the active probes could be achieved in vivo, and whether 
this would ultimately lead to a more efficient intermediate capture. 
In exploring possible protecting groups that would be easily hydrolysed in vivo, we considered the 
use of acetoxymethyl ester moiety, obtaining the compound 78 (Figure 62). 
 
Figure 62 
Acetoxymethyl (AM) esters are widely employed in prodrugs and chemical probes in eukaryotic 
cells to mask hydrophilic/charged bioactive functionalities, allowing effective compound cellular 
uptake through membrane permeation.130 Their hydrolysis in situ by nonspecific cellular esterases 
results in the formation of hemiacetals that spontaneously decompose to ‘unmask’ the bioactive 
compounds within cells.   
                                                          
130 P. D. Jobsis; E. C. Rothstein; R. S. Balaban; J Microsc. 2007, 226, 74. 
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7.3. Result 
7.3.1. Chemistry 
The malonyl-carba(dethia)-cysteamine analogue 77 was prepared from -aminobutyric acid GABA 
80 according to Scheme 36. Selective acetylation of 80 with decanoyl chloride 79 and treatment 
of the free carboxylate with Meldrum’s acid and DMAP led to the formation of the cyclic adduct 
82, which was purified by silica gel chromatography. Finally, the reaction at reflux of 16 in dry 
methanol afforded -ketoester 77 in 85% of yield. 
 
Scheme 36 
The target AM ester probe 78 was prepared according to Scheme 37. Briefly, the carbonyl groups 
of the methyl esters 77 were protected by conversion to thioketal 83 by reaction with 1,2-
ethanediol and boron trifluoride diethyl etherate. 83 were then hydrolysed to the corresponding 
carboxylates by treatment with potassium trimethyl silanolate, and converted to the 
acetoxymethyl ester 85 by reaction with bromomethyl acetate in dry THF. Finally, the desired 
compounds 78 was achieved by treatment of 85 with [bis-(trifluoroacetoxy)iodo]benzene.  
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Scheme 37 
AM esters are known to spontaneously hydrolyse over time, even in neutral conditions. Therefore 
78 was promptly purified by HPLC and stored for a limited amount of time at low temperature 
and in a lyophilised form prior to its use. 
7.3.2. Feeding experiments with methyl ester 77 
The malonyl-carba(dethia)-cysteamine analogue 77 was then employed as substrates in small-
scale fermentations (10 mL) of ACP mutant strains of Streptomyces lasaliensis. The strains, 
constructed from S. lasaliensis NRRL 3382 by point mutation of the active serine of ACP12 and 
ACP5 to alanine residues as previously reported,129 do not produce the natural polyketide product 
lasalocid A. However, they still harbour enzyme-bound biosynthetic intermediates. 
In the ethyl acetate extracts of the wild-type Streptomyces lasaliensis grown over 4 days in the 
presence of the methyl ester substrate 77 (supplemented daily to reach a 4.0 mM final 
concentration), the putative unnatural polyether undecaketide intermediate 77a was identified as 
the major polyketide products off-loaded from the lasA PKS (Scheme 38). 
 
133 
 
Scheme 38 
The postulated nature of this compound is supported by HRMSn experiments, and several careful 
repetition of these experiments and LC-MS analyses optimisation have allowed us to estimate 
that up to 10 times more of 77a is captured using the deca-probe 77 rather than the methyl ester 
of 73a (Figure 63). 
 
a)                                                                                       b) 
Figure 63: a) LC-ESI-HRMS analysis of two organic extracts of S. lasaliensis ACP12 (S970A) grown in the presence of 
probe 77 and the counterpart in absence: [M+Na]+ [M+H]+ extracted ion trace for the off-loaded polyketide 77a are 
shown. In both case the intensity is around 105. b) LC-ESI-HRMS analysis of the organic extract of S. lasaliensis ACP12 
(S970A) grown in the presence of probe 73a: [M+Na]+ [M+H]+ extracted ion trace for the off-loaded polyketide 74a are 
shown with an intensity around 104. 
 
Its stereochemistry is yet to be separately determined, as well as the origin of two peaks for 77a 
(possibly arising from the presence of isomers/conformers).  
The compound 77a was characterized by HR-MS2 and displayed a conserved fragmentation 
pattern involving McLafferty rearrangement and subsequent formation of m/z 377, a diagnostic 
polyether fragment. In addition, the loss of the C10 acyl chain occurring during fragmentation 
Intensity: 10
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afforded a m/z 260 fragment, which would correspond to a protonated cyclic imine and strongly 
supports the aromatic ketone nature of these derivatives (Figure 64). 
 
Figure 64 
Interestingly, for the first time, additional formation of short-chain products (e.g., the 
pentaketides 77e) was observed in quite high intensity. As well as expected species from ACP10 
such as 77c which were previously undetected, we also observed an unexpected putative 
dodekatide 77d, which were unequivocally characterised by HR-MS2. In fact this putative 
intermediate formally derives from KR and DH reactions taking place on the module before, and it 
could be due to a diffusion process into the active site of the previous module and therein 
processed by the KR and the DH domains to give 77d. To the best of our knowledge this diffusion 
effect would be the first time that is reported. Finally, it was possible to identify unnatural 
polyketide deriving from other modules, like ACP2-3-5 never seen before, but the intensity of the 
signals were too much low to carry out a complete characterization by HR-MS2.  
7.3.3. Feeding experiments with AM-ester 78 
In our effort to improve the titre of the off-loaded unnatural polyketides and therefore having a 
full kinetic picture of polyketide assembly chain, we started to investigate the attitude of the 
second generation of deca-probe 78 on the ACP mutant strains of Streptomyces lasaliensis in 
comparison to the first-generation methyl esters 77. Firstly, concentration-dependent effects of 
78 on bacterial cell growth and polyketide production was preliminarily evaluated on agar-plate 
cultures of S. erythraea, the soil bacterium responsible for the biosynthesis of erythromycin A. 
The growth of S. erythraea was critically affected by the presence of 78 in 10 mM and 5 mM 
concentration, whereas at lower concentrations (1-2 mM) normal cell growth and erythromycin 
production were observed (data not shown). Reasonably, the 78 toxicity on cells could be due to 
formaldehyde formation occurring during AM ester deprotection. To enable bacterial cells to 
survivor during the feeding experiments, the AM-ester 78 was added in small amounts (0.4-0.8 
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mM) over 5 days on bacterial liquid cultures. The overall outcome of the feeding experiments is 
summarized in Scheme 39. 
Scheme 39 
LC-HRMS analyses of the ethyl acetate extracts revealed complete hydrolysis of 78 and further 
enhancement in the titre of the unnatural polyethers 77a,b,d-f was clearly observed (Figure 65). 
 
Figure 65: a) LC-ESI-HRMS analysis of an organic extract of S. lasaliensis ACP12 (S970A) grown in the presence of probe 
78: [M+Na]+ [M+H]+ extracted ion trace for the off-loaded polyketide 77a is shown. The intensity is around 106. b) LC-
ESI-HRMS analysis of the organic extract of S. lasaliensis ACP12 (S970A) grown in the presence of probe 77: [M+Na]+ 
[M+H]+ extracted ion trace for the off-loaded polyketide 77a is shown with an intensity around 105. 
The unexpected putative dodekatide 77d, was again identified, confirming the possibility of a 
diffusion effect between PKS modules. Besides, the previous experiments using this substrates in 
vivo led for the first time to the off-loading of biosynthetic short chain intermediates 77f from the 
modular lasA polyketide assembly line. Further studies are essential to confirm the putative 
intermediates identified and to try to gain a complete set of biosynthetic intermediates from the 
modular lasA polyketide assembly line. 
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7.4. Conclusion 
In summary, with this work the chemical strategy developed by Manuela Tosin at al. about the 
trapping of biosynthetic intermediates of polyketide system has been optimized. In particular, 
using the methyl-ester deca probe 77 on S. lasaliensis it has been possible to identify many 
intermediates never seen before, even unexpected.  
Subsequently, the use of a more efficient protecting group of carboxylic moiety in term of in situ 
hydrolysis, led to obtain an evident enhancement of the titre of putative intermediates compared 
with the counterpart deriving from feeding with 77. Previous experiments are really promising for 
having a complete set of biosynthetic intermediates from the modular lasA polyketide assembly 
line, since the identification of short-chain intermediates. 
Finally, this chemical strategy represent an effective chemical biology tool for developing novel 
mutasynthesis and synthetic biology since its capacity to generate unnatural polyketides directly 
in vivo. Therefore this approach may give access to novel molecules of therapeutic interest, as 
well as helping illuminate their mechanism of action. 
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7.5. Experimental part 
7.5.1. General methods 
Unless specified otherwise, chemicals were purchased from Sigma Aldrich, Fisher Scientific, 
Carbosynth and Alfa Aesar and were used without further purification. Dry dichloromethane, 
tetrahydrofuran and N,N-dimethylformamide were purchased from VWR International (AR grade) 
and dried using solvent towers. Dry methanol and dry acetonitrile were purchased from Fisher 
Scientific. Reagent grade dichloromethane, ethyl acetate, methanol, acetonitrile, acetone, 
dimethyl sulfoxide and tetrahydrofuran were purchased from Fisher Scientific. Analytical thin-
layer chromatography (TLC) was performed on aluminium sheets precoated with silica gel 60 
(F254, Merck) and visualized under ultra-violet light (short and long-wave) and using potassium 
permanganate (KMnO4) or vanillin stains. Silica gel was purchased from Sigma Aldrich  
(Tech Grade, pore size 60Å, 230-400 mesh). 1H and 13C NMR spectra were recorded in d4-MeOD, 
CDCl3 or D2O on the following Bruker Avance instruments: DPX-300 300 MHz, DPX-400 400 MHz, 
DRX-500 500 MHz, AV-600 600 MHz or AV-700 700 MHz. High-resolution mass spectra (HRMS) 
were obtained using electrospray ionization (ESI) on a MaXis UHR-TOF (Bruker Daltonics) or on 
Bruker MaXis (ESI-HR-MS). Compounds were purified by preparative or semipreparative HPLC on 
Phenomenex synergi™ Polar RP 80Å (250 x 21.2 mm, 4µm) and Phenomenex synergi™ Polar RP 
80Å (250 x 10.0 mm, 4µm) columns respectively. The mobile phase consisted of a gradient of 
water and acetonitrile or methanol (HPLC grade, containing 0.1 % trifluoroacetic acid or 0.1% 
formic acid) at a flow rate of 20 or 2.5 mL/min, with UV detection at 210, 254 and 280 nm. 
 
7.5.2. Synthesis 
Compound 77 was prepared following the reported procedure.61 
Synthesis of methyl-2-(2-(3-decanamidopropyl)-1,3-dithiolan-2-yl)acetate (83) 
 
Compound 77 (800 mg, 2.55 mmol) and 1,2-ethanthiol (1.07 mL, 12.8 mmol) were 
dissolved in dichloromethane (16 mL) under argon atmosphere. The solution was cooled 
to 0 °C before BF3·OEt2 (1.57 mL, 12.8 mmol) was slowly added. The reaction was stirred 
under reflux overnight. Then, a saturated solution of NaHCO3 was added at 0 °C up to pH  
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9 and the mixture was extracted with CH2Cl2 (3x10 mL) The crude product was purified by 
column chromatography (cyclohexane: EtOAc, 7:3 to 1:1)) and 83 was obtained as a white 
powder.  
Yield 61%; 1H NMR (400 MHz, CDCl3):  5.51 (br s, 1H), 3.70 (s, 3H), 3.30 (s, 4H), 3.29 (m, 
2H), 3.04 (s, 2H), 2.14 (m, 2H), 2.14 (m, 2H), 1.75 (m, 2H), 1.58 (m, 2H), 1.27 (br s, 12H), 
0.87 (t, J = 6.5 Hz, 3H) ppm; 13C NMR (101 MHz, CDCl3):  173.1, 170.5, 66.6, 51.7, 48.2, 
39.8, 39.4, 39.1, 36.9, 29.4, 29.4, 29.3, 29.3, 27.1, 25.8, 22.6, 22.6, 14.1 ppm; HR-ESI-MS: 
calculated for C19H35NO3S2 412.1951, found: 412.1945 [M-H]-.  
Synthesis of potassium 2-(2-(3-decanamidopropyl)-1,3-dithiolan-2-yl)acetate (84) 
 
To a solution of Compound 83 (600 mg, 1.54 mmol) in dry THF (10 mL) containing 3 Ȧ 
molecular sieves, was added potassium trimethilsilanolate (789 mg, 6.16 mmol). The 
reaction was stirred under argon atmosphere for 3 h at room temperature. Then the 
reaction was filtered under vacuum and concentrated. The residue was dissolved in water 
(5 mL), EtOAc (5 mL) was added, and the two phases were separated. The aqueous layer 
was freeze-dried affording 84 as a white powder. 
Yield 86%; 1H NMR (400 MHz, D2O):  3.22 (m, 4H), 3.13 (m, 2H), 2.17 (t, J = 7.2 Hz, 2H), 2.01 (m, 
2H), 1.84 (s, 4H), 1.64 (br s, 2H), 1.53 (br s, 2H), 1.22 (br s, 12H), 0.79 (br s, 3H) ppm; 13C NMR (101 
MHz, D2O):  180.9, 177.4, 175.7, 67.1, 50.1, 39.4, 38.7, 38.2, 35.5, 31.1, 28.7, 28.5, 28.4, 28.2, 
26.1, 25.3, 21.9, 13.2 ppm. 
Synthesis of acetoxymethyl-2-(2-(3-decanamidopropyl)-1,3-dithiolan-2-yl)acetate (85) 
 
Compound 84 (545 mg, 1.32 mmol) was suspended in dry THF (9 mL) and bromoethylacetate 
(140 µL, 1.58 mmol) was added. The reaction was stirred at room temperature overnight and 
afterwards concentrated under vacuum. The crude product was purified by column 
chromatography (EtOAc/CycloHex 6:4) to yield 85 as a white powder (220 mg, 40%). 
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Yield 86%; 1H NMR (400 MHz, CDCl3):  5.75 (s, 1H), 5.55 (br s, 1H), 3.31 (s, 4H), 3.30 (m, 2H), 3.08 
(s, 2H), 2.13 (m, 2H), 2.13 (m, 2H), 2.12 (s, 3H), 1.56 (m, 2H), 1.27 (m, 2H), 1.29 (br s, 12H), 0.88 (t, 
J = 6.4 Hz, 3H); 13C NMR (101 MHz, CDCl3):  173.2, 169.9, 168.6, 79.2, 66.4, 48.2, 39.8, 39.4, 39.1, 
36.9, 29.5, 29.4, 29.3, 29.3, 27.1, 25.8, 22.7, 22.7, 20.7, 14.1 ppm. HR-ESI-MS: calculated for 
C21H37NO5S2 470.2005, found: 470.2006 [M-H]+.  
Synthesis of acetoxymethyl-6-decanamido-3-oxohexanoate (78) 
Compound 85 (200 mg, 0.45 mmol) was dissolved in acetonitrile (12 mL) and water (1.12 mL) and 
[bis(trifluoroacetoxy)iodo]benzene (576 mg, 1.34 mmol) was added. The reaction was stirred at 
room temperature for 10 minutes, quenched with H2O/NaHCO3 sat./Na2S2O3 sat. solution (1:1:1, 
12 mL). The organic solvent was separated and removed under reduced pressure. The final 
mixture was extracted with dichloromethane (3x5 mL), the organic layer was dried, filtered, 
concentrated and the crude was purified by column chromatography (eluent 7:3 
EtOAc/CycloHex). 78 was obtained as a white powder (80 mg, 40%).  
Yield 82%; 1H NMR (400 MHz, CDCl3):  5.75 (s, 1H), 5.73 (br s, 1H), 3.50 (s, 2H), 3.24 (m, 2H), 2.60 
(t, J = 6.8 Hz, 2H), 2.14 (m, 2H), 2.12 (s, 3H), 1.80 (m, 2H), 1.59 (m, 2H), 1.25 (br s, 12H), 0.86 (t, J = 
6.1 Hz, 3H) ppm; 13C NMR (101 MHz, CDCl3):  200.8, 173.4, 169.7, 166.1, 79.5, 48.7, 40.4, 40.4, 
38.5, 31.8, 31,8, 29.4, 29.3, 29.3, 25.8, 23.9, 22.1, 20.5, 14.1 ppm; HR-ESI-MS: calculated for 
C19H33NO6 394.2200, found: 394.2202 [M-H]+.  
 
7.5.3. Feeding experiments 
Microbiology methods: All media and glassware were sterilized prior to use by autoclave (Astell). 
Liquid cultures were grown with shaking in Innova 44 incubator/shaker (New Brunswick 
scientific). M79 medium: 2.5 g glucose, 2.5 g peptone, 0.5 g yeast extract, 1.5 g NaCl, 2.5 g casein 
hydrolysate in 250 ml of tap water adjusted to pH 7.1. MYM medium: 1.0 g maltose, 1.0 g yeast 
extract, 2.5 g malt extract in 250 ml of tap water adjusted to pH 7.1. 
Construction of mutant strains of Streptomyces lasaliensis: The cultivation of the wild type 
lasalocid-producing strain S. lasaliensis NRRL3382 was carried out as previously described.131 The 
construction of S. lasaliensis ACP12 (S970A) and ΔlasB ACP12 (S970A) mutant strains was 
previously reported. The ligated plasmid was transformed into E. coli strain DH10B and positive 
colonies tested by restriction mapping and sequencing before a correct clone was transferred to 
                                                          
131E. M. Sletten; C. R. Bertozzi; Angew. Chem. Int. Ed., 2009, 48, 6974. 
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E. coli ET12567/pUZ8002. The mutant was fermented and LC-MS analysis of the ethyl acetate 
extracts of each culture showed that lasalocid production was completely abolished.  
Growth of S. lasaliensis wild-type (WT), ACP12 (S970A) strain and mass spectrometry analysis: 
The S. lasaliensis strain was grown in M79 medium (10 mL) for 3 days at 30 °C in 50 mL 
Erlenmeyer flasks with spring. Seed cultures (100 µL) were used to inoculate MYM liquid cultures 
(10 mL, in duplicate/triplicate copy, in 50 mL Erlenmeyer flasks with spring). They were incubated 
at 30 °C for 5 days. After the first day of incubation, the probes (77-78, final concentration: 2.5 
mM) were added portionwise as follows: addition of 8.3 µmol dissolved in 100 l of MeOH on day 
2 and day 3; addition of 4.1 µmol dissolved in 50 l of MeOH on day 4 and 5. Control liquid 
cultures in absence of 77-78 of the strains were also prepared (in duplicate/triplicate copy). After 
5 days of fermentation, the liquid cultures were extracted with ethyl acetate (20 mL x 2). The 
extracts were concentrated and the residues were redissolved in HPLC-grade methanol (1 mL) for 
mass spectrometry analysis. UPLC-HR-ESI-MS analyses of S. lasaliensis ACP12 (S970A) strain was 
performed on a MaXis Impact UHR-TOF (Bruker Daltonics). Samples (5 l) were injected onto an 
Acquity UPLC HSS T3 (150 mm x 1.0 mm, 1.8 µm) or Agilent Eclipse C18 (1.8um, 100 mm x 2.1 
mm). The mobile phase consisted of a gradient of water and acetonitrile (HPLC grade, each with 
0.1 % trifluoroacetic acid). The following solvent (A =1% TFA in H2O, B =1% TFA in MeCN) gradient 
was applied: 
 10% B 0-2.7 min; 10-100% B 2.7-42.7 min; 100% B 42.7-62.7 min; 100-10% B 62.7-65.7 
min; 10% B 65.7-77.7 min, using an Acquity UPLC HSS T3 column at a flow rate of 0.05 
mL/min. 
Spectra were recorded in positive ionisation mode, scanning from m/z 100 to 3000, with the 
resolution set at 45K. Selected ion search within 5 ppm was performed, as well as high resolution 
fragmentation (collision energy set to 15-20%) for the putative biosynthetic intermediates. 
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Off-loading of functionalized polyketides from S. lasaliensis ACP12 (S970A) via chemical probe 
77 
 
 
 
Figure 66: LC-ESI-HRMS analysis of the organic extracts of S. lasaliensis ACP12 (S970A) grown in the absence and in the 
presence of probe 77 (final concentration 3.0 mM; day 2 and 3: 0.01 mmol, day 4 and 5: 0.005 mmol): [M+H]+, [M+Na]+ 
and [M+NH4]+extracted ion traces for the off-loaded polyketide 77a are shown. 
 
Figure 67: HR-ESI-MS2 analysis of the off-loaded dodecaketide 77a. McLafferty fragmentation of the [M+Na]+ adduct 
generates a left–hand fragment of m/z 377, characteristic of lasalocid A, as well as a right-hand fragment containing the 
long chain moiety (m/z 454). The distinctive peak at m/z 260 corresponds to the protonated imine generated by the 
cyclization of the aromatic ketone and the amine derived from loss of the decanoyl chain. 
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Figure 68: LC-ESI-HRMS analysis of the organic extracts of S. lasaliensis ACP12 (S970A) grown in the absence and in the 
presence of probe 77 (final concentration 3.0 mM; day 2 and 3: 0.01 mmol, day 4 and 5: 0.005 mmol): [M+H]+, [M+Na]+ 
and [M+NH4]+ extracted ion traces for the off-loaded polyketide 77b are shown. 
 
Figure 69: HR-ESI-MS2 analysis of the off-loaded dodecaketide 77b. McLafferty fragmentation of the [M+Na]+ adduct 
generates a left–hand fragment of m/z 377, as well as a right-hand fragment containing the long chain moiety (m/z 
456). The distinctive peak at m/z 262 corresponds to the protonated imine generated by the cyclization of the aromatic 
ketone and the amine derived from loss of the decanoyl chain. 
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Figure 70: LC-ESI-HRMS analysis of the organic extracts of S. lasaliensis ACP12 (S970A) grown in the absence and in the 
presence of probe 77 (final concentration 3.0 mM; day 2 and 3: 0.01 mmol, day 4 and 5: 0.005 mmol): [M+H]+, [M+Na]+ 
and [M+NH4]+extracted ion traces for the off-loaded polyketide 77c are shown. 
 
Figure 71: HR-ESI-MS2 analysis of the off-loaded dodecaketide 77c. McLafferty fragmentation of the [M+Na]+ adduct 
generates a left–hand fragment of m/z 377, as well as a right-hand fragment containing the long chain moiety (m/z 
472). The peak at m/z 278 corresponds to the protonated imine generated by the cyclization of the aromatic ketone 
and the amine derived from loss of the decanoyl chain. 
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Figure 72: LC-ESI-HRMS analysis of the organic extracts of S. lasaliensis ACP12 (S970A) grown in the absence and in the 
presence of probe 77 (final concentration 3.0 mM; day 2 and 3: 0.01 mmol, day 4 and 5: 0.005 mmol): [M+H]+, [M+Na]+ 
extracted ion traces for the off-loaded polyketide 77d are shown. 
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Figure 73: LC-ESI-HRMS analysis of the organic extracts of S. lasaliensis ACP12 (S970A) grown in the absence and in the 
presence of probe 77 (final concentration 3.0 mM; day 2 and 3: 0.01 mmol, day 4 and 5: 0.005 mmol): [M+H]+, [M+Na]+ 
extracted ion traces for the off-loaded polyketide 77e are shown. 
 
Figure 74: HR-ESI-MS2 analysis of the off-loaded dodecaketide 77e. The distinctive peak at m/z 262 corresponds to the 
protonated imine generated by the cyclization of the aromatic ketone and the amine derived from loss of the decanoyl 
chain 
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Off-loading of functionalized polyketides from S. lasaliensis ACP12 (S970A) via chemical probe 
78 
The analysis of feeding experiments carried out with the AM ester of deca probe 78 are still under 
investigations. Herein I will report previous LC-ESI-HRMS analysis only. 
 
 
 
Figure 75: LC-ESI-HRMS analysis of the organic extracts of S. lasaliensis ACP12 (S970A) grown in the presence of probe 
78 (A,B) (final concentration 3.0 mM; day 2 and 3: 0.01 mmol, day 4 and 5: 0.005 mmol) and in presence of probe 77 (C) 
as control: [M+H]+, [M+Na]+ and [M+NH4]+ extracted ion traces for the off-loaded polyketide 77a are shown. The higher 
intensity is clear in the experiment (B). 
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Figure 76: LC-ESI-HRMS analysis of the organic extracts of S. lasaliensis ACP12 (S970A) grown in the presence of probe 
78 (A,B) (final concentration 3.0 mM; day 2 and 3: 0.01 mmol, day 4 and 5: 0.005 mmol) and in presence of probe 77 (C) 
as control: [M+H]+, [M+Na]+ and [M+NH4]+ extracted ion traces for the off-loaded polyketide 77b are shown. The higher 
intensity is clear in the experiment (B). 
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Figure 77: LC-ESI-HRMS analysis of the organic extracts of S. lasaliensis ACP12 (S970A) grown in the presence of probe 
78 (A,B) (final concentration 3.0 mM; day 2 and 3: 0.01 mmol, day 4 and 5: 0.005 mmol) and in presence of probe 77 (C) 
as control: [M+H]+, [M+Na]+ extracted ion traces for the off-loaded polyketide 77c are shown. 
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Figure 78: LC-ESI-HRMS analysis of the organic extracts of S. lasaliensis ACP12 (S970A) grown in the presence of probe 
78 (A,B) (final concentration 3.0 mM; day 2 and 3: 0.01 mmol, day 4 and 5: 0.005 mmol) and in presence of probe 77 (C) 
as control: [M+H]+, [M+Na]+ extracted ion traces for the off-loaded polyketide 77d are shown. 
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Figure 79: LC-ESI-HRMS analysis of the organic extracts of S. lasaliensis ACP12 (S970A) grown in the presence of probe 
78 (A,B) (final concentration 3.0 mM; day 2 and 3: 0.01 mmol, day 4 and 5: 0.005 mmol) and in presence of probe 77 (C) 
as control: [M+H]+, [M+Na]+ and [M+NH4]+ extracted ion traces for the off-loaded polyketide 77e are shown. The higher 
intensity is clear in the experiment (B). 
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Figure 80: LC-ESI-HRMS analysis of the organic extracts of S. lasaliensis ACP12 (S970A) grown in the presence of probe 
78 (A,B) (final concentration 3.0 mM; day 2 and 3: 0.01 mmol, day 4 and 5: 0.005 mmol) and in presence of probe 77 (C) 
as control: [M+H]+, [M+Na]+ extracted ion traces for the off-loaded polyketide 77f are shown. The putative intermediate 
is identifiable in the experiment (B). 
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Figure 81: LC-ESI-HRMS analysis of the organic extracts of S. lasaliensis ACP12 (S970A) grown in the presence of probe 
78 (A,B) (final concentration 3.0 mM; day 2 and 3: 0.01 mmol, day 4 and 5: 0.005 mmol) and in presence of probe 77 (C) 
as control: [M+H]+, [M+Na]+ and [M+NH4]+ extracted ion traces for the off-loaded polyketide 77g are shown. The higher 
intensity is evident in the experiment (B). 
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Conclusion 
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The main topic of my PhD is the investigation of several privileged scaffolds arising from natural 
compounds, with the idea to prepare from them new potential anticancer compounds. 
Interesting results in term of anticancer activity were obtained either with the oxazole-pyridine 
series, through an effective double intramolecular domino palladium catalyzed process, or with 
pironetin-dumetorin hybrids, which come from modelling studies that confirmed a probable 
interaction with -tubulin. 
The development of two new synthetic approaches toward the synthesis of the racemic mixture 
and both enantiomers of boehmeriasin A, a potent alkaloid with high antiproliferative activity 
against several cancer cell lines, represents an additional issue to make more available novel 
topoisomerase and SIRT-2 inhibitors based on the boehmeriasin A scaffold.  
The disegn and synthesis of a new epothilone derivative (triazole-epothilone) is today a big 
challenge in the research for new cancer treatments, since the efficacy of epothilones against 
tumour cells. Many efforts will be spend to obtain the molecule, and to evaluate it as inhibitor of 
microtubule activity. 
Finally, the foreign period in Manuela Tosin group allowed to gain insight to one of the most 
efficient natural machine represented by type one polyketide synthase. The chemical strategy to 
isiolate biosynthetic intermediates from Streptomices lasaliensis, may represent an effective 
chemical biology tool to access to novel molecules of therapeutic interest through mutasynthesis 
and synthetic biology. 
To conclude, Nature has been a source of medicinal products for millennia, and during the past 
century, an impressive number of anti-cancer drugs have been developed from natural sources, 
particularly plants. It is clear that Nature will continue to be a major source of new drug leads. The 
drug potential of the marine environment remains relatively unexplored, but it is becoming 
increasingly evident that the microorganisms offers a vast untapped potential. However, only a 
multidisciplinary collaboration between chemists, biologists and biochemists will allow to 
discovery and optimize new effective drugs based on the incredible fantasy of Mother Nature. 
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